PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
30027841-1	2019	Genetic polymorphisms within the interferon lambda (IFN-lambda) chromosomal region, mainly rs12979860 of IFN-lambda4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- alpha and ribavirin.	pegylated interferon- alpha	252-279	interferon lambda 3	Homo sapiens	105-116
31165537-7	2019	The rate of IL28B T allele carriers was lower in PPD group (38.9%) in comparison with OPD group (66.7%, P = 0.005) and group without CMV disease (61.4%, P = 0.009).	opd	86-89	interferon lambda 3	Homo sapiens	12-17
31165537-8	2019	The impact of IL28B genotype on the risk of CMV OPD was significant neither in the allelic (TT + CT vs CC, P = 0.32) nor in the recessive model (TT vs CT + CC, P = 0.79).	tt + ct	92-99	interferon lambda 3	Homo sapiens	14-19
30589990-4	2019	Studies verified predisposition of HIV-positive carriers of UGT1A1*28 to severe atazanavir-induced hyperbilirubinaemia, intolerance to 5-fluorouracyl in gastrointestinal cancer patients with deleterious DPYD variants, failure of HCV-infected carriers of IFNL3 rs12979860 to obtain a sustained viral response to PEG-IFN-alpha, and hypersensitivity reactions to abacavir in HIV-positive carriers of HLA-B*57:01.	Atazanavir Sulfate	80-90	interferon lambda 3	Homo sapiens	254-259
30431653-0	2019	Polymorphism in interferon lambda3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.	daclatasvir	171-182	interferon lambda 3	Homo sapiens	16-34
30431653-0	2019	Polymorphism in interferon lambda3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.	daclatasvir	171-182	interferon lambda 3	Homo sapiens	35-50
30431653-0	2019	Polymorphism in interferon lambda3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.	Sofosbuvir	187-197	interferon lambda 3	Homo sapiens	16-34
30431653-0	2019	Polymorphism in interferon lambda3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.	Sofosbuvir	187-197	interferon lambda 3	Homo sapiens	35-50
30431653-2	2019	The present study was, therefore, initiated to investigate the association of polymorphism in interferon lambda3 (IFNL3) also known as interleukin-28B (IL-28B) gene with chronic HCV infection and association of these polymorphic variants with the combination daclatasvir and sofosbuvir HCV therapy response.	daclatasvir	259-270	interferon lambda 3	Homo sapiens	94-112
30431653-2	2019	The present study was, therefore, initiated to investigate the association of polymorphism in interferon lambda3 (IFNL3) also known as interleukin-28B (IL-28B) gene with chronic HCV infection and association of these polymorphic variants with the combination daclatasvir and sofosbuvir HCV therapy response.	daclatasvir	259-270	interferon lambda 3	Homo sapiens	114-119
30431653-2	2019	The present study was, therefore, initiated to investigate the association of polymorphism in interferon lambda3 (IFNL3) also known as interleukin-28B (IL-28B) gene with chronic HCV infection and association of these polymorphic variants with the combination daclatasvir and sofosbuvir HCV therapy response.	daclatasvir	259-270	interferon lambda 3	Homo sapiens	135-150
30431653-2	2019	The present study was, therefore, initiated to investigate the association of polymorphism in interferon lambda3 (IFNL3) also known as interleukin-28B (IL-28B) gene with chronic HCV infection and association of these polymorphic variants with the combination daclatasvir and sofosbuvir HCV therapy response.	daclatasvir	259-270	interferon lambda 3	Homo sapiens	152-158
30849550-11	2019	Priming of IECs with recombinant human IFN-lambda3 promoted cellular defense against C parvum infection and abrogated C parvum-induced loss of barrier function by decreasing paracellular permeability to sodium.	Sodium	203-209	interferon lambda 3	Homo sapiens	39-50
32749108-6	2020	We find that IL28B variants rs8099917 and rs12979860 strongly influence results of combined pegylated (PEG)-IFN/ribavirin (RBV) therapy.	pegylated (peg)-ifn/ribavirin	92-121	interferon lambda 3	Homo sapiens	13-18
32749108-6	2020	We find that IL28B variants rs8099917 and rs12979860 strongly influence results of combined pegylated (PEG)-IFN/ribavirin (RBV) therapy.	Ribavirin	123-126	interferon lambda 3	Homo sapiens	13-18
32368983-11	2020	Regarding response to DAAs treatment, HCV-infected patients with IL-28B rs8099917 GG genotype showed a significantly earlier viral response compared to those carrying TT alleles.	daas	22-26	interferon lambda 3	Homo sapiens	65-71
31683525-7	2019	The strain wtCSFV strongly inhibited IFN-lambdas transcription and IFN-lambda3 promoter activity in poly(I:C)-stimulated IPEC-J2 cells, whereas  Npro did not show such inhibition.	Poly I-C	100-109	interferon lambda 3	Homo sapiens	67-78
31383827-5	2019	The aim of the study is to determine the role of HCV NS5A-ISDR/PKR-BD mutation and SNP IL-28 polymorphism on the successfulness of Peg-IFN/RBV therapy in HCV-HIV coinfection.	peg-ifn	131-138	interferon lambda 3	Homo sapiens	87-92
31383827-5	2019	The aim of the study is to determine the role of HCV NS5A-ISDR/PKR-BD mutation and SNP IL-28 polymorphism on the successfulness of Peg-IFN/RBV therapy in HCV-HIV coinfection.	Ribavirin	139-142	interferon lambda 3	Homo sapiens	87-92
30988680-0	2019	The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin.	Ribavirin	147-156	interferon lambda 3	Homo sapiens	4-19
30988680-1	2019	Background: The present study aimed to determine the frequency of the IL28B polymorphism rs8099917 in patients with genotype 1 hepatitis C virus (HCV) infection treated with pegylated-interferon-alpha2b (PEG-IFN-alpha2b) and ribavirin (RBV) and its treatment outcome.	Ribavirin	225-234	interferon lambda 3	Homo sapiens	70-75
30988680-1	2019	Background: The present study aimed to determine the frequency of the IL28B polymorphism rs8099917 in patients with genotype 1 hepatitis C virus (HCV) infection treated with pegylated-interferon-alpha2b (PEG-IFN-alpha2b) and ribavirin (RBV) and its treatment outcome.	Ribavirin	236-239	interferon lambda 3	Homo sapiens	70-75
30027841-1	2019	Genetic polymorphisms within the interferon lambda (IFN-lambda) chromosomal region, mainly rs12979860 of IFN-lambda4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- alpha and ribavirin.	Ribavirin	284-293	interferon lambda 3	Homo sapiens	105-116
29254684-10	2018	CONCLUSION: Liver cirrhosis, high APRI levels, and IL28B rs12979860 at baseline are independent risk factors for HCC development in patients without SVR after peg-IFN combination therapy.	peg-ifn	159-166	interferon lambda 3	Homo sapiens	51-56
30450628-4	2018	In the current study, the rs12979860 polymorphism of IL28beta gene was analyzed and its association with the virological response to PEG-IFN treatment was determined.	peg-ifn	133-140	interferon lambda 3	Homo sapiens	53-61
30600305-8	2018	Alongside, cholesterol levels are modulated either by genetic variations in IL28B, ApoE, and LDLR or by dietary components.	Cholesterol	11-22	interferon lambda 3	Homo sapiens	76-81
30383478-0	2018	Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.	peg-ifn	51-58	interferon lambda 3	Homo sapiens	20-26
30383478-0	2018	Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.	Sofosbuvir	60-70	interferon lambda 3	Homo sapiens	20-26
30383478-0	2018	Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.	Ribavirin	76-85	interferon lambda 3	Homo sapiens	20-26
30398404-5	2018	RESULTS & CONCLUSION: Multinominal logistic regression analyses revealed that both genders favor IL28B rs12979860 CT genotype (OR: 4.80; CI: 2.22-10.35; p = 0.0005) and (OR: 3.47; CI: 1.63-7.43; p = 0.001) for male and female, respectively, are significant in spontaneous clearance of HCV infection.	Adenosine Monophosphate	9-12	interferon lambda 3	Homo sapiens	101-106
29705128-2	2018	In chronic hepatitis C virus (HCV) infections, where the IFNL variants were first identified to be associated with response to interferon-alpha-ribavirin therapy, the available data clearly suggests that the causal variant could be the dinucleotide polymorphism rs368234815 that causes an open reading frame-shift in the IFNL4 gene resulting in expression of a functional IFN-lambda4, a new type III IFN.	Ribavirin	144-153	interferon lambda 3	Homo sapiens	372-383
29851985-10	2018	CONCLUSIONS: Our study demonstrates that genetics of ITPA and IL28B may help identify patients protected from RBV-induced anemia when treated with IFN-free regimens.	Ribavirin	110-113	interferon lambda 3	Homo sapiens	62-67
29504692-6	2018	The SVR24 rate was lower with unfavorable IL28B rs8099917 SNP genotypes; specifically, the TT, TG and GG had SVR24 rates of 78%, 50% and 40%.	Thioguanine	95-97	interferon lambda 3	Homo sapiens	42-47
29509884-2	2018	Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes.	Ribavirin	175-184	interferon lambda 3	Homo sapiens	127-141
29962372-7	2018	HOSCN decreased polyI:C-induced apoptosis and the expression levels of IFNB1, IFNL1, IFNL2 and IFNL3 mRNAs.	Carbon	3-4	interferon lambda 3	Homo sapiens	95-100
29851985-0	2018	Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.	Ribavirin	76-85	interferon lambda 3	Homo sapiens	38-43
28892235-11	2018	In conclusion, this analysis showed high response rates in HCV genotype 1-infected patients treated with daclatasvir, ASV, and BCV irrespective of RBV use, prior interferon-based therapy, or restriction on non-cirrhotic patients, IL28B genotype, or baseline resistance-associated variants.	daclatasvir	105-116	interferon lambda 3	Homo sapiens	230-235
29910570-1	2018	Background: In hepatitis C virus (HCV), infection viral and IL28B genotype along with many clinical and biochemical factors can influence response rates to pegylated interferon plus ribavirin (Peg-IFN-a/R) therapy and progression to chronic hepatitis C (CHC).	Ribavirin	182-191	interferon lambda 3	Homo sapiens	60-65
29910570-1	2018	Background: In hepatitis C virus (HCV), infection viral and IL28B genotype along with many clinical and biochemical factors can influence response rates to pegylated interferon plus ribavirin (Peg-IFN-a/R) therapy and progression to chronic hepatitis C (CHC).	peg-ifn-a	193-202	interferon lambda 3	Homo sapiens	60-65
29408707-9	2018	Moreover, Poly-I:C treatment induced a marked antiviral response including increases of interferons IFNB, IL-28B and a group of interferon-stimulated genes.	Poly I-C	10-18	interferon lambda 3	Homo sapiens	106-112
29851985-11	2018	Our work demonstrates for the first time that IL28B genetics may also have an impact on RBV-induced anemia.	Ribavirin	88-91	interferon lambda 3	Homo sapiens	46-51
28884930-5	2018	Among the 6 patients receiving lead-in injections, viral relapse occurred in 2 patients who had an unfavorable IFN-lambda3-related gene single nucleotide polymorphism allele; both patients had been previously treated with simeprevir, and HCV carrying NS5A-L31V/Y93H mutations had emerged after DCV/ASV.	Simeprevir	222-232	interferon lambda 3	Homo sapiens	111-122
28884930-5	2018	Among the 6 patients receiving lead-in injections, viral relapse occurred in 2 patients who had an unfavorable IFN-lambda3-related gene single nucleotide polymorphism allele; both patients had been previously treated with simeprevir, and HCV carrying NS5A-L31V/Y93H mutations had emerged after DCV/ASV.	daclatasvir	294-297	interferon lambda 3	Homo sapiens	111-122
28884930-5	2018	Among the 6 patients receiving lead-in injections, viral relapse occurred in 2 patients who had an unfavorable IFN-lambda3-related gene single nucleotide polymorphism allele; both patients had been previously treated with simeprevir, and HCV carrying NS5A-L31V/Y93H mutations had emerged after DCV/ASV.	asunaprevir	298-301	interferon lambda 3	Homo sapiens	111-122
29284412-0	2017	CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV.	pegifn	114-120	interferon lambda 3	Homo sapiens	81-86
29429413-9	2018	The host genetic factor was found to be heterozygous guanine and thymine (GT) and cytosine and thymine (CT) genotypes of rs8099917 and rs12979860 polymorphism of IL28B, respectively.	Cytosine	82-90	interferon lambda 3	Homo sapiens	162-167
29429413-9	2018	The host genetic factor was found to be heterozygous guanine and thymine (GT) and cytosine and thymine (CT) genotypes of rs8099917 and rs12979860 polymorphism of IL28B, respectively.	ct	104-106	interferon lambda 3	Homo sapiens	162-167
27789659-6	2018	RESULTS: Higher serum IFN-lambda3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir).	adefovir	106-114	interferon lambda 3	Homo sapiens	22-33
27789659-6	2018	RESULTS: Higher serum IFN-lambda3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir).	Tenofovir	118-127	interferon lambda 3	Homo sapiens	22-33
27789659-6	2018	RESULTS: Higher serum IFN-lambda3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir).	entecavir	198-207	interferon lambda 3	Homo sapiens	22-33
28634723-9	2018	The use of adefovir dipivoxil was also associated with higher serum IFN-lambda3, which might have contributed to the reduction in patient HBsAg levels.	adefovir dipivoxil	11-29	interferon lambda 3	Homo sapiens	68-79
29380700-5	2018	Numerous reports including Genome-Wide Association Studies (GWAS), comprehensive meta-analysis and independent case-control studies in different population have revealed the association between certain Il-28B polymorphisms and response to the PEGIFN- RBV therapy in patients infected with HCV.	pegifn- rbv	243-254	interferon lambda 3	Homo sapiens	202-208
29271328-8	2018	This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-alpha/RBV among Chinese CHC patients.	pegifn-alpha	111-123	interferon lambda 3	Homo sapiens	44-49
29271328-8	2018	This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-alpha/RBV among Chinese CHC patients.	Ribavirin	124-127	interferon lambda 3	Homo sapiens	44-49
29284412-10	2017	CONCLUSIONS: IL28B genotype is the predictor for NR in GT-1 CHC patients treated with PegIFN/RBV, while baseline serum level of CCL4 is the only predictor for NR in GT-1 CHC patients with favorable IL28B genotype.	pegifn	86-92	interferon lambda 3	Homo sapiens	13-18
29284412-10	2017	CONCLUSIONS: IL28B genotype is the predictor for NR in GT-1 CHC patients treated with PegIFN/RBV, while baseline serum level of CCL4 is the only predictor for NR in GT-1 CHC patients with favorable IL28B genotype.	Ribavirin	93-96	interferon lambda 3	Homo sapiens	13-18
29104462-0	2017	Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.	Ribavirin	116-125	interferon lambda 3	Homo sapiens	15-20
28992878-4	2017	RESULTS: PegIFN in combination with ribavirin remains an important and relevant option for some patients, achieving SVR rates of up to 79% in genotype 1 and 89% in genotype 2 or 3 infections, which increases for patients with favorable IL28B genotypes.	pegifn	9-15	interferon lambda 3	Homo sapiens	236-241
28992878-4	2017	RESULTS: PegIFN in combination with ribavirin remains an important and relevant option for some patients, achieving SVR rates of up to 79% in genotype 1 and 89% in genotype 2 or 3 infections, which increases for patients with favorable IL28B genotypes.	Ribavirin	36-45	interferon lambda 3	Homo sapiens	236-241
28739427-1	2017	Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV).	Ribavirin	287-296	interferon lambda 3	Homo sapiens	48-63
28739427-1	2017	Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV).	Ribavirin	287-296	interferon lambda 3	Homo sapiens	65-70
28739427-1	2017	Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV).	Ribavirin	287-296	interferon lambda 3	Homo sapiens	73-92
28739427-1	2017	Single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B), interferon lambda 4 (IFNL4) and the human leukocyte antigen (HLA) gene are associated with treatment responses in patients with chronic hepatitis C (CHC) virus infection treated with pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV).	Ribavirin	287-296	interferon lambda 3	Homo sapiens	94-99
29104462-1	2017	BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis.	pegifn	132-138	interferon lambda 3	Homo sapiens	39-58
29104462-1	2017	BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis.	pegifn	132-138	interferon lambda 3	Homo sapiens	60-65
29104462-1	2017	BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis.	Ribavirin	144-153	interferon lambda 3	Homo sapiens	39-58
29104462-1	2017	BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis.	Ribavirin	144-153	interferon lambda 3	Homo sapiens	60-65
26521772-7	2017	Circulating CXCL10 levels, and the interleukin(IL)-28B gene polymorphisms, are associated with the success of the therapy both with DAAs or ribavirin and PEGylated interferon-alpha.	Ribavirin	140-149	interferon lambda 3	Homo sapiens	35-54
29062905-8	2017	CONCLUSIONS: The IFNL3 rs12979860 polymorphism may be considered a predictor for IFN/RBV effectiveness following liver transplantation.	Ribavirin	85-88	interferon lambda 3	Homo sapiens	17-22
28922437-3	2017	AIM: To analyse predictors of BC, by monitoring in the peripheral blood the biomarkers involved in the inflammation and hepatic fibrosis, such as the matrix metalloproteinases (MMP 2, 9) and their tissue inhibitors (TIMP1), the interleukins (IL 2, 8), alfa-TNF, the endothelins and their receptors.	biochar	30-32	interferon lambda 3	Homo sapiens	242-249
28852525-0	2017	Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism.	Ribavirin	52-61	interferon lambda 3	Homo sapiens	115-120
28852525-4	2017	The purpose of this study was to determine IL28B polymorphism and ITPA variation among hepatitis C genotype 1 patients who have undergone therapy with PEG-IFN and ribavirin and their association with sustained viral response (SVR).	peg-ifn	151-158	interferon lambda 3	Homo sapiens	43-48
28852525-4	2017	The purpose of this study was to determine IL28B polymorphism and ITPA variation among hepatitis C genotype 1 patients who have undergone therapy with PEG-IFN and ribavirin and their association with sustained viral response (SVR).	Ribavirin	163-172	interferon lambda 3	Homo sapiens	43-48
28852525-15	2017	Conclusion: Hepatitis C genotype 1 patients should be informed of the response rate for treatment with PEG-IFN and ribavirin in a population with favourable IL28B genotype before consideration of newer therapeutic options.	peg-ifn	103-110	interferon lambda 3	Homo sapiens	157-162
28852525-15	2017	Conclusion: Hepatitis C genotype 1 patients should be informed of the response rate for treatment with PEG-IFN and ribavirin in a population with favourable IL28B genotype before consideration of newer therapeutic options.	Ribavirin	115-124	interferon lambda 3	Homo sapiens	157-162
28315743-0	2017	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.	Ribavirin	27-36	interferon lambda 3	Homo sapiens	137-142
28315743-2	2017	Naive treated patients, who are not eligible for IFN-free therapies, could be selected for standard dual treatment with pegylated (PEG)-IFN and ribavirin (RBV), through IFN lambda 3 gene polymorphisms and fibrosis stage evaluation.	Ribavirin	144-153	interferon lambda 3	Homo sapiens	169-181
28315743-2	2017	Naive treated patients, who are not eligible for IFN-free therapies, could be selected for standard dual treatment with pegylated (PEG)-IFN and ribavirin (RBV), through IFN lambda 3 gene polymorphisms and fibrosis stage evaluation.	Ribavirin	155-158	interferon lambda 3	Homo sapiens	169-181
28036111-7	2017	IFNL4 expression was associated with non-response to PEG-IFN/ribavirin therapy.	Ribavirin	61-70	interferon lambda 3	Homo sapiens	0-5
28122304-7	2017	In addition, flow cytometry results confirmed that treatment with a combination of IFN-lambda3 and sorafenib promotes the loss of mitochondrial membrane potential and induces the production of ROS more than treatment with either alone.	ros	193-196	interferon lambda 3	Homo sapiens	83-94
28122304-8	2017	Furthermore, using a subcutaneous SMMC7721 tumor model, treatment with a combination of IFN-lambda3 and sorafenib significantly reduced the tumor growth/volume and induced apoptosis compared to treatment with sorafenib alone.	Sorafenib	209-218	interferon lambda 3	Homo sapiens	88-99
28235040-11	2017	In gene expression analyses, 25(OH)D was associated with higher IL-37, vitamin A with higher IFN-gamma and vitamin E with less IL-28 (P < 0.05).	Vitamin E	107-116	interferon lambda 3	Homo sapiens	127-132
28261382-17	2017	CONCLUSION: Both TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with genotype 1b chronic hepatitis C. Genotyping of the IL28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients.	Simeprevir	26-29	interferon lambda 3	Homo sapiens	175-180
28391873-0	2022	IL-10 and IL-28B gene variants as predictors of sustained response to peginterferon and ribavirin therapy in chronic HCV infection.	Ribavirin	88-97	interferon lambda 3	Homo sapiens	10-16
27541605-1	2016	AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy.	telaprevir	5-15	interferon lambda 3	Homo sapiens	104-119
27541605-1	2016	AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy.	telaprevir	17-20	interferon lambda 3	Homo sapiens	104-119
27541605-1	2016	AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy.	Polyethylene Glycols	223-226	interferon lambda 3	Homo sapiens	104-119
27541605-1	2016	AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy.	peg-ifn	239-246	interferon lambda 3	Homo sapiens	104-119
27541605-1	2016	AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy.	Ribavirin	248-257	interferon lambda 3	Homo sapiens	104-119
27541605-1	2016	AIM: Telaprevir (TVR) remarkably improves the efficacy of interferon treatment for chronic hepatitis C. Interleukin-28B (IL28B) genotype and interferon-gamma-inducible protein-10 (IP-10) level predict virologic response to peg-interferon (Peg-IFN)/ribavirin (RBV) therapy.	Ribavirin	259-262	interferon lambda 3	Homo sapiens	104-119
27541605-10	2016	CONCLUSIONS: Determination of serum IP-10 levels before treatment could be useful for predicting favorable virologic response to TVR-based triple therapy, especially in patients with IL28B non-TT genotype.	telaprevir	129-132	interferon lambda 3	Homo sapiens	183-188
27660680-3	2016	There is a strong relationship between single nucleotide polymorphisms at or near the IL-28B gene and the sustained virological response with pegylated interferon plus ribavirin treatment for chronic hepatitis C. Pakistan is a resource limited country, with very low per capita income and there is no proper social security (health insurance) system.	Ribavirin	168-177	interferon lambda 3	Homo sapiens	86-92
27664841-5	2016	However, higher glucose levels were found in T2D patients carrying the IL28B CT/TT rs12979860 and GT/GG rs8099917 HCV risk genotypes compared to those with the protective CC and TT genotype (p=0.06 and p=0.02, respectively).	Glucose	16-23	interferon lambda 3	Homo sapiens	71-76
27895405-10	2016	However, in the genotype analysis, only IL-28B rs12980275 was significantly associated with PR (AA vs AG-GG, P = 0.014, OR = 10.9, 95%CI: 1.3-93.9).	ag-gg	102-107	interferon lambda 3	Homo sapiens	40-46
27895405-11	2016	The association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group (P = 0.033) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group (P = 0.044, OR = 0.26, 95%CI: 0.07-0.88).	Chromium	29-31	interferon lambda 3	Homo sapiens	63-68
27895405-11	2016	The association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group (P = 0.033) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group (P = 0.044, OR = 0.26, 95%CI: 0.07-0.88).	Chromium	107-109	interferon lambda 3	Homo sapiens	63-68
27895405-11	2016	The association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group (P = 0.033) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group (P = 0.044, OR = 0.26, 95%CI: 0.07-0.88).	Chromium	107-109	interferon lambda 3	Homo sapiens	63-68
26991414-7	2016	RBV dosage affected SVR dose-dependently in patients with the IL28B non-TT genotype treated with SMV triple therapy.	Ribavirin	0-3	interferon lambda 3	Homo sapiens	62-67
26991414-7	2016	RBV dosage affected SVR dose-dependently in patients with the IL28B non-TT genotype treated with SMV triple therapy.	Simeprevir	97-100	interferon lambda 3	Homo sapiens	62-67
27498543-0	2016	Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?	Ribavirin	55-64	interferon lambda 3	Homo sapiens	4-9
27498543-1	2016	Favourable genotypes of IFNL3 polymorphism CC for rs12979860 and TT for rs8099917 are strongly associated with the interferon/ribavirin treatment outcome in hepatitis C virus (HCV) patients with genotypes 1 and 4.	Ribavirin	126-135	interferon lambda 3	Homo sapiens	24-29
28144454-0	2016	Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. BACKGROUND: The current medical treatment for hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, but just 50% of genotype 1 HCV patients and about 80% of HCV genotype 3 patients are treated completely.	Ribavirin	99-108	interferon lambda 3	Homo sapiens	8-12
27140229-0	2016	Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.	faldaprevir	15-26	interferon lambda 3	Homo sapiens	56-61
27140229-0	2016	Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.	Ribavirin	43-52	interferon lambda 3	Homo sapiens	56-61
27140229-19	2016	CONCLUSION: In this small study, the interferon-free regimen of faldaprevir, deleobuvir and ribavirin resulted in high rates of virological breakthrough and low rates of SVR12 in IL28B non-CC genotype patients infected with genotype-1a HCV (http://www.clinicaltrials.gov NCT01132313).	faldaprevir	64-75	interferon lambda 3	Homo sapiens	179-184
27140229-19	2016	CONCLUSION: In this small study, the interferon-free regimen of faldaprevir, deleobuvir and ribavirin resulted in high rates of virological breakthrough and low rates of SVR12 in IL28B non-CC genotype patients infected with genotype-1a HCV (http://www.clinicaltrials.gov NCT01132313).	deleobuvir	77-87	interferon lambda 3	Homo sapiens	179-184
27140229-19	2016	CONCLUSION: In this small study, the interferon-free regimen of faldaprevir, deleobuvir and ribavirin resulted in high rates of virological breakthrough and low rates of SVR12 in IL28B non-CC genotype patients infected with genotype-1a HCV (http://www.clinicaltrials.gov NCT01132313).	Ribavirin	92-101	interferon lambda 3	Homo sapiens	179-184
28144454-0	2016	Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. BACKGROUND: The current medical treatment for hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, but just 50% of genotype 1 HCV patients and about 80% of HCV genotype 3 patients are treated completely.	Ribavirin	264-273	interferon lambda 3	Homo sapiens	8-12
27799970-0	2016	Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1Patients Treated by Pegylated Interferon and Ribavirin.	Ribavirin	103-112	interferon lambda 3	Homo sapiens	16-22
27388623-5	2016	By multivariable regression including age, sex, HCV viral load, HCV genotype, liver fibrosis stage, prior treatments, immunosuppression and IL28b genotype, ribavirin levels consistently displayed significant influence on SVR and relapse without indication for a specific importance of higher concentrations early or late in the treatment course.	Ribavirin	156-165	interferon lambda 3	Homo sapiens	140-145
27799970-2	2016	The aim of this study was to detect the polymorphism of IL-28B gene (rs12979860) in HCV genotype 1 patients treated with pegylated Interferon and Ribavirin.	Ribavirin	146-155	interferon lambda 3	Homo sapiens	56-62
27799970-8	2016	CONCLUSION: IL-28B polymorphism has an effective impact on the therapeutic response to ribavirin and peginterferon combination therapy in chronic HCV patients infected by different genotypes.	Ribavirin	87-96	interferon lambda 3	Homo sapiens	12-18
26825765-8	2016	In 32 genotype-1 patients available for the IL28B genotype (rs8099917), SVR was achieved in more patients in the IL28B major allele group than in the minor allele group (15/17 vs 7/15, P = 0.021) after PEG-IFN/RBV combination therapy.	peg-ifn	202-209	interferon lambda 3	Homo sapiens	113-118
26825765-8	2016	In 32 genotype-1 patients available for the IL28B genotype (rs8099917), SVR was achieved in more patients in the IL28B major allele group than in the minor allele group (15/17 vs 7/15, P = 0.021) after PEG-IFN/RBV combination therapy.	Ribavirin	210-213	interferon lambda 3	Homo sapiens	113-118
26825765-10	2016	CONCLUSIONS: Overall, both therapies showed encouraging results, and were reasonably safe in children and adolescents with chronic hepatitis C. The IL28B genotype was useful for predicting the treatment response to PEG-IFN/RBV combination therapy in this cohort.	peg-ifn	215-222	interferon lambda 3	Homo sapiens	148-153
26825765-10	2016	CONCLUSIONS: Overall, both therapies showed encouraging results, and were reasonably safe in children and adolescents with chronic hepatitis C. The IL28B genotype was useful for predicting the treatment response to PEG-IFN/RBV combination therapy in this cohort.	Ribavirin	223-226	interferon lambda 3	Homo sapiens	148-153
27035616-6	2016	Furthermore, a borderline level of statistical significance association was found among the presence of amino acid Glutamine (Q) in the position 70 and IFNL3 genotype AG (P=0.054).	amino acid glutamine	104-124	interferon lambda 3	Homo sapiens	152-157
27367326-0	2016	HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.	Lamivudine	68-78	interferon lambda 3	Homo sapiens	152-158
27035616-6	2016	Furthermore, a borderline level of statistical significance association was found among the presence of amino acid Glutamine (Q) in the position 70 and IFNL3 genotype AG (P=0.054).	q	126-127	interferon lambda 3	Homo sapiens	152-157
27167219-5	2016	Conclusion: Ribavirin down-regulates IP-10, and may have an anti-viral effect differently regulated across IL28B genotypes.	Ribavirin	12-21	interferon lambda 3	Homo sapiens	107-112
26289410-1	2016	AIM: Protease inhibitors with pegylated interferon (PEG IFN)/ribavirin improve a sustained virological response (SVR) rate to approximately 90% in chronic hepatitis C genotype 1b patients with IL28B rs8099917 genotype TT, but yield only approximately 50% in those with the unfavorable non-TT.	Ribavirin	61-70	interferon lambda 3	Homo sapiens	193-198
27022224-15	2016	Among both daclatasvir and telaprevir treatment groups, across GT1b- or GT1a-infected patients, lower response rates were observed in patients with IL28B non-CC and cirrhosis - factors known to affect response to pegIFN/RBV.	daclatasvir	11-22	interferon lambda 3	Homo sapiens	148-153
27022224-15	2016	Among both daclatasvir and telaprevir treatment groups, across GT1b- or GT1a-infected patients, lower response rates were observed in patients with IL28B non-CC and cirrhosis - factors known to affect response to pegIFN/RBV.	telaprevir	27-37	interferon lambda 3	Homo sapiens	148-153
27022224-15	2016	Among both daclatasvir and telaprevir treatment groups, across GT1b- or GT1a-infected patients, lower response rates were observed in patients with IL28B non-CC and cirrhosis - factors known to affect response to pegIFN/RBV.	pegifn	213-219	interferon lambda 3	Homo sapiens	148-153
27313635-0	2016	The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNalpha-2a/RBV Combination Therapy in Azerbaijani Patients.	Ribavirin	140-143	interferon lambda 3	Homo sapiens	83-88
27313635-9	2016	CONCLUSIONS: The data of the present study suggest that amino acid substitutions at position 43, 70, 91, and 106 in the HCV-1b core protein are correlated with the response to the Peg-IFNalpha-2a/RBV treatment in Azerbaijani patients with chronic hepatitis C. Moreover, host genetic polymorphisms, such as those of the IL28B locus, might be useful for predicting the responsiveness to Peg-IFNalpha-2a/RBV combination therapy against HCV.	Ribavirin	196-199	interferon lambda 3	Homo sapiens	319-324
27313635-9	2016	CONCLUSIONS: The data of the present study suggest that amino acid substitutions at position 43, 70, 91, and 106 in the HCV-1b core protein are correlated with the response to the Peg-IFNalpha-2a/RBV treatment in Azerbaijani patients with chronic hepatitis C. Moreover, host genetic polymorphisms, such as those of the IL28B locus, might be useful for predicting the responsiveness to Peg-IFNalpha-2a/RBV combination therapy against HCV.	Ribavirin	401-404	interferon lambda 3	Homo sapiens	319-324
26280154-3	2016	To examine the association between different IL28B variants and the relapse of HCV infection after combined therapy with ribavirin and pegylated interferon (pegIFN).	Ribavirin	121-130	interferon lambda 3	Homo sapiens	45-50
26344576-1	2016	BACKGROUND & AIMS: Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10).	pegifn	85-91	interferon lambda 3	Homo sapiens	193-198
26344576-1	2016	BACKGROUND & AIMS: Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10).	Ribavirin	108-111	interferon lambda 3	Homo sapiens	193-198
26344576-9	2016	CONCLUSIONS: The associations of MIG with SVR status and IL28B genotype imply that higher MIG plasma levels could reflect a beneficial immunological state for response to pegIFN/RBV treatment.	pegifn	171-177	interferon lambda 3	Homo sapiens	57-62
26668696-8	2015	Patients in the SMV group were older, had higher serum HCV RNA levels, lower hemoglobin, higher prevalence of unfavorable interleukin-28B (IL28B) genotype (rs8099917), and poorer response to previous PEG-IFN and RBV treatment.	Simeprevir	16-19	interferon lambda 3	Homo sapiens	122-137
27110259-0	2016	The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. BACKGROUND: Hepatitis C Virus (HCV) is the major cause of liver failure in thalassemic patients.	Ribavirin	80-89	interferon lambda 3	Homo sapiens	35-40
27110259-2	2016	OBJECTIVES: We aimed to assess the impact of polymorphisms near the IL28B gene on virological response in HCV - infected thalassemic patients, who were treated with PEG-IFN and RBV.	peg-ifn	165-172	interferon lambda 3	Homo sapiens	68-73
27110259-2	2016	OBJECTIVES: We aimed to assess the impact of polymorphisms near the IL28B gene on virological response in HCV - infected thalassemic patients, who were treated with PEG-IFN and RBV.	Ribavirin	177-180	interferon lambda 3	Homo sapiens	68-73
26732192-12	2016	DISCUSSION: Core aa70 mutation and the IL28B non-TT genotype were identified as independent factors that influenced relapse after achievement of ETR for telaprevir-based triple therapy.	telaprevir	153-163	interferon lambda 3	Homo sapiens	39-44
27525598-0	2016	Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.	Ribavirin	82-91	interferon lambda 3	Homo sapiens	27-33
27525598-1	2016	BACKGROUND:   A polymorphism upstream of interleukin (IL)-28B was recently identified to be associated with a 2-fold difference in sustained virologic response (SVR) to pegylated interferon-alpha and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C (CHC) virus genotype 1 (HCV-1) infection.	Ribavirin	200-209	interferon lambda 3	Homo sapiens	41-61
27525598-12	2016	CONCLUSION: In treatment-naive HCV patients treated with pegylated interferon and ribavirin, a polymorphism upstream CC at the site rs12979860 of IL-28B is associated with increased sustained virologic response and effectively predicts treatment outcome.	Ribavirin	82-91	interferon lambda 3	Homo sapiens	146-152
27156332-0	2016	Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C. BACKGROUND: The current standard treatment for hepatitis C is a combination of pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV).	Ribavirin	257-266	interferon lambda 3	Homo sapiens	26-32
27156332-0	2016	Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C. BACKGROUND: The current standard treatment for hepatitis C is a combination of pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV).	peg-ifnalpha	268-280	interferon lambda 3	Homo sapiens	26-32
27156332-0	2016	Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C. BACKGROUND: The current standard treatment for hepatitis C is a combination of pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV).	Ribavirin	281-284	interferon lambda 3	Homo sapiens	26-32
26699619-3	2015	In this study, we compared the role of IFNL4 variants with IFNL3-(rs12979860) and IFNL3-(rs8099917) on response to pegylated (PEG)-IFN and Ribavirin (RBV) in patients with chronic hepatitis C GT2/3.	Polyethylene Glycols	126-129	interferon lambda 3	Homo sapiens	82-87
26699619-12	2015	CONCLUSION: IFNL3 genotyping from serum was highly efficient and can be used as an alternative if EDTA whole blood is not available.	Edetic Acid	98-102	interferon lambda 3	Homo sapiens	12-17
26670100-7	2015	Refined analysis showed that the effect of IL28B SNPs on sustained virological response was restricted to prior PegIFN/RBV relapse (OR = 3.80[1.82-8.92], P = 8x10(-4)).	pegifn	112-118	interferon lambda 3	Homo sapiens	43-48
26670100-7	2015	Refined analysis showed that the effect of IL28B SNPs on sustained virological response was restricted to prior PegIFN/RBV relapse (OR = 3.80[1.82-8.92], P = 8x10(-4)).	Ribavirin	119-122	interferon lambda 3	Homo sapiens	43-48
26668696-8	2015	Patients in the SMV group were older, had higher serum HCV RNA levels, lower hemoglobin, higher prevalence of unfavorable interleukin-28B (IL28B) genotype (rs8099917), and poorer response to previous PEG-IFN and RBV treatment.	Simeprevir	16-19	interferon lambda 3	Homo sapiens	139-144
26177560-3	2015	In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin.	Polyethylene Glycols	228-231	interferon lambda 3	Homo sapiens	105-110
25857516-2	2015	Recently, genome-wide association studies (GWAS) have identified that the IL28B gene rs8099917 polymorphism was associated with the response to the pegylated-interferon alpha/ribavirin (PegIFNalpha/RBV) combination therapy in patients infected with HCV genotype 1.	Ribavirin	175-184	interferon lambda 3	Homo sapiens	74-79
25857516-2	2015	Recently, genome-wide association studies (GWAS) have identified that the IL28B gene rs8099917 polymorphism was associated with the response to the pegylated-interferon alpha/ribavirin (PegIFNalpha/RBV) combination therapy in patients infected with HCV genotype 1.	pegifnalpha	186-197	interferon lambda 3	Homo sapiens	74-79
25857516-2	2015	Recently, genome-wide association studies (GWAS) have identified that the IL28B gene rs8099917 polymorphism was associated with the response to the pegylated-interferon alpha/ribavirin (PegIFNalpha/RBV) combination therapy in patients infected with HCV genotype 1.	Ribavirin	198-201	interferon lambda 3	Homo sapiens	74-79
25857516-4	2015	The aims of this study were to analyze the correlation between IL28B gene rs8099917 (T/G) polymorphism and PegIFNalpha/RBV therapy outcome in the Turkish population.	Ribavirin	119-122	interferon lambda 3	Homo sapiens	63-68
26284971-2	2015	In 2009 a genome-wide association study (GWAS) identified a single nucleotide polymorphism near the IL28B gene that was associated with treatment-induced viral clearance in chronic HCV infection treated with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV).	peg-ifn	236-243	interferon lambda 3	Homo sapiens	100-105
26284971-2	2015	In 2009 a genome-wide association study (GWAS) identified a single nucleotide polymorphism near the IL28B gene that was associated with treatment-induced viral clearance in chronic HCV infection treated with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV).	Ribavirin	249-258	interferon lambda 3	Homo sapiens	100-105
26284971-2	2015	In 2009 a genome-wide association study (GWAS) identified a single nucleotide polymorphism near the IL28B gene that was associated with treatment-induced viral clearance in chronic HCV infection treated with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV).	Ribavirin	260-263	interferon lambda 3	Homo sapiens	100-105
26284971-6	2015	In contrast, in HBV several retrospective studies yielded conflicting results of the association of IL28B with PEG-IFN-induced treatment response.	Polyethylene Glycols	111-114	interferon lambda 3	Homo sapiens	100-105
26485009-2	2015	IL28B SNPs were genotyped in 269 patients, 181 mono- and 88 co-infected, treated with pegylated interferon and ribavirin.	Ribavirin	111-120	interferon lambda 3	Homo sapiens	0-5
26095167-9	2015	CONCLUSIONS: Considering the effectiveness and safety, simeprevir-based triple therapy will continue to be a useful treatment option in Japan for treatment-naive or prior relapse patients with a favorable IL28B genotype.	Simeprevir	55-65	interferon lambda 3	Homo sapiens	205-210
26609346-11	2015	In addition, the interleukin-28B single nucleotide polymorphism and response to previous pegylated-IFN-alpha and ribavirin therapy were identified as independent factors for SVR.	Ribavirin	113-122	interferon lambda 3	Homo sapiens	17-32
26614853-6	2015	The three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA genotype of rs12980275) were associated with the SVR (p=0.029, p=0.016, and p=0.028, respectively) in the study patients with chronic hepatitis C treated with the combination therapy of PEGIFN alpha and RBV.	pegifn alpha	282-294	interferon lambda 3	Homo sapiens	10-15
26614853-6	2015	The three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA genotype of rs12980275) were associated with the SVR (p=0.029, p=0.016, and p=0.028, respectively) in the study patients with chronic hepatitis C treated with the combination therapy of PEGIFN alpha and RBV.	Ribavirin	299-302	interferon lambda 3	Homo sapiens	10-15
25580859-3	2015	The duration of ribavirin/pegylated interferon (PEG IFN)-alpha-2b therapy was prolonged to 48 weeks in patients with unfavorable IL28B alleles showing adherence rates of less than 80% for either drug during the first 12 weeks even if RVR had been achieved, and in those in whom cEVR, but not RVR, was achieved; furthermore, to 72 weeks in those showing partial early viral response.	Ribavirin	16-25	interferon lambda 3	Homo sapiens	129-134
25735432-0	2015	A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus.	thymine-adenine dinucleotide	2-30	interferon lambda 3	Homo sapiens	56-61
25735432-3	2015	We previously reported a wide variation in the length of a thymine-adenine (TA) dinucleotide repeat in the promoter region of IL28B and that the transcriptional activity of the promoter increased gradually in a TA repeat length-dependent manner.	thymine-adenine (ta) dinucleotide	59-92	interferon lambda 3	Homo sapiens	126-131
26177560-3	2015	In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin.	Polyethylene Glycols	228-231	interferon lambda 3	Homo sapiens	112-117
26177560-3	2015	In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin.	Ribavirin	268-277	interferon lambda 3	Homo sapiens	105-110
26177560-3	2015	In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin.	Ribavirin	268-277	interferon lambda 3	Homo sapiens	112-117
26177560-4	2015	IL28B (rs12979860 and rs8099917) single nucleotide polymorphisms (SNPs) have been recently found among the Pakistani population associated with response to chronic HCV infection INF-alpha + ribavirin therapy.	Ribavirin	190-199	interferon lambda 3	Homo sapiens	0-5
25958342-0	2015	The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. BACKGROUND/AIMS: There is increasing evidence for the effect of rs12979860 IL28B polymorphism in response to the standard treatment PEG-IFN/RBV (i.e. combination of pegylated interferon and ribavirin) in chronic hepatitis C virus (HCV) infection.	peg-ifn	281-288	interferon lambda 3	Homo sapiens	34-49
26526510-12	2015	CONCLUSION: Interleukin-28B polymorphism could be a possible predictor of response to pegylated interferon/ribavirin therapy (PEG-IFN/RBV).	Ribavirin	107-116	interferon lambda 3	Homo sapiens	12-27
26526510-12	2015	CONCLUSION: Interleukin-28B polymorphism could be a possible predictor of response to pegylated interferon/ribavirin therapy (PEG-IFN/RBV).	peg-ifn	126-133	interferon lambda 3	Homo sapiens	12-27
26526510-12	2015	CONCLUSION: Interleukin-28B polymorphism could be a possible predictor of response to pegylated interferon/ribavirin therapy (PEG-IFN/RBV).	Ribavirin	134-137	interferon lambda 3	Homo sapiens	12-27
26150150-2	2015	Host single-nucleotide polymorphisms related to IFNL3 and IFNL4 are associated with spontaneous clearance of HCV, and pegylated interferon- and DAA-based treatment outcomes.	single-nucleotide	5-22	interferon lambda 3	Homo sapiens	48-53
26150150-2	2015	Host single-nucleotide polymorphisms related to IFNL3 and IFNL4 are associated with spontaneous clearance of HCV, and pegylated interferon- and DAA-based treatment outcomes.	daa	144-147	interferon lambda 3	Homo sapiens	48-53
25958342-0	2015	The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. BACKGROUND/AIMS: There is increasing evidence for the effect of rs12979860 IL28B polymorphism in response to the standard treatment PEG-IFN/RBV (i.e. combination of pegylated interferon and ribavirin) in chronic hepatitis C virus (HCV) infection.	Ribavirin	289-292	interferon lambda 3	Homo sapiens	34-49
25958342-0	2015	The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. BACKGROUND/AIMS: There is increasing evidence for the effect of rs12979860 IL28B polymorphism in response to the standard treatment PEG-IFN/RBV (i.e. combination of pegylated interferon and ribavirin) in chronic hepatitis C virus (HCV) infection.	Ribavirin	339-348	interferon lambda 3	Homo sapiens	34-49
26279979-1	2015	In 2009, several groups reported that interleukin-28B (IL28B) genotypes are associated with the response to peginterferon plus ribavirin therapy for chronic hepatitis C virus (HCV) infection in a genome-wide association study, although the mechanism of this association is not yet well understood.	Ribavirin	127-136	interferon lambda 3	Homo sapiens	55-60
26032235-1	2015	BACKGROUND: The biological mechanism underlying the association between IFNL4/IFNL3 polymorphism and peginterferon/ribavirin (PR) response in HCV-1 is thought to involve differential intrahepatic interferon-stimulated gene expression.	Ribavirin	115-124	interferon lambda 3	Homo sapiens	78-83
26060059-0	2015	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.	peg-ifn	110-117	interferon lambda 3	Homo sapiens	8-13
26060059-6	2015	The IL28B rs8099917/rs12979860 TT/CC genotype was the most frequent in MC-positive patients with sustained virological response (SVR) (p < 0.001), while the TG/TC genotype was most frequent in non-SVR (p < 0.001).	Thioguanine	160-162	interferon lambda 3	Homo sapiens	4-9
26060059-6	2015	The IL28B rs8099917/rs12979860 TT/CC genotype was the most frequent in MC-positive patients with sustained virological response (SVR) (p < 0.001), while the TG/TC genotype was most frequent in non-SVR (p < 0.001).	Technetium	163-165	interferon lambda 3	Homo sapiens	4-9
26060059-9	2015	IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients.	peg-ifn	87-94	interferon lambda 3	Homo sapiens	0-5
26060059-9	2015	IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients.	Ribavirin	99-108	interferon lambda 3	Homo sapiens	0-5
26060059-9	2015	IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients.	Thioguanine	157-159	interferon lambda 3	Homo sapiens	0-5
26060059-9	2015	IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients.	Technetium	160-162	interferon lambda 3	Homo sapiens	0-5
26130141-8	2015	In conclusion, 48-week treatment with Peg-IFN plus weight-based RBV provides a greater SVR rate than 24-week treatment in treatment-naive HCV-2 patients with unfavorable IL-28B genotypes who fail to achieve RVR.	Polyethylene Glycols	38-41	interferon lambda 3	Homo sapiens	170-176
26130141-8	2015	In conclusion, 48-week treatment with Peg-IFN plus weight-based RBV provides a greater SVR rate than 24-week treatment in treatment-naive HCV-2 patients with unfavorable IL-28B genotypes who fail to achieve RVR.	Ribavirin	64-67	interferon lambda 3	Homo sapiens	170-176
26115415-0	2015	The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. The strong impact of interleukin 28B (IL28B) polymorphisms on sustained virological response (SVR) after peginterferon and ribavirin treatment in patients with chronic hepatitis C (CHC) is well-known.	Ribavirin	312-321	interferon lambda 3	Homo sapiens	14-19
26115415-5	2015	We showed that hepatic IFI27, ISG15, and MX1 expression was lower in the IL28B CC 12979860 and TT rs8099917 groups than in the CT-TT rs12979860 and TG-GG rs8099917 groups (P < 0.001).	Thioguanine	148-150	interferon lambda 3	Homo sapiens	73-78
26189761-2	2015	We undertook this study to investigate the distribution of IL28B SNP rs12979860 in Mexican patients with HCV infection and to assess its usefulness in predicting response to pegylated interferon-alpha and ribavirin (PegIFN-alpha/RVB) therapy.	Ribavirin	205-214	interferon lambda 3	Homo sapiens	59-64
26189761-2	2015	We undertook this study to investigate the distribution of IL28B SNP rs12979860 in Mexican patients with HCV infection and to assess its usefulness in predicting response to pegylated interferon-alpha and ribavirin (PegIFN-alpha/RVB) therapy.	pegifn	216-222	interferon lambda 3	Homo sapiens	59-64
26189761-2	2015	We undertook this study to investigate the distribution of IL28B SNP rs12979860 in Mexican patients with HCV infection and to assess its usefulness in predicting response to pegylated interferon-alpha and ribavirin (PegIFN-alpha/RVB) therapy.	methylphenyl carbinol	195-200	interferon lambda 3	Homo sapiens	59-64
26189761-12	2015	Genotyping IL28B SNP rs12979860 is useful to predict the response to a standard regimen with PegIFN-alpha/RVB, especially in those infected with HCV genotype 1.	pegifn-alpha/rvb	93-109	interferon lambda 3	Homo sapiens	11-16
26209404-0	2015	Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population.	Ribavirin	98-107	interferon lambda 3	Homo sapiens	18-23
25501286-2	2015	The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients.	Ribavirin	187-196	interferon lambda 3	Homo sapiens	47-52
25501286-2	2015	The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients.	Ribavirin	198-201	interferon lambda 3	Homo sapiens	47-52
26191484-0	2015	IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naive and treatment-experienced patients other than prior partial- and null-responders.	telaprevir	76-86	interferon lambda 3	Homo sapiens	0-5
26191484-0	2015	IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naive and treatment-experienced patients other than prior partial- and null-responders.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	90-100	interferon lambda 3	Homo sapiens	0-5
26191484-9	2015	Our study suggests that testing for the IL28B rs12979860 genotype may still be useful in predicting response to triple therapy with boceprevir and telaprevir in naive patients and treatment-experienced patients other than partial and null-responders.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	132-142	interferon lambda 3	Homo sapiens	40-45
26191484-9	2015	Our study suggests that testing for the IL28B rs12979860 genotype may still be useful in predicting response to triple therapy with boceprevir and telaprevir in naive patients and treatment-experienced patients other than partial and null-responders.	telaprevir	147-157	interferon lambda 3	Homo sapiens	40-45
24726260-7	2015	Those patients who had a lower value of infectivity ratio and median levels of LDL-cholesterol during the first month of bitherapy also achieved higher rates of sustained virological response: SVR group 100 (23) mg/dl against non-SVR group: 89 (28) mg/dl; odds ratio 1.1; 95% confidence interval (1.0-1.2); P<.05, these differences being more significant for genotype IL-28B-CC (P=.013).	Cholesterol	83-94	interferon lambda 3	Homo sapiens	371-377
25938236-2	2015	The length of thymine--adenine dinucleotide repeats, or (TA)n, in the regulatory region of IL28B can affect interferon transcription.	thymine--adenine dinucleotide	14-43	interferon lambda 3	Homo sapiens	91-96
26096654-0	2015	Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism.	Tryptophan	0-10	interferon lambda 3	Homo sapiens	69-74
26096654-4	2015	In this study, we investigated whether IL28B SNP in patients infected with HCV is related to the tryptophan breakdown rate.	Tryptophan	97-107	interferon lambda 3	Homo sapiens	39-44
25747035-9	2015	Moreover, a significant genotype-genotype interaction between IL-28B rs12979860 CC and PD-1 rs10204525 TC+CC was found to be associated with higher rates of spontaneous clearance (adjusted OR=0.689, P=0.032).	Technetium	103-105	interferon lambda 3	Homo sapiens	62-68
25611696-7	2015	RESULTS: When PBMCs were stimulated with IFNalpha and polyinosinic-polycytidylic acid, IL28B induction was significantly lower in patients with IL28B-unfavorable genotype (rs12979860 CT/TT) than those with IL28B-favorable genotype (rs12979860 CC; P=0.049).	Poly I-C	54-85	interferon lambda 3	Homo sapiens	87-92
25611696-7	2015	RESULTS: When PBMCs were stimulated with IFNalpha and polyinosinic-polycytidylic acid, IL28B induction was significantly lower in patients with IL28B-unfavorable genotype (rs12979860 CT/TT) than those with IL28B-favorable genotype (rs12979860 CC; P=0.049).	Poly I-C	54-85	interferon lambda 3	Homo sapiens	144-149
25611696-7	2015	RESULTS: When PBMCs were stimulated with IFNalpha and polyinosinic-polycytidylic acid, IL28B induction was significantly lower in patients with IL28B-unfavorable genotype (rs12979860 CT/TT) than those with IL28B-favorable genotype (rs12979860 CC; P=0.049).	Poly I-C	54-85	interferon lambda 3	Homo sapiens	144-149
25639146-11	2015	The proportions of IL28B genotypes were 78%, 21%, and 1% for TT/TG/GG at rs8099917, and 81%, 18%, and 1% for CC/TC/TT at rs12979860, respectively.	Thioguanine	64-66	interferon lambda 3	Homo sapiens	19-24
25639146-13	2015	IL28B genotype was significantly associated with SVR in patients infected by genotype 1 but not genotype 6 HCV, with 80% versus 38% of patients infected by genotype 1 achieved SVR carried TT versus TG/GG at rs8099917, respectively (P=0.003).	Thioguanine	198-200	interferon lambda 3	Homo sapiens	0-5
25382001-2	2015	Interferon alpha (IFNalpha) sensitivity in liver and IL28B genotype has been identified as important determinants of HCV clearance in the setting of pegylated interferon/ribavirin treatment.	Ribavirin	170-179	interferon lambda 3	Homo sapiens	53-58
25652367-0	2015	IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. The aim of this study was to describe the genetic characteristics of Pakistani patients infected with hepatitis C virus (HCV) in relation to IL28B polymorphisms and its association to interferon and ribavirin treatment response.	Ribavirin	322-331	interferon lambda 3	Homo sapiens	0-5
24849518-0	2015	Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.	telaprevir	66-76	interferon lambda 3	Homo sapiens	152-157
25703417-1	2015	Hepatitis C virus (HCV) genotypes and genetic variants of interleukin 28B (IL28B) are significantly associated with interferon plus ribavirin treatment of HCV infection.	Ribavirin	132-141	interferon lambda 3	Homo sapiens	75-80
25852275-8	2015	CONCLUSION: In response-guided Peg-IFNalpha/RBV combination therapy for chronically HCV G2-infected patients, the impact of the IFNL3 genotype on SVR was limited to non-RVR patients.	peg-ifnalpha	31-43	interferon lambda 3	Homo sapiens	128-133
25852275-8	2015	CONCLUSION: In response-guided Peg-IFNalpha/RBV combination therapy for chronically HCV G2-infected patients, the impact of the IFNL3 genotype on SVR was limited to non-RVR patients.	Ribavirin	44-47	interferon lambda 3	Homo sapiens	128-133
25687192-1	2015	Although the single-nucleotide polymorphism (SNP) rs12979860 in the IL28B gene is a better predictor of sustained virological response to treatment of chronic hepatitis C (CHC) than other baseline factors, some CHC patients with the favorable C allele cannot achieve a sustained virological response when treated with peginterferon plus ribavirin.	Ribavirin	337-346	interferon lambda 3	Homo sapiens	68-73
24849518-1	2015	AIM: Single nucleotide polymorphisms (SNP) near the interleukin-28B (IL28B) gene affect the outcome of 24-week telaprevir-based triple therapy with telaprevir, pegylated interferon-alpha and ribavirin for chronic hepatitis C virus (HCV) genotype 1b patients.	telaprevir	111-121	interferon lambda 3	Homo sapiens	69-74
24849518-1	2015	AIM: Single nucleotide polymorphisms (SNP) near the interleukin-28B (IL28B) gene affect the outcome of 24-week telaprevir-based triple therapy with telaprevir, pegylated interferon-alpha and ribavirin for chronic hepatitis C virus (HCV) genotype 1b patients.	telaprevir	148-158	interferon lambda 3	Homo sapiens	69-74
24849518-1	2015	AIM: Single nucleotide polymorphisms (SNP) near the interleukin-28B (IL28B) gene affect the outcome of 24-week telaprevir-based triple therapy with telaprevir, pegylated interferon-alpha and ribavirin for chronic hepatitis C virus (HCV) genotype 1b patients.	Ribavirin	191-200	interferon lambda 3	Homo sapiens	69-74
24849518-9	2015	CONCLUSION: In HCV genotype 1b patients with the minor IL28B SNP rs8099917 genotype, evaluating prior treatment response and achieving RVR and pretreatment serum fasting LDL-C concentrations were useful for predicting SVR achievement after 24-week telaprevir-based triple therapy.	telaprevir	248-258	interferon lambda 3	Homo sapiens	55-60
24840315-1	2015	BACKGROUND & AIMS: Aim of this study was to investigate whether a potential association exists between several single nucleotide polymorphisms (SNPs) of the IL-28B gene (rs12979860, rs1188122, rs8099917, rs8105790, rs12980275) and HBsAg persistence.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	161-167
25938745-1	2015	Single nucleotide polymorphisms (SNPs) of the IL28B locus are associated with a positive response to pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV) treatment of HCV-infected patients.	Ribavirin	132-141	interferon lambda 3	Homo sapiens	46-51
25703417-9	2015	In conclusion, HCV genotypes and IL28B rs12979860 are predictive markers for the efficiency of interferon plus ribavirin combinational therapy of HCV infection.	Ribavirin	111-120	interferon lambda 3	Homo sapiens	33-38
25041342-1	2015	BACKGROUND & AIMS: Several genome-wide association studies have revealed that HLA-DP/DQ, STAT4 and IL-28B associated with liver diseases.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	103-109
25391769-14	2015	Further studies are needed to determine the possible association between IL28B variants and response to pegylated-interferon-alpha plus ribavirin combination therapy among Filipino patients chronically infected with HBV.	Ribavirin	136-145	interferon lambda 3	Homo sapiens	73-78
25675103-3	2015	Recently, a dinucleotide polymorphism, ss469415590 (TT or DeltaG), has been discovered in the region upstream IFNL3 gene, which is in high linkage disequilibrium with rs12979860.	Dinucleoside Phosphates	12-24	interferon lambda 3	Homo sapiens	110-115
24517415-1	2015	AIMS: To investigate whether IL28B polymorphisms could affect the treatment response to peginterferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients in the Chinese Han population.	peg-ifn	109-116	interferon lambda 3	Homo sapiens	29-34
24910341-1	2014	Our in vitro study revealed that the numbers of (TA) dinucleotide repeats [(TA)n] of rs72258881, which is located in the promoter region of IL28B gene, might regulate IL28B transcription.	(ta) dinucleotide	48-65	interferon lambda 3	Homo sapiens	140-145
25039676-1	2015	BACKGROUND & AIMS: Different prevalence of favourable IL28BCC genotype have been reported in studies performed in different countries around the world.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	58-62
25470790-0	2015	Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.	telaprevir	51-61	interferon lambda 3	Homo sapiens	10-15
25470790-1	2015	BACKGROUND: IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR).	Ribavirin	96-105	interferon lambda 3	Homo sapiens	12-17
26078754-3	2015	In addition, single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL-28B, correlate strongly with the ability to achieve a sustained virological response (SVR) to therapy with pegylated IFN-alpha plus ribavirin in patients infected with chronic hepatitis C. Furthermore, we also discuss the most recent findings: IFN-lambda4 predicts treatment outcomes of HCV infection.	Ribavirin	220-229	interferon lambda 3	Homo sapiens	67-78
26078754-3	2015	In addition, single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL-28B, correlate strongly with the ability to achieve a sustained virological response (SVR) to therapy with pegylated IFN-alpha plus ribavirin in patients infected with chronic hepatitis C. Furthermore, we also discuss the most recent findings: IFN-lambda4 predicts treatment outcomes of HCV infection.	Ribavirin	220-229	interferon lambda 3	Homo sapiens	85-91
24995561-3	2015	The aim of this study was to investigate whether the SNP of IL28B (rs8099917) and amino acid substitutions in the NS5A region in patients with HCV genotype 2 affect the response to IFN and ribavirin combination therapy.	Ribavirin	189-198	interferon lambda 3	Homo sapiens	60-65
25811035-1	2015	Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients.	peg-ifn-a	121-130	interferon lambda 3	Homo sapiens	61-76
25811035-1	2015	Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients.	peg-ifn-a	121-130	interferon lambda 3	Homo sapiens	78-84
25811035-1	2015	Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients.	Ribavirin	131-134	interferon lambda 3	Homo sapiens	61-76
25811035-1	2015	Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients.	Ribavirin	131-134	interferon lambda 3	Homo sapiens	78-84
26021070-1	2015	The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin.	Ribavirin	272-281	interferon lambda 3	Homo sapiens	100-106
25764680-2	2015	A multicenter prospective study revealed that the triple therapy with telaprevir administered according to an algorithm based on the drug adherence, IL28B polymorphism and viral response yielded a high SVR rate through attenuation of viral relapse by prolonged ribavirin/Peg-IFN-alpha2b administration.	telaprevir	70-80	interferon lambda 3	Homo sapiens	149-154
26109548-6	2015	PHH stimulation with cytoplasmic poly I:C induced >1,000-fold expression of IFNL1, IFNL2 and IFNL3.	Poly I	33-39	interferon lambda 3	Homo sapiens	96-101
25462177-5	2015	METHODS: One hundred and fifty HCV genotype 3 patients were assessed to study the correlation of IL28B with a therapeutic regimen of PEG-IFN alpha plus ribavirin.	peg-ifn alpha	133-146	interferon lambda 3	Homo sapiens	97-102
25462177-5	2015	METHODS: One hundred and fifty HCV genotype 3 patients were assessed to study the correlation of IL28B with a therapeutic regimen of PEG-IFN alpha plus ribavirin.	Ribavirin	152-161	interferon lambda 3	Homo sapiens	97-102
25742144-9	2015	In a real life setting, the importance of RVR and IL28B SNPs was confirmed as predictive of SVR to identify patients with a higher likelihood of SVR to Peg-INF?+RBV, and also to designate a deferred therapy for patients with a low likelihood of SVR for whom it is preferable to wait for more successful options.	peg-inf	152-159	interferon lambda 3	Homo sapiens	50-55
25742144-9	2015	In a real life setting, the importance of RVR and IL28B SNPs was confirmed as predictive of SVR to identify patients with a higher likelihood of SVR to Peg-INF?+RBV, and also to designate a deferred therapy for patients with a low likelihood of SVR for whom it is preferable to wait for more successful options.	Ribavirin	161-164	interferon lambda 3	Homo sapiens	50-55
27785282-2	2014	We aimed to evaluate the treatment response of chronic HCV infection patients to pegile interferon (pegIFN) and ribavirin treatment with regard to IL28B rs12979860 C/T polymorphism.	pegifn	100-106	interferon lambda 3	Homo sapiens	147-152
27785282-2	2014	We aimed to evaluate the treatment response of chronic HCV infection patients to pegile interferon (pegIFN) and ribavirin treatment with regard to IL28B rs12979860 C/T polymorphism.	Ribavirin	112-121	interferon lambda 3	Homo sapiens	147-152
24612030-8	2014	Importantly, it seems that the IL28B status of the patients may influence the presence of Y93H mutations, resulting in different treatment responses to daclatasvir.	daclatasvir	152-163	interferon lambda 3	Homo sapiens	31-36
24628684-8	2014	CONCLUSION: Baseline serum IP-10 level is a useful predictor of virological response in patients with genotype 1 CHC treated with TVR-based triple therapy, especially in patients with IL28B risk allele.	telaprevir	130-133	interferon lambda 3	Homo sapiens	184-189
24910341-1	2014	Our in vitro study revealed that the numbers of (TA) dinucleotide repeats [(TA)n] of rs72258881, which is located in the promoter region of IL28B gene, might regulate IL28B transcription.	(ta) dinucleotide	48-65	interferon lambda 3	Homo sapiens	167-172
24910341-8	2014	CONCLUSIONS: IL28B genotype and (TA)n of rs72258881 may independently affect virological outcomes of peginterferon-alpha and ribavirin as host factors, even in response-guided therapy.	Ribavirin	125-134	interferon lambda 3	Homo sapiens	13-18
25393304-7	2014	Prediction of SVR with high accuracy (71-96%) was possible in genotype 1, 2, 3 and 4 infected patients who received PEG-IFN/ribavirin combination therapy by selection of beneficial IL28B rs12979860 C/C and/or ss469415590 TT/TT genotypes (p<0.001).	peg-ifn	116-123	interferon lambda 3	Homo sapiens	181-186
24417888-13	2014	Stratified analyses according to core a.a.70 substitution and IL28B genotype suggested that 25-hydroxyvitamin D3 influences the outcome of PEG IFN/RBV therapy for cirrhosis.	hydroxyvitamin d3	95-112	interferon lambda 3	Homo sapiens	62-67
24417888-13	2014	Stratified analyses according to core a.a.70 substitution and IL28B genotype suggested that 25-hydroxyvitamin D3 influences the outcome of PEG IFN/RBV therapy for cirrhosis.	Polyethylene Glycols	139-142	interferon lambda 3	Homo sapiens	62-67
25393304-7	2014	Prediction of SVR with high accuracy (71-96%) was possible in genotype 1, 2, 3 and 4 infected patients who received PEG-IFN/ribavirin combination therapy by selection of beneficial IL28B rs12979860 C/C and/or ss469415590 TT/TT genotypes (p<0.001).	Ribavirin	124-133	interferon lambda 3	Homo sapiens	181-186
25469117-10	2014	The genotypes of IL28B rs8099917, rs12979860, rs7248668, MxA rs2071430, and MxA rs17000900 were strong SVR predictors for PEG-IFN/ ribavirin -treated HCV patients in Han Chinese population.	peg-ifn	122-129	interferon lambda 3	Homo sapiens	17-22
25469117-10	2014	The genotypes of IL28B rs8099917, rs12979860, rs7248668, MxA rs2071430, and MxA rs17000900 were strong SVR predictors for PEG-IFN/ ribavirin -treated HCV patients in Han Chinese population.	Ribavirin	131-140	interferon lambda 3	Homo sapiens	17-22
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	192-204
24287582-1	2014	BACKGROUND: Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy.	telaprevir	193-203	interferon lambda 3	Homo sapiens	39-54
24287582-1	2014	BACKGROUND: Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy.	telaprevir	193-203	interferon lambda 3	Homo sapiens	56-61
24287582-1	2014	BACKGROUND: Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy.	telaprevir	205-208	interferon lambda 3	Homo sapiens	39-54
24287582-1	2014	BACKGROUND: Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy.	telaprevir	205-208	interferon lambda 3	Homo sapiens	56-61
24287582-6	2014	RESULTS: Multiple logistic regression analysis for SVR in TVR-based therapy identified the IL28B TT genotype, a reduction of >= 4.7 log10 IU/mL in HCV RNA levels at week 1, RVR, and treatment-naive/relapse.	telaprevir	58-61	interferon lambda 3	Homo sapiens	91-96
25130512-1	2014	BACKGROUND: Recent studies in chronic hepatitis C patients have shown that rs368234815 polymorphism nearby IL28B is a better predictor of response to antiviral treatment with pegylated interferon and ribavirin than IL28B polymorphisms (rs12979860 and rs8099917).	Ribavirin	200-209	interferon lambda 3	Homo sapiens	107-112
25130512-1	2014	BACKGROUND: Recent studies in chronic hepatitis C patients have shown that rs368234815 polymorphism nearby IL28B is a better predictor of response to antiviral treatment with pegylated interferon and ribavirin than IL28B polymorphisms (rs12979860 and rs8099917).	Ribavirin	200-209	interferon lambda 3	Homo sapiens	215-220
25657752-0	2014	Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus.	Ribavirin	91-100	interferon lambda 3	Homo sapiens	0-15
25349647-7	2014	IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 3.38, 14.66, 7.84 and 2.91, respectively.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	95-105	interferon lambda 3	Homo sapiens	0-6
25349647-7	2014	IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 3.38, 14.66, 7.84 and 2.91, respectively.	Simeprevir	107-117	interferon lambda 3	Homo sapiens	0-6
25349647-7	2014	IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 3.38, 14.66, 7.84 and 2.91, respectively.	telaprevir	119-129	interferon lambda 3	Homo sapiens	0-6
25349647-7	2014	IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 3.38, 14.66, 7.84 and 2.91, respectively.	vaniprevir	133-143	interferon lambda 3	Homo sapiens	0-6
23841718-0	2014	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection.	Ribavirin	82-91	interferon lambda 3	Homo sapiens	15-20
23841718-0	2014	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection.	Ribavirin	287-296	interferon lambda 3	Homo sapiens	15-20
23841718-0	2014	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection.	peg-ifn	298-305	interferon lambda 3	Homo sapiens	15-20
23841718-0	2014	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection.	Ribavirin	306-309	interferon lambda 3	Homo sapiens	15-20
23841718-0	2014	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection.	peg-ifn	492-499	interferon lambda 3	Homo sapiens	15-20
23841718-0	2014	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. AIM: The objective of the current study was to find baseline predictive factors of response to therapy with pegylated interferon and ribavirin (PEG-IFN/RBV therapy) in children and adolescents with chronic hepatitis C. METHODS: IL28B genotype and mutations in the core of hepatitis C virus (HCV) were analyzed in 30 patients treated with PEG-IFN/RBV for HCV infection.	Ribavirin	500-503	interferon lambda 3	Homo sapiens	15-20
25219480-0	2014	Biliary strictures after liver transplantation: role of interleukin 28B genotypes in cyclosporine treated.	Cyclosporine	85-97	interferon lambda 3	Homo sapiens	56-71
25219480-9	2014	IL-28B rs12979860C/C genotype in association with cyclosporin was found to be an independent predictor of anastomotic strictures occurrence (p = 0.008).	Cyclosporine	50-61	interferon lambda 3	Homo sapiens	0-6
25219480-11	2014	CONCLUSIONS: In recipients carrying rs12979860 IL-28B C/C genotype the use of cyclosporine seems to contribute to enhance the probability of developing biliary complications which in hepatitis B and C positives appear to reduce patient survival.	Cyclosporine	78-90	interferon lambda 3	Homo sapiens	47-53
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	261-266
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Dinucleoside Phosphates	115-127	interferon lambda 3	Homo sapiens	192-204
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Dinucleoside Phosphates	115-127	interferon lambda 3	Homo sapiens	261-266
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Polyethylene Glycols	334-337	interferon lambda 3	Homo sapiens	192-204
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Polyethylene Glycols	334-337	interferon lambda 3	Homo sapiens	261-266
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Ribavirin	353-362	interferon lambda 3	Homo sapiens	192-204
25283962-1	2014	BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin.	Ribavirin	353-362	interferon lambda 3	Homo sapiens	261-266
25132781-9	2014	CONCLUSION: The IL28B genotype was linked to an impact on early viral kinetics in response to PEG-IFN/RBV therapy in HCV-6 infected patients.	Polyethylene Glycols	94-97	interferon lambda 3	Homo sapiens	16-21
25278709-0	2014	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.	Ribavirin	94-103	interferon lambda 3	Homo sapiens	0-5
25232239-1	2014	Interleukin (IL) 28B genetic polymorphism is significantly associated with the sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-alpha (PEG-IFN) plus ribavirin and with spontaneous hepatitis C virus clearance.	Ribavirin	207-216	interferon lambda 3	Homo sapiens	0-20
24602156-6	2014	CONCLUSIONS: Mericitabine-containing triple therapy reduces the impact of IL28B genotype on RVR and cEVR compared with peginterferon alfa-2a and ribavirin dual therapy.	2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine	13-25	interferon lambda 3	Homo sapiens	74-79
25059552-2	2014	Daclatasvir combined with peginterferon alpha-2a and ribavirin in Japanese patients infected with genotype 1b HCV achieved sustained virological response (SVR) in 100% of treatment-naive patients, due to high rates of favorable IL28B allele and genotype 1b.	daclatasvir	0-11	interferon lambda 3	Homo sapiens	228-233
25059552-2	2014	Daclatasvir combined with peginterferon alpha-2a and ribavirin in Japanese patients infected with genotype 1b HCV achieved sustained virological response (SVR) in 100% of treatment-naive patients, due to high rates of favorable IL28B allele and genotype 1b.	Ribavirin	53-62	interferon lambda 3	Homo sapiens	228-233
24400682-11	2014	In those with G1H, IL28B polymorphism may predict SVR and guide treatment duration: SVR rates were higher in those with the TT allele treated for more than 48 weeks and those with the TG/GG alleles treated for more than 72 weeks.	Thioguanine	184-186	interferon lambda 3	Homo sapiens	19-24
25132781-9	2014	CONCLUSION: The IL28B genotype was linked to an impact on early viral kinetics in response to PEG-IFN/RBV therapy in HCV-6 infected patients.	Ribavirin	102-105	interferon lambda 3	Homo sapiens	16-21
25337144-0	2014	The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin.	Ribavirin	130-139	interferon lambda 3	Homo sapiens	12-27
25337144-1	2014	BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan.	Ribavirin	176-185	interferon lambda 3	Homo sapiens	12-27
25337144-1	2014	BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan.	Ribavirin	176-185	interferon lambda 3	Homo sapiens	29-34
24911972-7	2014	In particular, the presence of these polymorphisms may be of relevance in poorly interferon-responsive patients (i.e., null responders and non-CC IL28B) under DAA-based therapies in combination with pegylated interferon-alpha plus ribavirin.	daa	159-162	interferon lambda 3	Homo sapiens	146-151
24929144-6	2014	In conclusion, IL28B and KIR3DL1/HLA-Bw4 are independent predictors of an SVR in Japanese patients infected with genotype 1b HCV receiving TVR/PEG-IFN/RBV or PEG-IFN/RBV therapy.	telaprevir	139-142	interferon lambda 3	Homo sapiens	15-20
24929144-6	2014	In conclusion, IL28B and KIR3DL1/HLA-Bw4 are independent predictors of an SVR in Japanese patients infected with genotype 1b HCV receiving TVR/PEG-IFN/RBV or PEG-IFN/RBV therapy.	Ribavirin	151-154	interferon lambda 3	Homo sapiens	15-20
24929144-6	2014	In conclusion, IL28B and KIR3DL1/HLA-Bw4 are independent predictors of an SVR in Japanese patients infected with genotype 1b HCV receiving TVR/PEG-IFN/RBV or PEG-IFN/RBV therapy.	Ribavirin	166-169	interferon lambda 3	Homo sapiens	15-20
24994464-0	2014	Low IL10 serum levels as key factor for predicting the sustained virological response to IFNalpha/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.	Ribavirin	98-107	interferon lambda 3	Homo sapiens	148-153
24994464-1	2014	PROPOSE: IL28B polymorphisms rs12979860 CC genotype was associated to protection of HCV infection and sustained virological response (SVR) in HCV infected patients treated with pegIFNalpha/ribavirin (IFNalpha/RIB), however, this polymorphism frequency varies depending on genetic components.	pegifnalpha	177-188	interferon lambda 3	Homo sapiens	9-14
24994464-1	2014	PROPOSE: IL28B polymorphisms rs12979860 CC genotype was associated to protection of HCV infection and sustained virological response (SVR) in HCV infected patients treated with pegIFNalpha/ribavirin (IFNalpha/RIB), however, this polymorphism frequency varies depending on genetic components.	Ribavirin	189-198	interferon lambda 3	Homo sapiens	9-14
24768758-1	2014	BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	92-97
24768758-1	2014	BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection.	Ribavirin	237-246	interferon lambda 3	Homo sapiens	92-97
24118788-1	2014	BACKGROUND & AIMS: Several genome-wide association studies have shown that genetic variations in the chromosomal region containing interleukin-28B (IL28B) gene are associated with response to treatment in hepatitis C virus (HCV) infection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	152-157
25071317-2	2014	Many studies in adults have demonstrated that genetic variation in IFNL3 is a strong predictor of the virological response in treatment-naive patients with HCV genotype 1 who were treated with Pegylated-IFN-alpha and ribavirin.	Ribavirin	217-226	interferon lambda 3	Homo sapiens	67-72
25013899-11	2014	CONCLUSIONS: In HIV/HCV coinfected patients with HCV genotypes 1 or 4, RVR, mainly influenced by genotype IL28B and HCV-RNA levels, reliably predicted SVR after 4 weeks of therapy with Peg-IFN plus RBV.	peg-ifn	185-192	interferon lambda 3	Homo sapiens	106-111
24400682-0	2014	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.	Ribavirin	54-63	interferon lambda 3	Homo sapiens	0-15
25337144-1	2014	BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan.	peg-ifn	187-194	interferon lambda 3	Homo sapiens	12-27
25337144-1	2014	BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan.	peg-ifn	187-194	interferon lambda 3	Homo sapiens	29-34
25337144-1	2014	BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan.	Ribavirin	195-198	interferon lambda 3	Homo sapiens	12-27
25337144-1	2014	BACKGROUND: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) rs8099917 has been described to be associated with response to treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) in patients with chronic hepatitis C from the North America, Europe, Asia countries like Japan and Taiwan.	Ribavirin	195-198	interferon lambda 3	Homo sapiens	29-34
24726902-0	2014	Identification of naive HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.	Ribavirin	88-97	interferon lambda 3	Homo sapiens	111-116
24750345-10	2014	In conclusion, ITPA genetic variants were associated with severe RBV-induced anaemia and could influence the efficacy of PEG-IFN plus RBV treatment among elderly patients with IL28B favourable type.	Ribavirin	65-68	interferon lambda 3	Homo sapiens	176-181
24750345-10	2014	In conclusion, ITPA genetic variants were associated with severe RBV-induced anaemia and could influence the efficacy of PEG-IFN plus RBV treatment among elderly patients with IL28B favourable type.	peg-ifn	121-128	interferon lambda 3	Homo sapiens	176-181
24750345-10	2014	In conclusion, ITPA genetic variants were associated with severe RBV-induced anaemia and could influence the efficacy of PEG-IFN plus RBV treatment among elderly patients with IL28B favourable type.	Ribavirin	134-137	interferon lambda 3	Homo sapiens	176-181
24102823-1	2014	BACKGROUND: A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-alpha (PEG IFNalpha) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1.	Polyethylene Glycols	143-146	interferon lambda 3	Homo sapiens	83-88
24102823-1	2014	BACKGROUND: A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-alpha (PEG IFNalpha) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1.	Ribavirin	161-170	interferon lambda 3	Homo sapiens	83-88
24102823-1	2014	BACKGROUND: A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-alpha (PEG IFNalpha) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1.	Ribavirin	172-175	interferon lambda 3	Homo sapiens	83-88
24969847-1	2014	BACKGROUND: The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV).	Ribavirin	324-333	interferon lambda 3	Homo sapiens	134-140
24969847-1	2014	BACKGROUND: The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNalpha-RBV).	peg-ifnalpha-rbv	335-351	interferon lambda 3	Homo sapiens	134-140
24969847-8	2014	CONCLUSIONS: These results suggest that SNPs of IL-28B and MRC-1 can be used as genetic markers for predicting the outcome of PEG-IFNalpha-RBV treatment of HCV infections.	peg-ifnalpha-rbv	126-142	interferon lambda 3	Homo sapiens	48-54
24792632-1	2014	OBJECTIVE: Recent genome-wide association studies performed in adults correlated single-nucleotide polymorphisms (SNPs rs12979860 and rs8099917) located on chromosome 19, upstream of the interleukin 28B gene, with spontaneous clearance of hepatitis C virus and with response to treatment with paginated interferon and ribavirin.	Ribavirin	318-327	interferon lambda 3	Homo sapiens	187-202
25032184-1	2014	BACKGROUND/AIMS: There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients.	peg-ifn	227-234	interferon lambda 3	Homo sapiens	161-166
25032184-1	2014	BACKGROUND/AIMS: There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients.	Ribavirin	241-250	interferon lambda 3	Homo sapiens	161-166
25032184-1	2014	BACKGROUND/AIMS: There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients.	Ribavirin	252-255	interferon lambda 3	Homo sapiens	161-166
24654629-4	2014	RESULTS: A landmark genome-wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance.	Ribavirin	210-219	interferon lambda 3	Homo sapiens	89-94
24654629-4	2014	RESULTS: A landmark genome-wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance.	Ribavirin	221-224	interferon lambda 3	Homo sapiens	89-94
24654629-8	2014	In chronic hepatitis B patients treated with PEG-IFN several retrospective analyses of IL28B rs12980275 and rs12979860 genotypes yielded conflicting results which can be explained by the heterogeneity between the study populations.	peg-ifn	45-52	interferon lambda 3	Homo sapiens	87-92
24654629-10	2014	CONCLUSIONS: The determination of IL28B polymorphisms may be useful to individualise treatment options when using PEG/RBV based therapies for chronic hepatitis C infection.	Polyethylene Glycols	114-117	interferon lambda 3	Homo sapiens	34-39
24654629-10	2014	CONCLUSIONS: The determination of IL28B polymorphisms may be useful to individualise treatment options when using PEG/RBV based therapies for chronic hepatitis C infection.	Ribavirin	118-121	interferon lambda 3	Homo sapiens	34-39
24367041-3	2014	We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies.	daa	44-47	interferon lambda 3	Homo sapiens	252-263
24367041-3	2014	We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies.	Sofosbuvir	48-58	interferon lambda 3	Homo sapiens	252-263
24367041-3	2014	We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies.	Ribavirin	70-73	interferon lambda 3	Homo sapiens	252-263
24672032-1	2014	IFNL3 (lambda-3 interferon gene) polymorphisms and the expression of miR-122 have been associated with sustained virological response (SVR) to treatment with pegylated interferon plus ribavirin in patients with chronic hepatitis C (CHC).	Ribavirin	184-193	interferon lambda 3	Homo sapiens	0-5
24316030-10	2014	IL28-B polymorphisms are related to different response in the treatment of CHB HBeAg-negative with PEG-IFN, and the E genotype is a novel negative predictive factor.	peg-ifn	99-106	interferon lambda 3	Homo sapiens	0-6
24415442-4	2014	The association of IL28b polymorphism with virological response was studied in 356 patients with genotype 3 chronic HCV undergoing treatment with peg-interferon and ribavirin and was compared with matched controls.	Ribavirin	165-174	interferon lambda 3	Homo sapiens	19-24
24532585-3	2014	IL-28B is a type III IFN, and genetic polymorphisms upstream of its gene are strongly associated with the efficacy of polyethylene glycol-IFN and ribavirin therapy.	polyethylene glycol-ifn	118-141	interferon lambda 3	Homo sapiens	0-6
24532585-3	2014	IL-28B is a type III IFN, and genetic polymorphisms upstream of its gene are strongly associated with the efficacy of polyethylene glycol-IFN and ribavirin therapy.	Ribavirin	146-155	interferon lambda 3	Homo sapiens	0-6
23689989-1	2014	BACKGROUND: IL28B polymorphisms were shown to be associated with a response to peg-interferon-based treatment in chronic hepatitis C (CHC) and spontaneous clearance.	Polyethylene Glycols	79-82	interferon lambda 3	Homo sapiens	12-17
24642705-13	2014	CONCLUSIONS: The favorable IL-28B rs12979860 genotype is a statistically significant predictor of SVR, RVR and ETR in HCV-4 monoinfected patients treated with Peg-IFN plus Rbv.	peg-ifn	159-166	interferon lambda 3	Homo sapiens	27-33
24642705-13	2014	CONCLUSIONS: The favorable IL-28B rs12979860 genotype is a statistically significant predictor of SVR, RVR and ETR in HCV-4 monoinfected patients treated with Peg-IFN plus Rbv.	Ribavirin	172-175	interferon lambda 3	Homo sapiens	27-33
24637774-1	2014	BACKGROUND & AIMS: IL28B polymorphisms were shown to be strongly associated with the response to interferon therapy in chronic hepatitis C (CHC) and spontaneous viral clearance.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	23-28
24387618-6	2014	In genotype 1 (G1) patients, the addition of sofosbuvir to peginterferon plus ribavirin yielded sustained virological response rates at week 12 after discontinuation of treatment (SVR12) of about 90% with slightly lower levels in G1b and in patients with cirrhosis, but with no major impact of IL28B genotype, high viral load, body mass index (BMI), alanine aminotransferase (ALT) or race/ethnicity.	Sofosbuvir	45-55	interferon lambda 3	Homo sapiens	294-299
24166425-0	2014	alpha-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.	telaprevir	76-86	interferon lambda 3	Homo sapiens	183-188
23978349-1	2014	BACKGROUND & AIMS: Interleukin (IL)-28B (interferon-lambda 3) genotype is the strongest predictor of response of patients with hepatitis C virus (HCV) infection to antiviral therapy.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	23-43
23978349-1	2014	BACKGROUND & AIMS: Interleukin (IL)-28B (interferon-lambda 3) genotype is the strongest predictor of response of patients with hepatitis C virus (HCV) infection to antiviral therapy.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	45-64
24338811-7	2014	HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (>=1.40 m/sec) experienced a non-virologic response (6/6).	peg-ifn	115-122	interferon lambda 3	Homo sapiens	46-51
24338811-7	2014	HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (>=1.40 m/sec) experienced a non-virologic response (6/6).	peg-ifn	115-122	interferon lambda 3	Homo sapiens	256-261
24338811-7	2014	HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (>=1.40 m/sec) experienced a non-virologic response (6/6).	Ribavirin	128-137	interferon lambda 3	Homo sapiens	46-51
24338811-7	2014	HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (>=1.40 m/sec) experienced a non-virologic response (6/6).	Ribavirin	128-137	interferon lambda 3	Homo sapiens	256-261
24338811-9	2014	It is concluded that the combination of ARFI at cut off of 1.4 m/sec and IL28B may be useful for patients with chronic hepatitis C with genotype 1 treated with peg-IFN/ribavirin combination therapy.	peg-ifn	160-167	interferon lambda 3	Homo sapiens	73-78
24338811-9	2014	It is concluded that the combination of ARFI at cut off of 1.4 m/sec and IL28B may be useful for patients with chronic hepatitis C with genotype 1 treated with peg-IFN/ribavirin combination therapy.	Ribavirin	168-177	interferon lambda 3	Homo sapiens	73-78
24022240-5	2014	In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-lambda3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients.	Ribavirin	236-239	interferon lambda 3	Homo sapiens	123-128
24398031-1	2014	BACKGROUND: Previous studies have shown that single nucleotide polymorphisms (SNP) in IL28B and IL10R are associated with sustained virological response (SVR) in chronic hepatitis C patients treated with pegilated interferon plus ribavirin (P/R).	Ribavirin	230-239	interferon lambda 3	Homo sapiens	86-91
24081655-5	2014	CONCLUSION: Ophthalmologic examinations should be done carefully during triple therapy, since the incidence was higher than that in previous Peg-IFN therapy, and lesions may develop as adverse effects by telaprevir, but not by Peg-IFN, especially in those showing preferable IL28B SNPs allele and/or anemia during the therapy.	telaprevir	204-214	interferon lambda 3	Homo sapiens	275-280
24325405-1	2014	Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV.	peg-ifn	165-172	interferon lambda 3	Homo sapiens	63-78
24325405-1	2014	Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV.	peg-ifn	165-172	interferon lambda 3	Homo sapiens	80-85
24325405-1	2014	Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV.	Ribavirin	178-187	interferon lambda 3	Homo sapiens	63-78
24325405-1	2014	Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV.	Ribavirin	178-187	interferon lambda 3	Homo sapiens	80-85
24325405-1	2014	Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV.	Ribavirin	189-192	interferon lambda 3	Homo sapiens	63-78
24325405-1	2014	Genome-wide association studies recently revealed that certain interleukin-28B (IL28B) polymorphisms are strongly associated with responses to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients chronically infected with hepatitis C virus (HCV) genotype 1, as well as with spontaneous clearance of HCV.	Ribavirin	189-192	interferon lambda 3	Homo sapiens	80-85
24553484-6	2014	Severe steatosis and the minor alleles of IL28B SNP were significantly associated with null or partial virological response in patients with HCV genotype 1, as were female gender, and low LDL cholesterol (p=0.049, and <0.001, respectively).	Cholesterol	192-203	interferon lambda 3	Homo sapiens	42-47
24162072-11	2014	CONCLUSIONS: Evaluations of viral reduction at 2 weeks or both IL-28B and ISDR are useful to predict SVR to low-dose PEG-IFN-alpha2a plus ribavirin therapy for elderly and/or cirrhotic patients.	Ribavirin	138-147	interferon lambda 3	Homo sapiens	63-69
24523350-1	2014	BACKGROUND: In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported.	peg-ifn	201-208	interferon lambda 3	Homo sapiens	75-80
24523350-1	2014	BACKGROUND: In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported.	Ribavirin	214-223	interferon lambda 3	Homo sapiens	75-80
24523350-1	2014	BACKGROUND: In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported.	Ribavirin	225-228	interferon lambda 3	Homo sapiens	75-80
24117654-0	2014	Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.	telaprevir	41-51	interferon lambda 3	Homo sapiens	10-15
24205831-0	2014	Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC).	Ribavirin	92-101	interferon lambda 3	Homo sapiens	40-45
24205831-0	2014	Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC).	Ribavirin	92-101	interferon lambda 3	Homo sapiens	156-161
24205831-0	2014	Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC).	Ribavirin	219-228	interferon lambda 3	Homo sapiens	156-161
24205831-0	2014	Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC).	Polyethylene Glycols	230-233	interferon lambda 3	Homo sapiens	156-161
24205831-0	2014	Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC).	Ribavirin	234-237	interferon lambda 3	Homo sapiens	156-161
24192751-0	2014	Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-alpha2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	telaprevir	0-10	interferon lambda 3	Homo sapiens	132-137
25328696-6	2014	In conclusion, evaluation of viral reduction at 2 weeks or the combination of IL28B polymorphism and amino acid substitution at core 70 are useful for predicting SVR to telaprevir with PEG-IFN and ribavirin therapy.	telaprevir	169-179	interferon lambda 3	Homo sapiens	78-83
25328696-6	2014	In conclusion, evaluation of viral reduction at 2 weeks or the combination of IL28B polymorphism and amino acid substitution at core 70 are useful for predicting SVR to telaprevir with PEG-IFN and ribavirin therapy.	peg-ifn	185-192	interferon lambda 3	Homo sapiens	78-83
25328696-6	2014	In conclusion, evaluation of viral reduction at 2 weeks or the combination of IL28B polymorphism and amino acid substitution at core 70 are useful for predicting SVR to telaprevir with PEG-IFN and ribavirin therapy.	Ribavirin	197-206	interferon lambda 3	Homo sapiens	78-83
23591768-0	2014	Ex vivo induction of IFN-lambda3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.	peg-ifn	74-81	interferon lambda 3	Homo sapiens	21-32
23591768-0	2014	Ex vivo induction of IFN-lambda3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.	Ribavirin	82-91	interferon lambda 3	Homo sapiens	21-32
23591768-1	2014	BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC).	Ribavirin	137-146	interferon lambda 3	Homo sapiens	54-59
23591768-1	2014	BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC).	Ribavirin	137-146	interferon lambda 3	Homo sapiens	71-82
23591768-1	2014	BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC).	peg-ifn	148-155	interferon lambda 3	Homo sapiens	54-59
23591768-1	2014	BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC).	peg-ifn	148-155	interferon lambda 3	Homo sapiens	71-82
23591768-1	2014	BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC).	Ribavirin	156-159	interferon lambda 3	Homo sapiens	54-59
23591768-1	2014	BACKGROUND: Genetic variation around interleukin-28B (IL28B), encoding IFN-lambda3, predict non-responders to pegylated interferon-alpha/ribavirin (Peg-IFN/RBV) therapy in chronic hepatitis C (CHC).	Ribavirin	156-159	interferon lambda 3	Homo sapiens	71-82
23591768-6	2014	Detectable levels of IFN-lambdas were inducible even in a small amount of PBMC, and IFN-lambda3 was more robustly up-regulated by R-837 in PBMC of CHC patients with favorable genotype for the response to Peg-IFN/RBV (TT in rs8099917) than those with TG/GG.	peg-ifn	204-211	interferon lambda 3	Homo sapiens	84-95
23591768-6	2014	Detectable levels of IFN-lambdas were inducible even in a small amount of PBMC, and IFN-lambda3 was more robustly up-regulated by R-837 in PBMC of CHC patients with favorable genotype for the response to Peg-IFN/RBV (TT in rs8099917) than those with TG/GG.	Ribavirin	212-215	interferon lambda 3	Homo sapiens	84-95
23591768-6	2014	Detectable levels of IFN-lambdas were inducible even in a small amount of PBMC, and IFN-lambda3 was more robustly up-regulated by R-837 in PBMC of CHC patients with favorable genotype for the response to Peg-IFN/RBV (TT in rs8099917) than those with TG/GG.	Thioguanine	250-252	interferon lambda 3	Homo sapiens	84-95
23591768-7	2014	Importantly, the protein levels of IFN-lambda3 induced by R-837 clearly differentiated the response to Peg-IFN/RBV treatment (p = 1.0 x 10(-10)), including cases that IL28B genotyping failed to predict the treatment response.	peg-ifn	103-110	interferon lambda 3	Homo sapiens	35-46
23591768-7	2014	Importantly, the protein levels of IFN-lambda3 induced by R-837 clearly differentiated the response to Peg-IFN/RBV treatment (p = 1.0 x 10(-10)), including cases that IL28B genotyping failed to predict the treatment response.	Ribavirin	111-114	interferon lambda 3	Homo sapiens	35-46
23829453-0	2014	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.	Ribavirin	141-150	interferon lambda 3	Homo sapiens	9-24
24379617-3	2013	Although new treatment regimens based on combination of DAA with or without IFN are in the approval phase, until combination regimens with a backbone of Peg-IFN will be used, we can expect that IL28B holds its importance.	Polyethylene Glycols	153-156	interferon lambda 3	Homo sapiens	194-199
24349500-8	2013	In conclusion, combinations of KIR3DL1/HLA-Bw4, KIR2DL2/HLA-C1, and a genetic variant of the IL28B gene are predictive of the response to PEG-IFN and ribavirin therapy in Japanese patients infected with genotype 1b HCV.	Ribavirin	150-159	interferon lambda 3	Homo sapiens	93-98
24117654-10	2014	CONCLUSIONS: The IL28B single nucleotide polymorphism still remained informative as a predictor of SVR to 24-week telaprevir-based triple combination therapy for East Asian patients infected with hepatitis C virus genotype 1b.	telaprevir	114-124	interferon lambda 3	Homo sapiens	17-22
24334180-11	2013	NTZ may be associated with an attenuation of the effect of IL28B on HCV treatment response.	nitazoxanide	0-3	interferon lambda 3	Homo sapiens	59-64
23942546-8	2013	A univariate logistic regression analysis indicated that a plasma RBV concentration of <1960 ng/mL at the end of the treatment was strongly associated with relapse (odds ratio, 55; 95% confidence interval, 7.24- ; P = 0.0001) independently of age, body weight, RBV dose, baseline viral load, the interleukin-28B genotype, and response to previous courses of treatment.	Ribavirin	66-69	interferon lambda 3	Homo sapiens	299-314
24244641-1	2013	BACKGROUND AND AIMS: Recently, several genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of hepatitis C virus (HCV) infection as well as outcome following pegylated interferon and ribavirin therapy among genotype 1 infected patients.	Ribavirin	272-281	interferon lambda 3	Homo sapiens	145-150
24039107-5	2013	The interleukin-28B (IL-28B) genotype is important in an HCV infection: it is related to the clinical severity of an acute infection and may play a role in the development of FCH as well.	fluorocholine	175-178	interferon lambda 3	Homo sapiens	21-27
24039107-14	2013	There was a nonsignificant increase in recipient IL-28B non-CC genotypes in cases developing FCH.	fluorocholine	93-96	interferon lambda 3	Homo sapiens	49-55
24348648-0	2013	Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4.	Ribavirin	75-84	interferon lambda 3	Homo sapiens	15-20
24348648-10	2013	CONCLUSIONS: IL-28B polymorphisms were the strongest pretreatment predictors of response to pegylated interferon and ribavirin in Polish patients chronically infected with HCV genotype 1 and 4.	Ribavirin	117-126	interferon lambda 3	Homo sapiens	13-19
23842134-1	2013	OBJECTIVE: To identify genetic factors that predict sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin (RBV) in HIV/hepatitis C virus (HCV) genotype 1 or 4-coinfected patients and that enhance the predictive capacity of IL28B genotype in this population.	peg-ifn	114-121	interferon lambda 3	Homo sapiens	250-255
23842134-1	2013	OBJECTIVE: To identify genetic factors that predict sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin (RBV) in HIV/hepatitis C virus (HCV) genotype 1 or 4-coinfected patients and that enhance the predictive capacity of IL28B genotype in this population.	Ribavirin	123-132	interferon lambda 3	Homo sapiens	250-255
23842134-1	2013	OBJECTIVE: To identify genetic factors that predict sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin (RBV) in HIV/hepatitis C virus (HCV) genotype 1 or 4-coinfected patients and that enhance the predictive capacity of IL28B genotype in this population.	Ribavirin	134-137	interferon lambda 3	Homo sapiens	250-255
23715768-8	2013	There is a complementary effect between the IL28B and LDLR genotypes on the probability of achieving SVR after Peg-IFN/RBV therapy in patients with HCV 1 or 4.	peg-ifn	111-118	interferon lambda 3	Homo sapiens	44-49
23715768-8	2013	There is a complementary effect between the IL28B and LDLR genotypes on the probability of achieving SVR after Peg-IFN/RBV therapy in patients with HCV 1 or 4.	Ribavirin	119-122	interferon lambda 3	Homo sapiens	44-49
24057245-1	2013	The aim of this study is to evaluate the role of IL28B rs12979860 polymorphism on pegylated interferon (peg IFN) and oral antiviral treatment in chronic hepatitis B (CHB) patients and to investigate the relationship between the severities of illness with this polymorphism.	Polyethylene Glycols	82-85	interferon lambda 3	Homo sapiens	49-54
23850880-1	2013	BACKGROUND & AIMS: IL28B polymorphisms, jaundice, decline in HCV-RNA, IP-10, and gender have been proposed to be indicative of spontaneous clearance of acute hepatitis C virus infection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	23-28
24168256-1	2013	The IL-28 gene is associated with sustained viral response (SVR) after treatment with peg-IFN and ribavirin in liver transplant recipients with chronic hepatitis C genotype 1 infection.	Ribavirin	98-107	interferon lambda 3	Homo sapiens	4-9
24579307-5	2013	The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV).	Ribavirin	242-251	interferon lambda 3	Homo sapiens	104-115
24579307-5	2013	The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV).	Ribavirin	253-256	interferon lambda 3	Homo sapiens	104-115
24204859-1	2013	BACKGROUND & AIMS: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	51-70
24204859-1	2013	BACKGROUND & AIMS: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	77-82
24204859-1	2013	BACKGROUND & AIMS: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	84-89
24204859-6	2013	RESULTS: A significant correlation was found between the IFNL3 polymorphisms and biochemical as well as virologic predictors of treatment outcome such as ALT, GGT, cholesterol, and HCV RNA levels.	Cholesterol	164-175	interferon lambda 3	Homo sapiens	57-62
24147097-7	2013	Moreover, we found that IL28B rs8099917 G variants (TG+GG) interact with HCV genotype 1(G1) to result in higher risk of NVR (P=0.009), and that they are also associated with HBV DNA reactivation (TG+GG vs. TT, P=0.005).	Thioguanine	52-54	interferon lambda 3	Homo sapiens	24-29
24984327-12	2013	IL-28 genotype is an important predictor of SVR in patients treated with a combination of interferon-alpha and ribavirin as well as in patients with HCV genotype 1 receiving triple therapy.	Ribavirin	111-120	interferon lambda 3	Homo sapiens	0-5
23281610-0	2013	Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C. AIM: Interleukin (IL)-28B gene polymorphism is closely linked with treatment response to peginterferon plus ribavirin combination therapy for hepatitis C virus genotype 1.	Ribavirin	70-79	interferon lambda 3	Homo sapiens	11-17
23861088-8	2013	Further analysis showed that 67% (6 of 9 elderly patients) with IL28B gene (rs8099917) genotype TT, treated with telaprevir 1,500 mg, achieved sustained virological response-12.	telaprevir	113-123	interferon lambda 3	Homo sapiens	64-69
24000086-10	2013	According to the base-case analysis, using dual therapy as the comparator, the alternative IL28B-guided therapy presents a more favorable ICER ($18,079/QALY for boceprevir and $25,914/QALY for telaprevir) than the universal triple therapy option ($27,594/QALY for boceprevir and $33,751/QALY for telaprevir), with an ICER clearly below the efficiency threshold for medical interventions in the Spanish setting.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	161-171	interferon lambda 3	Homo sapiens	91-96
24000086-10	2013	According to the base-case analysis, using dual therapy as the comparator, the alternative IL28B-guided therapy presents a more favorable ICER ($18,079/QALY for boceprevir and $25,914/QALY for telaprevir) than the universal triple therapy option ($27,594/QALY for boceprevir and $33,751/QALY for telaprevir), with an ICER clearly below the efficiency threshold for medical interventions in the Spanish setting.	telaprevir	193-203	interferon lambda 3	Homo sapiens	91-96
24000086-10	2013	According to the base-case analysis, using dual therapy as the comparator, the alternative IL28B-guided therapy presents a more favorable ICER ($18,079/QALY for boceprevir and $25,914/QALY for telaprevir) than the universal triple therapy option ($27,594/QALY for boceprevir and $33,751/QALY for telaprevir), with an ICER clearly below the efficiency threshold for medical interventions in the Spanish setting.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	264-274	interferon lambda 3	Homo sapiens	91-96
24000086-10	2013	According to the base-case analysis, using dual therapy as the comparator, the alternative IL28B-guided therapy presents a more favorable ICER ($18,079/QALY for boceprevir and $25,914/QALY for telaprevir) than the universal triple therapy option ($27,594/QALY for boceprevir and $33,751/QALY for telaprevir), with an ICER clearly below the efficiency threshold for medical interventions in the Spanish setting.	telaprevir	296-306	interferon lambda 3	Homo sapiens	91-96
23135762-1	2013	OBJECTIVE: Recent studies have demonstrated that genetic polymorphisms near the IL28B gene are associated with the clinical outcome of pegylated interferon alpha (peg-IFN-alpha) plus ribavirin therapy for patients with chronic hepatitis C virus (HCV).	Ribavirin	183-192	interferon lambda 3	Homo sapiens	80-85
23281610-9	2013	CONCLUSION: In genotype 2 patients treated with peginterferon plus ribavirin combination therapy, IL-28B gene polymorphism was a significant independent predictor of SVR as well as RVR.	Ribavirin	67-76	interferon lambda 3	Homo sapiens	98-104
26357605-1	2013	In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively.	Ribavirin	278-287	interferon lambda 3	Homo sapiens	99-114
26357605-1	2013	In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively.	Ribavirin	278-287	interferon lambda 3	Homo sapiens	121-126
26357605-1	2013	In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively.	Ribavirin	289-292	interferon lambda 3	Homo sapiens	99-114
26357605-1	2013	In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively.	Ribavirin	289-292	interferon lambda 3	Homo sapiens	121-126
23522062-1	2013	BACKGROUND & AIMS: Both polymorphisms in the IL28B gene locus and ISG expression levels are associated with the outcome of hepatitis C virus (HCV) infection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	49-54
24065997-0	2013	The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis.	Ribavirin	113-122	interferon lambda 3	Homo sapiens	14-29
23874902-1	2013	BACKGROUND/AIMS: Single-nucleotide polymorphisms (SNPs) near the interleukin 28B gene (IL28B; interferon [IFN]-lambda-3) are associated with outcomes of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection treated with peginterferon (PEG-IFN) alpha-based antiviral therapy.	peginterferon	236-249	interferon lambda 3	Homo sapiens	87-92
23874902-1	2013	BACKGROUND/AIMS: Single-nucleotide polymorphisms (SNPs) near the interleukin 28B gene (IL28B; interferon [IFN]-lambda-3) are associated with outcomes of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection treated with peginterferon (PEG-IFN) alpha-based antiviral therapy.	Polyethylene Glycols	251-254	interferon lambda 3	Homo sapiens	87-92
23542783-0	2013	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.	Ribavirin	26-35	interferon lambda 3	Homo sapiens	53-58
23542783-1	2013	OBJECTIVE: Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon (Peg-IFN) plus ribavirin (RBV).	peg-ifn	154-161	interferon lambda 3	Homo sapiens	101-106
23916907-11	2013	Pegylated interferon plus ribavirin treated patients with the IL28B CC genotype achieved higher sustained virological response rate than those with the CT genotype (58.6% vs 40.8%, OR 2.057, p = 0.002), and those who carried the T allele (41.8%, OR1.976, p = 0.002).	Ribavirin	26-35	interferon lambda 3	Homo sapiens	62-67
23916907-14	2013	The IL28B CC polymorphism is associated with increased Th1 cytokine production of activated peripheral blood monocytes and lymphocytes, which may play a role in interferon-induced rapid immune control and sustained virological response of pegylated interferon plus ribavirin treated patients.	Ribavirin	265-274	interferon lambda 3	Homo sapiens	4-9
23359491-6	2013	SVR rates were higher in mericitabine- than placebo-treated patients when subdivided by IL28B genotype (CC, 77.8% versus 56.0%; non-CC, 44.1% versus 16.2%) and hepatic fibrosis (noncirrhotic, 63.3% versus 41.9%; cirrhotic, 38.1% versus 21.7%).	2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine	25-37	interferon lambda 3	Homo sapiens	88-93
23439262-0	2013	A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.	Ribavirin	111-120	interferon lambda 3	Homo sapiens	124-129
23439262-2	2013	The goal of this study was to evaluate the safety, tolerability, and efficacy of the peginterferon-free combination of ABT-450/r and ABT-072 with ribavirin in treatment-naive patients with IL28B CC genotype, infected with HCV genotype 1.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	119-122	interferon lambda 3	Homo sapiens	189-194
23439262-2	2013	The goal of this study was to evaluate the safety, tolerability, and efficacy of the peginterferon-free combination of ABT-450/r and ABT-072 with ribavirin in treatment-naive patients with IL28B CC genotype, infected with HCV genotype 1.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	133-136	interferon lambda 3	Homo sapiens	189-194
23439262-2	2013	The goal of this study was to evaluate the safety, tolerability, and efficacy of the peginterferon-free combination of ABT-450/r and ABT-072 with ribavirin in treatment-naive patients with IL28B CC genotype, infected with HCV genotype 1.	Ribavirin	146-155	interferon lambda 3	Homo sapiens	189-194
23542783-1	2013	OBJECTIVE: Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon (Peg-IFN) plus ribavirin (RBV).	Ribavirin	168-177	interferon lambda 3	Homo sapiens	101-106
23542783-1	2013	OBJECTIVE: Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon (Peg-IFN) plus ribavirin (RBV).	Ribavirin	179-182	interferon lambda 3	Homo sapiens	101-106
23730840-1	2013	IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection.	Ribavirin	107-116	interferon lambda 3	Homo sapiens	0-5
23542783-11	2013	SUMMARY: Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring the favorable IL28B genotype CC should be treated with interferon plus ribavirin.	Ribavirin	170-179	interferon lambda 3	Homo sapiens	113-118
23542783-14	2013	Therefore, treatment-naive HCV-genotype 1-infected patients bearing favorable IL28B genotype who do not achieve RVR should be considered candidates for more effective therapy with direct-acting antivirals like boceprevir or telaprevir.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	210-220	interferon lambda 3	Homo sapiens	78-83
23542783-14	2013	Therefore, treatment-naive HCV-genotype 1-infected patients bearing favorable IL28B genotype who do not achieve RVR should be considered candidates for more effective therapy with direct-acting antivirals like boceprevir or telaprevir.	telaprevir	224-234	interferon lambda 3	Homo sapiens	78-83
23918536-2	2013	Polymorphisms in the human IL28B gene and amino acid substitutions in the core and interferon sensitivity-determining region (ISDR) in NS5A of HCV genotype 1b (G1b) were also shown to strongly affect the outcome of Peg-IFN plus RBV therapy.	peg-ifn	215-222	interferon lambda 3	Homo sapiens	27-32
23918536-2	2013	Polymorphisms in the human IL28B gene and amino acid substitutions in the core and interferon sensitivity-determining region (ISDR) in NS5A of HCV genotype 1b (G1b) were also shown to strongly affect the outcome of Peg-IFN plus RBV therapy.	Ribavirin	228-231	interferon lambda 3	Homo sapiens	27-32
23826153-0	2013	Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.	Ribavirin	77-86	interferon lambda 3	Homo sapiens	18-23
23314745-0	2013	Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.	Ribavirin	60-69	interferon lambda 3	Homo sapiens	10-16
23314745-3	2013	We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV).	Ribavirin	161-170	interferon lambda 3	Homo sapiens	28-34
23314745-3	2013	We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV).	peg-ifnalpha	172-184	interferon lambda 3	Homo sapiens	28-34
23314745-3	2013	We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNalpha/RBV).	Ribavirin	185-188	interferon lambda 3	Homo sapiens	28-34
23314745-11	2013	In children and adolescents chronically infected with HCV genotypes 1 and 4, IL-28B rs12979860 and rs8099917 polymorphisms were the only predictors of response to peg-IFN/RBV.	peg-ifn	163-170	interferon lambda 3	Homo sapiens	77-83
23314745-11	2013	In children and adolescents chronically infected with HCV genotypes 1 and 4, IL-28B rs12979860 and rs8099917 polymorphisms were the only predictors of response to peg-IFN/RBV.	Ribavirin	171-174	interferon lambda 3	Homo sapiens	77-83
23011083-5	2013	RESULTS: The presence of an IL28B CC genotype with either low viral load (VL), young donor age, or cyclosporine A (CsA)-based immunosuppression identified individuals with 69-80 % probabilities of SVR.	Cyclosporine	99-113	interferon lambda 3	Homo sapiens	28-33
23356752-4	2013	The aim of this study was to determine whether the SNP of IL-28B (rs8099917) and amino acid substitutions in the ISDR among patients with low HCV levels affect the response to PEG IFN monotherapy.	Polyethylene Glycols	176-179	interferon lambda 3	Homo sapiens	58-64
23011083-5	2013	RESULTS: The presence of an IL28B CC genotype with either low viral load (VL), young donor age, or cyclosporine A (CsA)-based immunosuppression identified individuals with 69-80 % probabilities of SVR.	Cyclosporine	115-118	interferon lambda 3	Homo sapiens	28-33
23741313-2	2013	A genome-wide association study identified a single nucleotide polymorphism near the IL-28B gene that strongly predicts response to hepatitis C treatment with interferon and ribavirin.	Ribavirin	174-183	interferon lambda 3	Homo sapiens	85-91
24396987-2	2013	Genome-wide association studies have shown that single nucleotide polymorphisms (SNPs) near IL 28B gene on chromosome 19 are strong predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin.	Ribavirin	209-218	interferon lambda 3	Homo sapiens	92-98
23586360-0	2013	Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B.	Lamivudine	64-74	interferon lambda 3	Homo sapiens	42-47
23586360-1	2013	OBJECTIVE: To assess the association between gene polymorphisms (single nucleotide polymorphisms [SNPs]) of rs8099917 and rs12980602 in the IL-28 gene and the response to lamivudine treatment in naive of Chinese rural patients.	Lamivudine	171-181	interferon lambda 3	Homo sapiens	140-145
23586360-5	2013	RESULTS: The IL-28 genotypes were independently associated with responses at 1 year post-treatment with lamivudine in CHB patients (OR for rs8099917 GT/GG vs. TT, 4.097 [95% CI, 1.342-12.512; p = 0.015]; OR for rs12980602CT/CC vs. TT, 2.27 [95% CI, 1.202-4.284; p =0.014]).	Lamivudine	104-114	interferon lambda 3	Homo sapiens	13-18
23647954-2	2013	The aim of this meta-analysis was to obtain a pooled odds ratio (OR) of the impact of IL-28B genotype on achieving sustained virologic response (SVR) in patients with HCV genotype 2/3 infection treated with pegIFN and ribavirin.	pegifn	207-213	interferon lambda 3	Homo sapiens	86-92
23647954-2	2013	The aim of this meta-analysis was to obtain a pooled odds ratio (OR) of the impact of IL-28B genotype on achieving sustained virologic response (SVR) in patients with HCV genotype 2/3 infection treated with pegIFN and ribavirin.	Ribavirin	218-227	interferon lambda 3	Homo sapiens	86-92
23647954-5	2013	In Caucasians, the pooled OR of SVR with the favourable IL-28B genotype was 1.36 (95%CI: 0.98-1.88, P = 0.07) in all patients and 1.55 (95%CI: 1.10-2.18, P = 0.01) in patients treated with pegIFN and ribavirin for >=24 weeks.	pegifn	189-195	interferon lambda 3	Homo sapiens	56-62
23647954-5	2013	In Caucasians, the pooled OR of SVR with the favourable IL-28B genotype was 1.36 (95%CI: 0.98-1.88, P = 0.07) in all patients and 1.55 (95%CI: 1.10-2.18, P = 0.01) in patients treated with pegIFN and ribavirin for >=24 weeks.	Ribavirin	200-209	interferon lambda 3	Homo sapiens	56-62
23647954-8	2013	The favourable IL-28B genotype is a statistically significant predictor of SVR and RVR in Caucasian patients treated with pegIFN and ribavirin for 24 weeks.	pegifn	122-128	interferon lambda 3	Homo sapiens	15-21
23647954-8	2013	The favourable IL-28B genotype is a statistically significant predictor of SVR and RVR in Caucasian patients treated with pegIFN and ribavirin for 24 weeks.	Ribavirin	133-142	interferon lambda 3	Homo sapiens	15-21
23213063-12	2013	The treatments of BDCA3(+) DCs with anti-CD81 antibody, cloroquine, or bafilomycin A1 reduced HCVcc-induced IL-28B release, whereas BDCA3(+) DCs comparably produced IL-28B upon replication-defective HCVcc.	Chloroquine	56-66	interferon lambda 3	Homo sapiens	108-114
23967025-3	2013	However, after the discovery of single nucleotide polymorphisms near the IL28B gene (rs8099917 and rs12979860) as potent predictive factors affecting the response to peg-IFN plus RBV, lipid factors are thought to be confounding factors.	peg-ifn	166-173	interferon lambda 3	Homo sapiens	73-78
23967025-3	2013	However, after the discovery of single nucleotide polymorphisms near the IL28B gene (rs8099917 and rs12979860) as potent predictive factors affecting the response to peg-IFN plus RBV, lipid factors are thought to be confounding factors.	Ribavirin	179-182	interferon lambda 3	Homo sapiens	73-78
23717463-10	2013	RESULTS: 1(OH) vitamin D3/Peg-IFN/RBV treatment could induce rapid viral reduction, especially in IL28B T/T polymorphism.	Cholecalciferol	15-25	interferon lambda 3	Homo sapiens	98-103
23717463-10	2013	RESULTS: 1(OH) vitamin D3/Peg-IFN/RBV treatment could induce rapid viral reduction, especially in IL28B T/T polymorphism.	Ribavirin	34-37	interferon lambda 3	Homo sapiens	98-103
23274935-13	2013	CONCLUSIONS: IL28B genotype, pretreatment CXCL10, and HCV RNA levels have very good capacity to predict pegylated interferon/ribavirin-treatment outcome in both HIV/HCV coinfected and HCV monoinfected patients.	Ribavirin	125-134	interferon lambda 3	Homo sapiens	13-18
23321318-1	2013	BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV).	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	81-86
23321318-1	2013	BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV).	peginterferon	197-210	interferon lambda 3	Homo sapiens	81-86
23321318-1	2013	BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV).	Ribavirin	211-220	interferon lambda 3	Homo sapiens	81-86
23321318-1	2013	BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV).	pegifn	222-228	interferon lambda 3	Homo sapiens	81-86
23321318-1	2013	BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV).	Ribavirin	229-232	interferon lambda 3	Homo sapiens	81-86
23321318-7	2013	SVR rates were higher in the pooled telaprevir versus placebo group for all IL28B genotypes; CC: 79% versus 29%, respectively; CT: 60% versus 16%, respectively; TT: 61% versus 13%, respectively.	telaprevir	36-46	interferon lambda 3	Homo sapiens	76-81
23321318-11	2013	CONCLUSIONS: Our findings suggest that IL28B genotype has a limited impact on SVR rates with telaprevir-based therapy in treatment-experienced patients.	telaprevir	93-103	interferon lambda 3	Homo sapiens	39-44
23333445-1	2013	BACKGROUND & AIMS: IL28B single nucleotide polymorphisms are strongly associated with spontaneous HCV clearance and treatment response in non-transplant populations.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	23-28
23490373-1	2013	Genetic variation in the IL-28B (interleukin-28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C treated with peginterferon-alpha and ribavirin.	Ribavirin	220-229	interferon lambda 3	Homo sapiens	25-31
23490373-1	2013	Genetic variation in the IL-28B (interleukin-28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C treated with peginterferon-alpha and ribavirin.	Ribavirin	220-229	interferon lambda 3	Homo sapiens	33-69
23219017-4	2013	The aim of the study was to evaluate the association of of IL28B rs12979860, TGF-beta1-509, TNF-alpha 308, and IL-10-1082 polymorphisms with the susceptibility to hepatitis C virus genotype 4 infection and response to pegylated interferon-alpha and ribavirin therapy.	Ribavirin	249-258	interferon lambda 3	Homo sapiens	59-64
23220171-6	2013	RESULTS: Patients with the CC polymorphism in IL28B had higher levels of total and low-density lipoprotein cholesterol, lower levels of triglycerides, and a lower prevalence of IR and moderate-severe steatosis (P < .05) than patients without this genotype.	Triglycerides	136-149	interferon lambda 3	Homo sapiens	46-51
23328301-0	2013	IL28B in the era of direct-acting antivirals for hepatitis C. The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-alpha and ribavirin.	Ribavirin	180-189	interferon lambda 3	Homo sapiens	0-5
23328301-0	2013	IL28B in the era of direct-acting antivirals for hepatitis C. The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-alpha and ribavirin.	Ribavirin	180-189	interferon lambda 3	Homo sapiens	66-71
23328301-1	2013	In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-alpha and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response.	Ribavirin	114-123	interferon lambda 3	Homo sapiens	193-198
23328301-1	2013	In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-alpha and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	129-139	interferon lambda 3	Homo sapiens	193-198
23328301-1	2013	In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-alpha and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response.	telaprevir	144-154	interferon lambda 3	Homo sapiens	193-198
23173698-0	2013	Lead-in treatment with interferon-beta/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.	Ribavirin	39-48	interferon lambda 3	Homo sapiens	194-199
23383658-1	2013	The IL28 gene is highly associated with sustained viral response (SVR) in patients infected with genotype 1 after standard of care (SOC) treatment with peg-IFN and ribavirin.	peg-ifn	152-159	interferon lambda 3	Homo sapiens	4-8
23383658-1	2013	The IL28 gene is highly associated with sustained viral response (SVR) in patients infected with genotype 1 after standard of care (SOC) treatment with peg-IFN and ribavirin.	Ribavirin	164-173	interferon lambda 3	Homo sapiens	4-8
23286842-3	2013	Naive patients with mild fibrosis and the IL28B CC polymorphism and/or with a rapid virological response (RVR) to DT can still benefit from DT, while TT is preferable in all others.	Thymidine	140-142	interferon lambda 3	Homo sapiens	42-47
23286842-4	2013	Phase 3 trials have clearly shown that a 1 log(10) decrease in HCVRNA after 4 weeks of DT associated with a favourable IL28B genotype and a low stage of fibrosis, and a pattern of previous response to DT in treatment-experienced patients are the strongest predictors of an SVR to TT.	Thymidine	87-89	interferon lambda 3	Homo sapiens	119-124
23142377-0	2013	Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.	Polyethylene Glycols	128-131	interferon lambda 3	Homo sapiens	21-26
23440114-8	2013	Thus, the IL28B genotype appears to be a strong predictor of SVR following PEG-IFN/RBV therapy in treatment-naive Brazilian patients infected with HCV genotype 1.	peg-ifn	75-82	interferon lambda 3	Homo sapiens	10-15
23440114-8	2013	Thus, the IL28B genotype appears to be a strong predictor of SVR following PEG-IFN/RBV therapy in treatment-naive Brazilian patients infected with HCV genotype 1.	Ribavirin	83-86	interferon lambda 3	Homo sapiens	10-15
23142377-0	2013	Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.	Furonazide	132-135	interferon lambda 3	Homo sapiens	21-26
23142377-0	2013	Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.	Ribavirin	136-139	interferon lambda 3	Homo sapiens	21-26
23142377-1	2013	Recently, genome-wide associated studies (GWAS) have identified that host genetics IL28B SNPs rs12979860 and rs8099917 were significantly associated with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy.	peg-inf	210-217	interferon lambda 3	Homo sapiens	83-88
23142377-1	2013	Recently, genome-wide associated studies (GWAS) have identified that host genetics IL28B SNPs rs12979860 and rs8099917 were significantly associated with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy.	Ribavirin	218-221	interferon lambda 3	Homo sapiens	83-88
23142377-9	2013	The IL-28B SNPs rs12979860 genotype CC and rs8099917 genotype TT significantly positive associated with SVR in patients infected chronic HCV genotype 1 to PEG-INF/RBV therapy (OR=4.473, 95% CI=3.814-5.246, OR=5.171, 95% CI=4.372-6.117 respectively).	peg-inf	155-162	interferon lambda 3	Homo sapiens	4-10
23142377-9	2013	The IL-28B SNPs rs12979860 genotype CC and rs8099917 genotype TT significantly positive associated with SVR in patients infected chronic HCV genotype 1 to PEG-INF/RBV therapy (OR=4.473, 95% CI=3.814-5.246, OR=5.171, 95% CI=4.372-6.117 respectively).	Ribavirin	163-166	interferon lambda 3	Homo sapiens	4-10
23859951-6	2013	Interleukin 28B (IL28B) genotype was recently and convincingly associated with response to pegIFN and RBV therapy.	pegifn	91-97	interferon lambda 3	Homo sapiens	0-15
23121166-9	2013	The analyses also showed that degree of steatosis, HOMA-IR >2, mild fibrosis and IL28B CC genotype were significantly related to SVR in patients infected with HCV genotypes 1&4, but not in those with genotypes 2&3.	Adenosine Monophosphate	178-181	interferon lambda 3	Homo sapiens	84-89
23173698-0	2013	Lead-in treatment with interferon-beta/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.	Ribavirin	130-139	interferon lambda 3	Homo sapiens	194-199
23173698-1	2013	BACKGROUND AND AIM: The most important factor influencing the effect of pegylated interferon (PEG-IFN)/ribavirin therapy (PEG) for chronic hepatitis C genotype 1b with high viral load is the interleukin 28B (IL28B) genotype.	Ribavirin	103-112	interferon lambda 3	Homo sapiens	208-213
23173698-9	2013	CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype.	Ribavirin	63-72	interferon lambda 3	Homo sapiens	252-257
23173698-9	2013	CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype.	Ribavirin	103-112	interferon lambda 3	Homo sapiens	252-257
23173698-9	2013	CONCLUSION: It was suggested that lead-in twice-daily IFN-beta/ribavirin treatment followed by PEG-IFN/ribavirin combination therapy may modify the HCV-RNA dynamics compared with that by PEG-IFN/ribavirin therapy, and it is particularly useful for the IL28B minor genotype.	Ribavirin	103-112	interferon lambda 3	Homo sapiens	252-257
23936821-0	2013	Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.	Ribavirin	63-72	interferon lambda 3	Homo sapiens	110-115
23936821-1	2013	BACKGROUND: The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients.	pegifn	171-177	interferon lambda 3	Homo sapiens	63-68
23936821-1	2013	BACKGROUND: The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients.	Ribavirin	183-192	interferon lambda 3	Homo sapiens	63-68
23936821-1	2013	BACKGROUND: The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients.	Ribavirin	194-197	interferon lambda 3	Homo sapiens	63-68
24281016-7	2013	CONCLUSION: The NS5A sequence heterogeneity and IL28B SNP are useful factors to predict the sensitivity to PEG-IFN/RBV therapy in HCV-2a and HCV-2b infections.	Ribavirin	115-118	interferon lambda 3	Homo sapiens	48-53
24281017-7	2013	CONCLUSION: Patients whose HCV is not eradicated by previous PEG-IFN/RBV would be good candidates for combined DFPP and IFN/RBV retreatment provided they demonstrate IL28B major and have achieved RVR.	dfpp	111-115	interferon lambda 3	Homo sapiens	166-171
24223458-3	2013	Several viral and host factors have been proved to affect response to the treatment PEG-IFN and ribavirin; the strongest of them is polymorphisms near IL28B; nonetheless, nonresponse in patients with favorable IL28B is still unexplained, which implies the importance of studying other immunological factors that may correlate with response.	Ribavirin	96-105	interferon lambda 3	Homo sapiens	151-156
24223458-3	2013	Several viral and host factors have been proved to affect response to the treatment PEG-IFN and ribavirin; the strongest of them is polymorphisms near IL28B; nonetheless, nonresponse in patients with favorable IL28B is still unexplained, which implies the importance of studying other immunological factors that may correlate with response.	Ribavirin	96-105	interferon lambda 3	Homo sapiens	210-215
23306941-1	2013	OBJECTIVES: The aim of this study was to evaluate rapid virologic response (RVR) rate after peginterferon (PegIFN) and ribavirin (RBV) dual combination therapy in Korean hepatitis C virus (HCV) genotype 1 patients whose IL28B polymorphism is generally favorable.	pegifn	107-113	interferon lambda 3	Homo sapiens	220-225
23306941-1	2013	OBJECTIVES: The aim of this study was to evaluate rapid virologic response (RVR) rate after peginterferon (PegIFN) and ribavirin (RBV) dual combination therapy in Korean hepatitis C virus (HCV) genotype 1 patients whose IL28B polymorphism is generally favorable.	Ribavirin	119-128	interferon lambda 3	Homo sapiens	220-225
23306941-1	2013	OBJECTIVES: The aim of this study was to evaluate rapid virologic response (RVR) rate after peginterferon (PegIFN) and ribavirin (RBV) dual combination therapy in Korean hepatitis C virus (HCV) genotype 1 patients whose IL28B polymorphism is generally favorable.	Ribavirin	130-133	interferon lambda 3	Homo sapiens	220-225
23859951-6	2013	Interleukin 28B (IL28B) genotype was recently and convincingly associated with response to pegIFN and RBV therapy.	pegifn	91-97	interferon lambda 3	Homo sapiens	17-22
23859951-6	2013	Interleukin 28B (IL28B) genotype was recently and convincingly associated with response to pegIFN and RBV therapy.	Ribavirin	102-105	interferon lambda 3	Homo sapiens	0-15
23859951-6	2013	Interleukin 28B (IL28B) genotype was recently and convincingly associated with response to pegIFN and RBV therapy.	Ribavirin	102-105	interferon lambda 3	Homo sapiens	17-22
22842190-2	2012	This meta-analysis aimed to derive a more precise estimation of the effects of IL-28B SNPs locus (rs12979860 and rs8099917) on SVR in naive CHC patients receiving pegylated interferon alpha (PEG-IFN-alpha) plus ribavirin.	Ribavirin	211-220	interferon lambda 3	Homo sapiens	79-85
23323251-0	2012	Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. BACKGROUND/AIMS: Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits.	Ribavirin	30-39	interferon lambda 3	Homo sapiens	63-68
23109451-3	2012	Our aim was to establish an association between three IL28B SNPs (rs8099917, rs12979860, and rs8103142) and the peg-IFNalpha/RBV treatment response in a Mexican population cohort with chronic HCV.	Ribavirin	125-128	interferon lambda 3	Homo sapiens	54-59
23020144-0	2012	Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy.	Ribavirin	178-187	interferon lambda 3	Homo sapiens	36-51
23080496-0	2012	A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.	Ribavirin	125-134	interferon lambda 3	Homo sapiens	36-41
23080496-1	2012	Interleukin-28B (IL28B) polymorphisms are associated with viral response to peginterferon and ribavirin (RBV) in chronic hepatitis C (HCV).	Ribavirin	94-103	interferon lambda 3	Homo sapiens	17-22
23080496-1	2012	Interleukin-28B (IL28B) polymorphisms are associated with viral response to peginterferon and ribavirin (RBV) in chronic hepatitis C (HCV).	Ribavirin	105-108	interferon lambda 3	Homo sapiens	17-22
23080496-4	2012	The IL-28B variants are hypothesized to have a differential impact on HCV quasispecies evolution during treatment with pegylated interferon (PEG-IFN) and RBV.	peg-ifn	141-148	interferon lambda 3	Homo sapiens	4-10
23080496-4	2012	The IL-28B variants are hypothesized to have a differential impact on HCV quasispecies evolution during treatment with pegylated interferon (PEG-IFN) and RBV.	Ribavirin	154-157	interferon lambda 3	Homo sapiens	4-10
22930507-0	2012	Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.	Ribavirin	100-109	interferon lambda 3	Homo sapiens	15-20
22536875-1	2012	AIM:   IL28B polymorphisms serve to predict response to pegylated interferon plus ribavirin therapy (PEG IFN/RBV) in Japanese patients with chronic hepatitis C (CHC) very reliably.	Ribavirin	82-91	interferon lambda 3	Homo sapiens	7-12
22536875-1	2012	AIM:   IL28B polymorphisms serve to predict response to pegylated interferon plus ribavirin therapy (PEG IFN/RBV) in Japanese patients with chronic hepatitis C (CHC) very reliably.	peg ifn	101-108	interferon lambda 3	Homo sapiens	7-12
22536875-1	2012	AIM:   IL28B polymorphisms serve to predict response to pegylated interferon plus ribavirin therapy (PEG IFN/RBV) in Japanese patients with chronic hepatitis C (CHC) very reliably.	Ribavirin	109-112	interferon lambda 3	Homo sapiens	7-12
22536875-2	2012	However, the prediction by the IL28B polymorphism contradicted the virological response to PEG IFN/RBV in some patients.	peg ifn	91-98	interferon lambda 3	Homo sapiens	31-36
22536875-2	2012	However, the prediction by the IL28B polymorphism contradicted the virological response to PEG IFN/RBV in some patients.	Ribavirin	99-102	interferon lambda 3	Homo sapiens	31-36
22612669-10	2012	Based on genetic variations near the IL28B gene (rs8099917), SVR was 44.1% (15/34) in patients with TT and 0% (0/11) in patients with TG (P = 0.008).	Thioguanine	134-136	interferon lambda 3	Homo sapiens	37-42
22612669-11	2012	CONCLUSION:   The reduction therapy of IFN-beta and ribavirin in elderly HCV patients with genotype 1b, high viral load, IL28B gene (rs8099917) of TT who had complications of anemia, low bodyweight, diabetes mellitus and/or hypertension is one possible selection of treatment.	Ribavirin	52-61	interferon lambda 3	Homo sapiens	121-126
22967098-1	2012	IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg-IFN) and ribavirin (RBV).	peg-ifn	212-219	interferon lambda 3	Homo sapiens	0-5
22967098-1	2012	IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg-IFN) and ribavirin (RBV).	Ribavirin	225-234	interferon lambda 3	Homo sapiens	0-5
22967098-1	2012	IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg-IFN) and ribavirin (RBV).	Ribavirin	236-239	interferon lambda 3	Homo sapiens	0-5
22967098-4	2012	IL28B genotype remains relevant to both telaprevir and boceprevir treatment regimens, although the strength of association with virological response is attenuated.	telaprevir	40-50	interferon lambda 3	Homo sapiens	0-5
22967098-4	2012	IL28B genotype remains relevant to both telaprevir and boceprevir treatment regimens, although the strength of association with virological response is attenuated.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	55-65	interferon lambda 3	Homo sapiens	0-5
22967098-5	2012	The association between IL28B genotype and outcomes of treatment regimens that involve peg-IFN plus combination DAA therapy, or IFN-free regimens, is currently being evaluated.	peg-ifn	87-94	interferon lambda 3	Homo sapiens	24-29
22967098-5	2012	The association between IL28B genotype and outcomes of treatment regimens that involve peg-IFN plus combination DAA therapy, or IFN-free regimens, is currently being evaluated.	daa	112-115	interferon lambda 3	Homo sapiens	24-29
22930507-7	2012	As significant or marginal significant determinants of non-sustained virological response regardless of rapid virological response, multivariate analysis identified IL28B rs8099917 genotype TG + GG and lower level of albumin.	Thioguanine	190-192	interferon lambda 3	Homo sapiens	165-170
22524382-1	2012	Identification of the relationship between the interleukin (IL)-28B genotype and the effect of peginterferon plus ribavirin treatment has had a great impact on the study of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection.	Ribavirin	114-123	interferon lambda 3	Homo sapiens	47-67
22639111-7	2012	These findings suggest that optimization of ribavirin plasma concentrations during the first week of ribavirin dosing is most critical in AA patients in order to increase the rate of SVR, especially those with the IL-28B TT genotype.	Ribavirin	44-53	interferon lambda 3	Homo sapiens	214-220
22639111-7	2012	These findings suggest that optimization of ribavirin plasma concentrations during the first week of ribavirin dosing is most critical in AA patients in order to increase the rate of SVR, especially those with the IL-28B TT genotype.	Ribavirin	101-110	interferon lambda 3	Homo sapiens	214-220
22727259-0	2012	Different impact of IL28B polymorphisms on response to peginterferon-alpha plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.	Ribavirin	80-89	interferon lambda 3	Homo sapiens	20-25
22727259-12	2012	CONCLUSIONS: The rate of SVR to pegIFN/RBV therapy tends to be lower in HIV-infected patients with chronic hepatitis C due to HCV-1a than HCV-1b; being the impact of IL28B variants significantly stronger on HCV-1a than HCV-1b.	pegifn	32-38	interferon lambda 3	Homo sapiens	166-171
22727259-12	2012	CONCLUSIONS: The rate of SVR to pegIFN/RBV therapy tends to be lower in HIV-infected patients with chronic hepatitis C due to HCV-1a than HCV-1b; being the impact of IL28B variants significantly stronger on HCV-1a than HCV-1b.	Ribavirin	39-42	interferon lambda 3	Homo sapiens	166-171
22432893-1	2012	BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT).	pegifn	303-309	interferon lambda 3	Homo sapiens	20-35
22382633-8	2012	PegIFNalpha-2a was more effective than PegIFNalpha-2b (81.8 vs. 62.7%, P = 0.014) in IL28B TT genotype patients, despite similarly low SVR rates in patients with TG or GG genotypes (36.4 vs. 35.9%).	pegifnalpha	0-11	interferon lambda 3	Homo sapiens	85-90
22382633-8	2012	PegIFNalpha-2a was more effective than PegIFNalpha-2b (81.8 vs. 62.7%, P = 0.014) in IL28B TT genotype patients, despite similarly low SVR rates in patients with TG or GG genotypes (36.4 vs. 35.9%).	Stearyldimethylbenzylammonium chloride	51-53	interferon lambda 3	Homo sapiens	85-90
22432893-0	2012	Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.	Ribavirin	123-132	interferon lambda 3	Homo sapiens	0-15
22432893-1	2012	BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT).	Ribavirin	292-301	interferon lambda 3	Homo sapiens	20-35
22432893-1	2012	BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT).	Ribavirin	292-301	interferon lambda 3	Homo sapiens	37-42
22613000-8	2012	CONCLUSIONS: For HCV genotype 1, both IL28B and baseline HOMA-IR are independent pretreatment predictors of SVR in patients treated with PegIFNalpha-2b and RBV.	Ribavirin	156-159	interferon lambda 3	Homo sapiens	38-43
22634340-0	2012	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. BACKGROUND & AIMS: Insulin resistance, fibrosis and steatosis are established predictors of response to peg-interferon/ribavirin therapy in chronic hepatitis C (CHC).	Adenosine Monophosphate	108-111	interferon lambda 3	Homo sapiens	19-24
22634340-0	2012	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. BACKGROUND & AIMS: Insulin resistance, fibrosis and steatosis are established predictors of response to peg-interferon/ribavirin therapy in chronic hepatitis C (CHC).	Ribavirin	219-228	interferon lambda 3	Homo sapiens	19-24
22613675-1	2012	A single nucleotide polymorphism (SNP) upstream of the IL28 gene (rs12979860) has been reported to predict sustained virological response to peginterferon-ribavirin therapy in chronic HCV patients.	Ribavirin	155-164	interferon lambda 3	Homo sapiens	55-59
22863265-10	2012	Being male and major genotype IL28B single nucleotide polymorphisms (SNPs) were independent predictive factors for SVR among patients on fluvastatin with multivariate analysis.	Fluvastatin	137-148	interferon lambda 3	Homo sapiens	30-35
22863265-12	2012	Male and major genotype IL28B SNPs were independent predictors for SVR among patients on fluvastatin combination therapy.	Fluvastatin	89-100	interferon lambda 3	Homo sapiens	24-29
23199501-4	2012	Genome-wide association studies have recently identified several clinically important host determinants of the outcomes of peginterferon-alpha and ribavirin treatment outcome: IL28B polymorphism is associated with spontaneous clearance and treatment responsiveness; ITPA polymorphism protects against ribavirin-induced anaemia and dose reductions; genetic determinants of liver fibrosis progression rate have been proposed.	Ribavirin	147-156	interferon lambda 3	Homo sapiens	176-181
23199501-4	2012	Genome-wide association studies have recently identified several clinically important host determinants of the outcomes of peginterferon-alpha and ribavirin treatment outcome: IL28B polymorphism is associated with spontaneous clearance and treatment responsiveness; ITPA polymorphism protects against ribavirin-induced anaemia and dose reductions; genetic determinants of liver fibrosis progression rate have been proposed.	Ribavirin	301-310	interferon lambda 3	Homo sapiens	176-181
23087747-1	2012	BACKGROUND: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-alpha and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR).	Ribavirin	178-187	interferon lambda 3	Homo sapiens	50-64
23087747-1	2012	BACKGROUND: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-alpha and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR).	Ribavirin	178-187	interferon lambda 3	Homo sapiens	66-71
22521237-3	2012	Recent studies indicate association of several single nucleotide polymorphisms near IL28B gene and response of hepatitis C patients to combined interferon/ribavirin treatment.	Ribavirin	155-164	interferon lambda 3	Homo sapiens	84-89
23012624-0	2012	Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.	Ribavirin	98-107	interferon lambda 3	Homo sapiens	18-23
22331604-1	2012	UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)/ribavirin.	Ribavirin	264-273	interferon lambda 3	Homo sapiens	109-114
22711348-11	2012	This finding may help to early identify responders to standard PEG-IFN-alpha and ribavirin treatment even within those with unfavorable IL28B genotype.	Ribavirin	81-90	interferon lambda 3	Homo sapiens	136-141
23012624-1	2012	It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients.	Ribavirin	86-95	interferon lambda 3	Homo sapiens	156-161
23012624-1	2012	It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients.	Ribavirin	231-240	interferon lambda 3	Homo sapiens	156-161
22432893-1	2012	BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT).	pegifn	303-309	interferon lambda 3	Homo sapiens	37-42
22432893-1	2012	BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT).	Ribavirin	310-313	interferon lambda 3	Homo sapiens	20-35
22432893-1	2012	BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT).	Ribavirin	310-313	interferon lambda 3	Homo sapiens	37-42
22432893-9	2012	CONCLUSION: Measurement of donors" and recipients" IL28B SNP can predict the response to PEGIFN/RBV therapy, and the donors" IL28B SNP might be a more significant predictor than that of the recipients.	pegifn	89-95	interferon lambda 3	Homo sapiens	51-56
22432893-9	2012	CONCLUSION: Measurement of donors" and recipients" IL28B SNP can predict the response to PEGIFN/RBV therapy, and the donors" IL28B SNP might be a more significant predictor than that of the recipients.	Ribavirin	96-99	interferon lambda 3	Homo sapiens	51-56
22612303-1	2012	BACKGROUND: Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin.	peginterferon	167-180	interferon lambda 3	Homo sapiens	33-39
22612303-1	2012	BACKGROUND: Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin.	pegifn	182-188	interferon lambda 3	Homo sapiens	33-39
22612303-1	2012	BACKGROUND: Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin.	Ribavirin	194-203	interferon lambda 3	Homo sapiens	33-39
22612303-10	2012	CONCLUSIONS: IL-28B genotype is significantly associated with SVR in HCV genotype 1 patients of varying race, as well as in HIV co-infected patients, receiving pegIFN and ribavirin.	pegifn	160-166	interferon lambda 3	Homo sapiens	13-19
22612303-10	2012	CONCLUSIONS: IL-28B genotype is significantly associated with SVR in HCV genotype 1 patients of varying race, as well as in HIV co-infected patients, receiving pegIFN and ribavirin.	Ribavirin	171-180	interferon lambda 3	Homo sapiens	13-19
22350701-1	2012	BACKGROUND: Several single nucleotide polymorphisms (SNPs) within the interleukin 28B (IL28B) locus are associated with sustained viral response in chronic hepatitis C (HCV) patients who were treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	peg-ifn	227-234	interferon lambda 3	Homo sapiens	87-92
22882858-1	2012	The aim of this research was to evaluate the role of IL-28B single nucleotide polymorphism (SNP) variations in Chinese patients undergoing pegylated interferon-alpha plus ribavirin (PEG-IFN-alpha/RBV) treatment.	Ribavirin	171-180	interferon lambda 3	Homo sapiens	53-59
22350701-1	2012	BACKGROUND: Several single nucleotide polymorphisms (SNPs) within the interleukin 28B (IL28B) locus are associated with sustained viral response in chronic hepatitis C (HCV) patients who were treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	Ribavirin	241-250	interferon lambda 3	Homo sapiens	87-92
22350701-1	2012	BACKGROUND: Several single nucleotide polymorphisms (SNPs) within the interleukin 28B (IL28B) locus are associated with sustained viral response in chronic hepatitis C (HCV) patients who were treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	Ribavirin	252-255	interferon lambda 3	Homo sapiens	87-92
22098610-10	2012	CONCLUSIONS: The H63D mutation has little impact on the clinical characteristics of CHC, but is related to favorable response to PEG-IFN plus ribavirin therapy, particularly in patients with the TT allele in IL28B.	Ribavirin	142-151	interferon lambda 3	Homo sapiens	208-213
25755419-1	2012	BACKGROUND: The single nucleotide polymorphism (SNP) of IL28B gene on chromosome 19, encoding for the interferon (IFN)-lambda-3 is strongly associated with treatment response to pegylated-IFN and ribavirin in patients infected with different genotypes of hepatitis C virus (HCV).	Ribavirin	196-205	interferon lambda 3	Homo sapiens	56-61
25755419-1	2012	BACKGROUND: The single nucleotide polymorphism (SNP) of IL28B gene on chromosome 19, encoding for the interferon (IFN)-lambda-3 is strongly associated with treatment response to pegylated-IFN and ribavirin in patients infected with different genotypes of hepatitis C virus (HCV).	Ribavirin	196-205	interferon lambda 3	Homo sapiens	102-127
22641049-1	2012	The IL28B locus attracted the attention of HCV researchers after a series of genome-wide association studies independently identified a strong association between common IL28B polymorphisms and the outcome of PEG-IFN-alpha plus ribavirin combination therapy in patients chronically infected with HCV genotype 1.	Ribavirin	228-237	interferon lambda 3	Homo sapiens	4-9
22641049-1	2012	The IL28B locus attracted the attention of HCV researchers after a series of genome-wide association studies independently identified a strong association between common IL28B polymorphisms and the outcome of PEG-IFN-alpha plus ribavirin combination therapy in patients chronically infected with HCV genotype 1.	Ribavirin	228-237	interferon lambda 3	Homo sapiens	170-175
22495472-8	2012	The association between IL-28B polymorphism and ACR occurrence was evident in tacrolimus but not in cyclosporine-treated patients.	Tacrolimus	78-88	interferon lambda 3	Homo sapiens	24-30
22382144-0	2012	LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.	peg-ifn	105-112	interferon lambda 3	Homo sapiens	37-42
22382144-0	2012	LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.	Ribavirin	113-116	interferon lambda 3	Homo sapiens	37-42
22573217-3	2012	Moreover, recent genomewide association studies found a highly significant and strong association between genetic variants near the IFNlambda3 gene, designated the IL28B genotype, with spontaneous clearance of hepatitis C virus as well as with response to treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin.	Ribavirin	325-334	interferon lambda 3	Homo sapiens	164-169
22323501-2	2012	The aim of this study was to produce recombinant human IL28B (rhIL28B) in yeast and explore the action mechanisms of rhIL28B as a novel anti-HCV agent.	rhil28b	62-69	interferon lambda 3	Homo sapiens	55-60
32898985-0	2012	Erratum to: "Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin" [J Hepatol 2012;56:34-40].	peginterferon	128-141	interferon lambda 3	Homo sapiens	13-28
32898985-0	2012	Erratum to: "Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin" [J Hepatol 2012;56:34-40].	Ribavirin	142-151	interferon lambda 3	Homo sapiens	13-28
22431022-2	2012	The C/C genotype is associated with higher serum cholesterol, predictor of a favorable outcome in chronic hepatitis C. Whether IL-28B polymorphism and serum cholesterol play a role in modulating the history of mild hepatitis C is unknown.	Cholesterol	49-60	interferon lambda 3	Homo sapiens	127-133
22431022-8	2012	In conclusion, the interaction between IL-28B rs12979860 T/T genotype and low serum cholesterol concentration is an independent predictor of a worse disease course among patients infected with HCV with normal or near-normal transaminases.	Cholesterol	84-95	interferon lambda 3	Homo sapiens	39-45
22497812-1	2012	Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection.	pegifn	171-177	interferon lambda 3	Homo sapiens	72-77
22537149-1	2012	IL28B polymorphism is associated with the response to pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment in chronic hepatitis C patients.	Ribavirin	86-95	interferon lambda 3	Homo sapiens	0-5
22537149-1	2012	IL28B polymorphism is associated with the response to pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment in chronic hepatitis C patients.	peg-ifn-alpha	97-110	interferon lambda 3	Homo sapiens	0-5
22537149-1	2012	IL28B polymorphism is associated with the response to pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment in chronic hepatitis C patients.	Ribavirin	111-114	interferon lambda 3	Homo sapiens	0-5
22497812-1	2012	Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection.	Ribavirin	178-181	interferon lambda 3	Homo sapiens	72-77
22497812-9	2012	LDL-C remains significantly associated with SVR for heterozygous IL28B genotype patients, where LDL-C and HCV RNA burden may identify those patients with high or low likelihood of cure with pegIFN/RBV therapy.	pegifn	190-196	interferon lambda 3	Homo sapiens	65-70
22497812-9	2012	LDL-C remains significantly associated with SVR for heterozygous IL28B genotype patients, where LDL-C and HCV RNA burden may identify those patients with high or low likelihood of cure with pegIFN/RBV therapy.	Ribavirin	197-200	interferon lambda 3	Homo sapiens	65-70
22448788-4	2012	Recent times has seen a major breakthrough in the field with the description of the IL28B genotype as an independent association factor for pegylated IFN-alpha2b/ribavirin treatment response.	Ribavirin	162-171	interferon lambda 3	Homo sapiens	84-89
22387386-1	2012	Recent studies showed that two single nucleotide polymorphisms (SNPs) (rs12979860 and rs8099917) near the gene IL28B coding for IFNlambda3 were associated with the antiviral treatment response of the combination therapy of pegIFN plus RBV.	pegifn	223-229	interferon lambda 3	Homo sapiens	111-116
22387386-1	2012	Recent studies showed that two single nucleotide polymorphisms (SNPs) (rs12979860 and rs8099917) near the gene IL28B coding for IFNlambda3 were associated with the antiviral treatment response of the combination therapy of pegIFN plus RBV.	pegifn	223-229	interferon lambda 3	Homo sapiens	128-138
22387386-1	2012	Recent studies showed that two single nucleotide polymorphisms (SNPs) (rs12979860 and rs8099917) near the gene IL28B coding for IFNlambda3 were associated with the antiviral treatment response of the combination therapy of pegIFN plus RBV.	Ribavirin	235-238	interferon lambda 3	Homo sapiens	111-116
22387386-1	2012	Recent studies showed that two single nucleotide polymorphisms (SNPs) (rs12979860 and rs8099917) near the gene IL28B coding for IFNlambda3 were associated with the antiviral treatment response of the combination therapy of pegIFN plus RBV.	Ribavirin	235-238	interferon lambda 3	Homo sapiens	128-138
22616502-5	2012	Additionally, the study of variants of IL28 helps in the identification of patients with more chances of response to the treatment of hepatitis C with interferon and ribavirin.	Ribavirin	166-175	interferon lambda 3	Homo sapiens	39-43
22248659-0	2012	Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. BACKGROUND & AIMS: Although interleukin 28B (interferon, lambda 3) (IL28B) genotype affects the response of patients with chronic hepatitis C to peginterferon and ribavirin, little is known regarding its effect on response to direct-acting antivirals in interferon-free combinations.	Ribavirin	287-296	interferon lambda 3	Homo sapiens	152-190
22300408-9	2012	Multivariate Cox regression analysis correcting for donor age, body mass index, baseline serum glucose, baseline serum cholesterol, recipient age and treated rejection, showed that recipient IL28B genotype TT was independently associated with posttransplant DM (hazard ratio 2.51; 95% confidence interval 1.17-5.40; p = 0.011).	Glucose	95-102	interferon lambda 3	Homo sapiens	191-196
22300408-9	2012	Multivariate Cox regression analysis correcting for donor age, body mass index, baseline serum glucose, baseline serum cholesterol, recipient age and treated rejection, showed that recipient IL28B genotype TT was independently associated with posttransplant DM (hazard ratio 2.51; 95% confidence interval 1.17-5.40; p = 0.011).	Cholesterol	119-130	interferon lambda 3	Homo sapiens	191-196
21951981-0	2012	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections.	Adenosine Monophosphate	118-121	interferon lambda 3	Homo sapiens	0-5
22108195-11	2012	CONCLUSIONS: Polymorphisms near IL28B are independently associated with serologic response to PEG-IFN in patients with HBeAg-positive chronic hepatitis B.	peg-ifn	94-101	interferon lambda 3	Homo sapiens	32-37
21951981-0	2012	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections.	Adenosine Monophosphate	118-121	interferon lambda 3	Homo sapiens	164-183
21951981-0	2012	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections.	Polyethylene Glycols	237-240	interferon lambda 3	Homo sapiens	0-5
22497812-1	2012	Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection.	Ribavirin	160-169	interferon lambda 3	Homo sapiens	72-77
21951981-0	2012	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections.	Polyethylene Glycols	237-240	interferon lambda 3	Homo sapiens	164-183
21951981-0	2012	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections.	Ribavirin	250-259	interferon lambda 3	Homo sapiens	0-5
21951981-0	2012	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections.	Ribavirin	250-259	interferon lambda 3	Homo sapiens	164-183
22027585-1	2012	BACKGROUND & AIMS: We studied the relationship between IL28B gene-related SNP rs12979860 and early viral kinetics (day 0-28) during peginterferon and ribavirin treatment, in 173 African Americans (AA) and 188 Caucasian Americans (CA) with HCV genotype 1.	Ribavirin	154-163	interferon lambda 3	Homo sapiens	59-64
22313623-0	2012	The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.	Ribavirin	141-150	interferon lambda 3	Homo sapiens	14-19
22246829-0	2012	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.	Ribavirin	235-244	interferon lambda 3	Homo sapiens	139-154
22313623-1	2012	BACKGROUND: Recent studies of CH-C patients have demonstrated a strong association between IL28B CC genotype and sustained virologic response (SVR) after PEG-IFN/RBV treatment.	peg-ifn	154-161	interferon lambda 3	Homo sapiens	91-96
22313623-1	2012	BACKGROUND: Recent studies of CH-C patients have demonstrated a strong association between IL28B CC genotype and sustained virologic response (SVR) after PEG-IFN/RBV treatment.	Ribavirin	162-165	interferon lambda 3	Homo sapiens	91-96
22313623-2	2012	We aimed to assess whether IL28B alleles rs12979860 genotype influences gene expression in response to PEG-IFN/RBV in CH-C patients.	peg-ifn	103-110	interferon lambda 3	Homo sapiens	27-32
22313623-2	2012	We aimed to assess whether IL28B alleles rs12979860 genotype influences gene expression in response to PEG-IFN/RBV in CH-C patients.	Ribavirin	111-114	interferon lambda 3	Homo sapiens	27-32
22313623-16	2012	These data may provide some mechanistic explanation for higher rate of SVR in IL28B CC patients who are treated with PEG-IFN/RBV.	peg-ifn	117-124	interferon lambda 3	Homo sapiens	78-83
22313623-16	2012	These data may provide some mechanistic explanation for higher rate of SVR in IL28B CC patients who are treated with PEG-IFN/RBV.	Ribavirin	125-128	interferon lambda 3	Homo sapiens	78-83
21932415-0	2012	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.	Ribavirin	64-73	interferon lambda 3	Homo sapiens	0-15
22168813-4	2012	A correlated set of polymorphisms in the region of the interleukin-28B (IL-28B) gene on chromosome 19, coding for interferon (IFN)-lambda3 were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with PEG-IFN-alpha and RBV.	peg-ifn-alpha	233-246	interferon lambda 3	Homo sapiens	72-78
22168813-4	2012	A correlated set of polymorphisms in the region of the interleukin-28B (IL-28B) gene on chromosome 19, coding for interferon (IFN)-lambda3 were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with PEG-IFN-alpha and RBV.	Ribavirin	251-254	interferon lambda 3	Homo sapiens	72-78
21932415-1	2012	UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection.	pegifn	188-194	interferon lambda 3	Homo sapiens	60-75
21932415-1	2012	UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection.	pegifn	188-194	interferon lambda 3	Homo sapiens	77-82
21932415-1	2012	UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection.	Ribavirin	200-209	interferon lambda 3	Homo sapiens	60-75
21932415-1	2012	UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection.	Ribavirin	200-209	interferon lambda 3	Homo sapiens	77-82
21932415-1	2012	UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection.	Ribavirin	211-214	interferon lambda 3	Homo sapiens	60-75
21932415-1	2012	UNLABELLED: Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection.	Ribavirin	211-214	interferon lambda 3	Homo sapiens	77-82
21932415-3	2012	The aim was to investigate the predictive power of the rs12979860 IL28B SNP for a response to Peg-IFN and Rbv in HCV-4 patients.	peg-ifn	94-101	interferon lambda 3	Homo sapiens	66-71
21932415-3	2012	The aim was to investigate the predictive power of the rs12979860 IL28B SNP for a response to Peg-IFN and Rbv in HCV-4 patients.	Ribavirin	106-109	interferon lambda 3	Homo sapiens	66-71
21932415-11	2012	CONCLUSION: The IL28B rs12979860 SNP may have an added value in the treatment algorithm of HCV-4 patients because it is the strongest predictor of an SVR to PegIFN/Rbv therapy.	pegifn	157-163	interferon lambda 3	Homo sapiens	16-21
21932415-11	2012	CONCLUSION: The IL28B rs12979860 SNP may have an added value in the treatment algorithm of HCV-4 patients because it is the strongest predictor of an SVR to PegIFN/Rbv therapy.	Ribavirin	164-167	interferon lambda 3	Homo sapiens	16-21
22052088-0	2012	Interleukin-28B genotypes determine response to pegylated-interferon             plus ribavirin therapy in patients with hepatitis C virus infection.	Ribavirin	86-95	interferon lambda 3	Homo sapiens	0-15
22212565-5	2012	Furthermore, the important role of host polymorphisms of the IL28B gene on virological response to treatment with pegylated interferon (PEG-IFN) alpha and ribavirin (RBV) has recently been clearly demonstrated.	Ribavirin	155-164	interferon lambda 3	Homo sapiens	61-66
22212570-4	2012	Although data sets were not complete, patients with IL28B CT and TT genotype appear to significantly improve when these agents are combined with PEG-INF and RBV.	peg-inf	145-152	interferon lambda 3	Homo sapiens	52-57
22212570-4	2012	Although data sets were not complete, patients with IL28B CT and TT genotype appear to significantly improve when these agents are combined with PEG-INF and RBV.	Ribavirin	157-160	interferon lambda 3	Homo sapiens	52-57
22212576-1	2012	An association between variations at the IL28B gene locus and HCV clearance (spontaneous recovery or sustained virological response under pegylated interferon (PEG-IFN) and ribavirin (RBV) has been extensively described.	peg-ifn	160-167	interferon lambda 3	Homo sapiens	41-46
22212576-1	2012	An association between variations at the IL28B gene locus and HCV clearance (spontaneous recovery or sustained virological response under pegylated interferon (PEG-IFN) and ribavirin (RBV) has been extensively described.	Ribavirin	173-182	interferon lambda 3	Homo sapiens	41-46
22212576-1	2012	An association between variations at the IL28B gene locus and HCV clearance (spontaneous recovery or sustained virological response under pegylated interferon (PEG-IFN) and ribavirin (RBV) has been extensively described.	Ribavirin	184-187	interferon lambda 3	Homo sapiens	41-46
22212576-2	2012	In genotype 1-infected patients, the new direct antiviral agents (DAA) including the two approved protease inhibitors boceprevir and telaprevir, in association with the PEG-IFN/RBV combination is the new standard of care making it necessary to redefine the interest of the IL28B genotype in the decision to treat and how to treat genotype 1-infected patients.	telaprevir	133-143	interferon lambda 3	Homo sapiens	273-278
22212576-2	2012	In genotype 1-infected patients, the new direct antiviral agents (DAA) including the two approved protease inhibitors boceprevir and telaprevir, in association with the PEG-IFN/RBV combination is the new standard of care making it necessary to redefine the interest of the IL28B genotype in the decision to treat and how to treat genotype 1-infected patients.	peg-ifn	169-176	interferon lambda 3	Homo sapiens	273-278
22212576-2	2012	In genotype 1-infected patients, the new direct antiviral agents (DAA) including the two approved protease inhibitors boceprevir and telaprevir, in association with the PEG-IFN/RBV combination is the new standard of care making it necessary to redefine the interest of the IL28B genotype in the decision to treat and how to treat genotype 1-infected patients.	Ribavirin	177-180	interferon lambda 3	Homo sapiens	273-278
22212584-10	2012	The role of the IL28B polymorphism as a predictor of response to the current standard of care (SoC), PEG-IFN and RBV treatment is the subject of debate, but this mainly seems to be because of the small size of the samples in the studies performed so far.	Ribavirin	113-116	interferon lambda 3	Homo sapiens	16-21
22052088-2	2012	The present study investigated the relationship between IL-28 genotypes and the virological response to PEG-IFN/RBV therapy at 24 and 48 weeks.	peg-ifn	104-111	interferon lambda 3	Homo sapiens	56-61
22052088-2	2012	The present study investigated the relationship between IL-28 genotypes and the virological response to PEG-IFN/RBV therapy at 24 and 48 weeks.	Ribavirin	112-115	interferon lambda 3	Homo sapiens	56-61
22052088-10	2012	The IL-28B genotype is a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy at 48 weeks in patients with HCV infection.	peg-ifn	80-87	interferon lambda 3	Homo sapiens	4-10
22052088-10	2012	The IL-28B genotype is a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy at 48 weeks in patients with HCV infection.	Ribavirin	88-91	interferon lambda 3	Homo sapiens	4-10
22301466-0	2012	Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.	Ribavirin	145-154	interferon lambda 3	Homo sapiens	0-15
22924160-0	2012	Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.	Ribavirin	151-160	interferon lambda 3	Homo sapiens	33-38
22924160-9	2012	CONCLUSIONS: These data suggest that age, HCV genotype and IL28B polymorphism are useful for prediction of the response to treatment with Peg-IFN-alpha and ribavirin.	peg-ifn-alpha	138-151	interferon lambda 3	Homo sapiens	59-64
22924160-9	2012	CONCLUSIONS: These data suggest that age, HCV genotype and IL28B polymorphism are useful for prediction of the response to treatment with Peg-IFN-alpha and ribavirin.	Ribavirin	156-165	interferon lambda 3	Homo sapiens	59-64
22536498-9	2012	For example, patients infected with HCV genotype 2/3 with a certain IL-28B polymorphism can be treated with a shorter course of interferon and ribavirin which can also help reduce costs.	Ribavirin	143-152	interferon lambda 3	Homo sapiens	68-74
22898703-0	2012	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.	Ribavirin	161-170	interferon lambda 3	Homo sapiens	0-15
22301466-1	2012	BACKGROUND: Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin.	Ribavirin	232-241	interferon lambda 3	Homo sapiens	12-27
22619706-17	2012	The most common genotype of IL28B in Latvia is CT/TC, with an incidence of 53%.	Carbon Tetrachloride	47-49	interferon lambda 3	Homo sapiens	28-33
22619706-17	2012	The most common genotype of IL28B in Latvia is CT/TC, with an incidence of 53%.	Technetium	50-52	interferon lambda 3	Homo sapiens	28-33
21879313-1	2012	Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.	peg-ifn	95-102	interferon lambda 3	Homo sapiens	179-194
21879313-1	2012	Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.	Ribavirin	103-106	interferon lambda 3	Homo sapiens	179-194
21879313-1	2012	Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.	peg-ifn	318-325	interferon lambda 3	Homo sapiens	179-194
21879313-1	2012	Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.	Ribavirin	326-329	interferon lambda 3	Homo sapiens	179-194
21879313-3	2012	Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum apoB-100 and low-density lipoprotein (LDL) cholesterol levels.	Cholesterol	229-240	interferon lambda 3	Homo sapiens	134-139
21889467-1	2012	BACKGROUND & AIMS: Recipient and donor IL28B polymorphisms seem to play an important role in the response to hepatitis C treatment after liver transplantation (LT).	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	43-48
22192885-1	2012	BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in IL28B and serum levels of interferon gamma inducible protein 10 (IP-10) predict outcomes of antiviral therapy in patients with chronic hepatitis C. We associated IL28B SNPs rs12979860 and rs8099917, along with serum levels of IP-10, with outcomes of patients with acute hepatitis C (AHC).	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	65-70
21898478-2	2012	Recently, single nucleotide polymorphisms (SNPs) of IL28B and host response to peginterferon alpha (PEG-IFNalpha) and ribavirin (RBV) were shown to be strongly associated.	Ribavirin	118-127	interferon lambda 3	Homo sapiens	52-57
21898478-2	2012	Recently, single nucleotide polymorphisms (SNPs) of IL28B and host response to peginterferon alpha (PEG-IFNalpha) and ribavirin (RBV) were shown to be strongly associated.	Ribavirin	129-132	interferon lambda 3	Homo sapiens	52-57
21898478-11	2012	CONCLUSION: Gene expression involving innate immunity is strongly associated with IL28B genotype and response to PEG-IFNalpha/RBV.	Ribavirin	126-129	interferon lambda 3	Homo sapiens	82-87
21325786-0	2012	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.	telaprevir	114-124	interferon lambda 3	Homo sapiens	74-79
21325786-0	2012	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.	Ribavirin	144-153	interferon lambda 3	Homo sapiens	74-79
21325786-1	2012	OBJECTIVES: Genetic variation near the IL28B gene and substitution of aa 70 and 91 in the core region of HCV-1b are useful as predictors of treatment efficacy to telaprevir/pegylated interferon (PEG-IFN)/ribavirin, but its impact on viral dynamics is not clear.	telaprevir	162-172	interferon lambda 3	Homo sapiens	39-44
21325786-1	2012	OBJECTIVES: Genetic variation near the IL28B gene and substitution of aa 70 and 91 in the core region of HCV-1b are useful as predictors of treatment efficacy to telaprevir/pegylated interferon (PEG-IFN)/ribavirin, but its impact on viral dynamics is not clear.	peg-ifn	195-202	interferon lambda 3	Homo sapiens	39-44
21325786-1	2012	OBJECTIVES: Genetic variation near the IL28B gene and substitution of aa 70 and 91 in the core region of HCV-1b are useful as predictors of treatment efficacy to telaprevir/pegylated interferon (PEG-IFN)/ribavirin, but its impact on viral dynamics is not clear.	Ribavirin	204-213	interferon lambda 3	Homo sapiens	39-44
21734353-0	2012	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.	Ribavirin	131-140	interferon lambda 3	Homo sapiens	75-80
21734353-10	2012	CONCLUSION: aa substitution in core/NS5A region and genetic variation near IL28B were important predictors of treatment efficacy to IFN/ribavirin.	Ribavirin	136-145	interferon lambda 3	Homo sapiens	75-80
21990051-10	2012	CONCLUSIONS: The IL-28B genotype impacts on viral kinetics during the first week of treatment with PEG-IFN/RBV in patients with HCV genotype 1/4.	peg-ifn	99-106	interferon lambda 3	Homo sapiens	17-23
21990051-10	2012	CONCLUSIONS: The IL-28B genotype impacts on viral kinetics during the first week of treatment with PEG-IFN/RBV in patients with HCV genotype 1/4.	Ribavirin	107-110	interferon lambda 3	Homo sapiens	17-23
21703176-0	2012	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.	peginterferon	115-128	interferon lambda 3	Homo sapiens	0-15
21703176-0	2012	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.	Ribavirin	129-138	interferon lambda 3	Homo sapiens	0-15
21703176-3	2012	METHODS: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin.	Ribavirin	109-118	interferon lambda 3	Homo sapiens	9-24
22095536-0	2012	Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.	Ribavirin	66-75	interferon lambda 3	Homo sapiens	136-141
22095536-1	2012	A study was carried out to determine whether early viral dynamics retain prediction of the outcome of peginterferon (PEG-IFN) and ribavirin combination therapy based on different genetic polymorphisms near the IL28B gene, the strongest baseline predictor of response to this therapy.	Polyethylene Glycols	117-120	interferon lambda 3	Homo sapiens	210-215
22301466-1	2012	BACKGROUND: Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin.	Ribavirin	232-241	interferon lambda 3	Homo sapiens	29-34
23133602-15	2012	CONCLUSIONS: In HCV-HIV coinfected patients treated with PegIFNalpha and ribavirin, SVR is associated with IL28B rs8099917 polymorphism.	pegifnalpha	57-68	interferon lambda 3	Homo sapiens	107-112
23173032-1	2012	BACKGROUND & AIMS: A combination of pegylated interferon-alpha and ribavirin (PR) is the standard therapy for patients with chronic hepatitis C. The impact of polymorphism of interleukin-28B (IL28B) on sustained virological response (SVR) to PR has been well documented in patients with CHC genotype-1 (GT1), but it is controversial in genotype-2 (GT2) CHC patients.	Ribavirin	71-80	interferon lambda 3	Homo sapiens	179-194
23133602-15	2012	CONCLUSIONS: In HCV-HIV coinfected patients treated with PegIFNalpha and ribavirin, SVR is associated with IL28B rs8099917 polymorphism.	Ribavirin	73-82	interferon lambda 3	Homo sapiens	107-112
21907615-0	2011	Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.	Ribavirin	112-121	interferon lambda 3	Homo sapiens	22-27
23029188-0	2012	Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.	pegifn	73-79	interferon lambda 3	Homo sapiens	8-13
23029188-0	2012	Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.	Ribavirin	84-93	interferon lambda 3	Homo sapiens	8-13
23029188-1	2012	BACKGROUND: Many studies have been published on the association between single nucleotide polymorphisms (SNP) near the IL28B gene and response to the combined treatments of pegylated-interferon (PegIFN) and ribavirin (RBV) in chronic HCV-infected patients, but without identical conclusions.	Ribavirin	207-216	interferon lambda 3	Homo sapiens	119-124
23029188-1	2012	BACKGROUND: Many studies have been published on the association between single nucleotide polymorphisms (SNP) near the IL28B gene and response to the combined treatments of pegylated-interferon (PegIFN) and ribavirin (RBV) in chronic HCV-infected patients, but without identical conclusions.	Ribavirin	218-221	interferon lambda 3	Homo sapiens	119-124
23029188-10	2012	CONCLUSION: Polymorphisms of rs12979860 and rs8099917 near IL28B only associate with the treatment response to PegIFN/RBV in patients infected with HCV genotype 1 or 4 but not with genotype 2 or 3, irrespective of the previous treatment history or HIV co-infected status.	pegifn	111-117	interferon lambda 3	Homo sapiens	59-64
23029188-10	2012	CONCLUSION: Polymorphisms of rs12979860 and rs8099917 near IL28B only associate with the treatment response to PegIFN/RBV in patients infected with HCV genotype 1 or 4 but not with genotype 2 or 3, irrespective of the previous treatment history or HIV co-infected status.	Ribavirin	118-121	interferon lambda 3	Homo sapiens	59-64
22253847-1	2012	Several SNPs located in or around the IL28B gene are associated with response of patients infected with Hepatitis C virus to treatment with pegylated interferon-alpha +/- ribavirin or with spontaneous clearance of the virus.	Ribavirin	171-180	interferon lambda 3	Homo sapiens	38-43
22328925-5	2012	Haplotypes carrying the major alleles at IL28B SNPs were highly associated with sustained virological responses (SVRs) after treatment with peg-IFN-alpha and RBV [odds ratio (OR) = 2.5, 95% confidence interval (CI) = 1.6-4.0, 4.0x10(-5)].	Ribavirin	158-161	interferon lambda 3	Homo sapiens	41-46
23284866-11	2012	CONCLUSIONS: Sequential rapid stopping rules using on-treatment virological responses and interleukin-28B genotype can rapidly identify additional peginterferon/ribavirin non-responders.	Ribavirin	161-170	interferon lambda 3	Homo sapiens	90-105
22649509-1	2012	BACKGROUND: The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV) infection and response to PEG-IFN/RBV treatment in western populations.	peg-ifn	145-152	interferon lambda 3	Homo sapiens	38-43
22649509-1	2012	BACKGROUND: The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV) infection and response to PEG-IFN/RBV treatment in western populations.	Ribavirin	153-156	interferon lambda 3	Homo sapiens	38-43
22649509-9	2012	CONCLUSIONS: Thus, the rs12979860-CC variant upstream of IL28B gene is associated with spontaneous clearance of HCV, susceptible to IFN/RBV treatment and increased IL-28B levels in this Chinese population.	Ribavirin	136-139	interferon lambda 3	Homo sapiens	57-62
22253715-1	2012	BACKGROUND AND AIMS: Recently, several genome-wide association studies have revealed that single nucleotide polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of HCV infection as well as outcome following peginterferon and ribavirin therapy among HCV genotype 1 infected patients.	Ribavirin	245-254	interferon lambda 3	Homo sapiens	145-150
21907615-2	2011	OBJECTIVES: The aim of this study was to investigate the association between genetic variation near the IL28B gene and treatment outcome prediction in Korean patients receiving peg-interferon (PEG-IFN) plus ribavirin therapy.	peg-interferon	177-191	interferon lambda 3	Homo sapiens	104-109
21907615-2	2011	OBJECTIVES: The aim of this study was to investigate the association between genetic variation near the IL28B gene and treatment outcome prediction in Korean patients receiving peg-interferon (PEG-IFN) plus ribavirin therapy.	peg-ifn	193-200	interferon lambda 3	Homo sapiens	104-109
21907615-2	2011	OBJECTIVES: The aim of this study was to investigate the association between genetic variation near the IL28B gene and treatment outcome prediction in Korean patients receiving peg-interferon (PEG-IFN) plus ribavirin therapy.	Ribavirin	207-216	interferon lambda 3	Homo sapiens	104-109
21918436-4	2011	IL28B variations are strongly associated with response to pegylated-IFN plus ribavirin (Peg-IFN/RBV) in patients with chronic infection by HCV genotype 1 or 4.	Ribavirin	77-86	interferon lambda 3	Homo sapiens	0-5
21703198-0	2011	Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. BACKGROUND & AIMS: IL28B polymorphisms have been associated with both treatment induced and spontaneous clearance of hepatitis C virus (HCV).	Adenosine Monophosphate	129-132	interferon lambda 3	Homo sapiens	11-16
21703198-1	2011	We previously found that LDL cholesterol levels were higher in chronic hepatitis C (CHC) patients with the CC genotype at the rs12979860 polymorphism, located proximal to the IL28 gene.	Cholesterol	29-40	interferon lambda 3	Homo sapiens	175-179
21993426-1	2011	The achievement of response to the current standard of care-pegylated interferon plus ribavirin-has recently been described to be associated with single-nucleotide polymorphisms (SNPs) near the IL-28B gene.	Ribavirin	86-95	interferon lambda 3	Homo sapiens	194-200
21918436-4	2011	IL28B variations are strongly associated with response to pegylated-IFN plus ribavirin (Peg-IFN/RBV) in patients with chronic infection by HCV genotype 1 or 4.	Ribavirin	96-99	interferon lambda 3	Homo sapiens	0-5
21918436-10	2011	SUMMARY: IL28B genotyping can aid in Peg-IFN/RBV clinical decision-making, and it may be useful in the selection of candidates for triple therapy with Peg-IFN/RBV plus direct-acting antiviral drugs.	Ribavirin	45-48	interferon lambda 3	Homo sapiens	9-14
21354446-0	2011	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-alpha/ribavirin therapy of chronic hepatitis C virus (HCV) infection.	Adenosine Monophosphate	115-118	interferon lambda 3	Homo sapiens	0-5
21596633-2	2011	In the complex network of interacting factors determining sustained virological response independently of known predictive factors related to host and virus, two modern tools are emerging: polymorphisms in the IL28B gene and very early exposure to ribavirin.	Ribavirin	248-257	interferon lambda 3	Homo sapiens	210-215
22006276-1	2011	UNLABELLED: The IL28B genotype is the most important pretreatment predictor of treatment outcome in patients with chronic hepatitis C. The impact of the rs12979860 genotype on relapse was retrospectively evaluated in genotype 1/4 patients who received response-guided therapy with peginterferon alpha-2a 180 mug/week plus ribavirin 1,000/1,200 mg/day in a large, randomized, multicenter study.	Ribavirin	322-331	interferon lambda 3	Homo sapiens	16-21
21354446-0	2011	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-alpha/ribavirin therapy of chronic hepatitis C virus (HCV) infection.	Ribavirin	232-241	interferon lambda 3	Homo sapiens	0-5
21354446-0	2011	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-alpha/ribavirin therapy of chronic hepatitis C virus (HCV) infection.	Ribavirin	232-241	interferon lambda 3	Homo sapiens	181-186
21354446-7	2011	CONCLUSIONS: Polymorphisms in IL28B are strongly associated with the first phase viral decline during peginterferon-alpha/ribavirin therapy of chronic HCV infection, irrespective of HCV genotype.	Ribavirin	122-131	interferon lambda 3	Homo sapiens	30-35
21147186-1	2011	BACKGROUND & AIMS: Recent studies have described a major impact of genetic variations near the IL28B gene on the natural course and outcome of antiviral therapy in chronic hepatitis C. We therefore, aimed to explore the impact of donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV) liver graft reinfection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	99-104
21911885-1	2011	BACKGROUND AND AIMS: Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-alpha/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from North America, Europe and Asia.	Ribavirin	141-150	interferon lambda 3	Homo sapiens	64-69
21900787-1	2011	BACKGROUND: Recent studies have suggested that host genetics may be useful for predicting drug response and have supported the recommendation that single polynucleotide polymorphisms (SNPs) of IL28B should be investigated when treating hepatitis C virus (HCV)-1 infected patients.	Polynucleotides	154-168	interferon lambda 3	Homo sapiens	193-198
21914076-7	2011	Multivariate analysis also identified IL-28B genotype GG+TG (OR 14.1, P = 0.021) and alpha-fetoprotein >30 (OR 5.4, P = 0.031) as independent predictors of null response.	Thioguanine	57-59	interferon lambda 3	Homo sapiens	38-44
21914076-11	2011	IL-28B genotype is a potentially useful marker for the response to PEGIFN/RBV therapy administered after curative treatment of HCV-related HCC.	pegifn	67-73	interferon lambda 3	Homo sapiens	0-6
21914076-11	2011	IL-28B genotype is a potentially useful marker for the response to PEGIFN/RBV therapy administered after curative treatment of HCV-related HCC.	Ribavirin	74-77	interferon lambda 3	Homo sapiens	0-6
20659305-1	2011	Recently, genome-wide association studies in patients affected by HCV infection have identified a strong association between sustained virological response to peg-interferon/ribavirin and spontaneous viral clearance and common single nucleotide polymorphisms (SNPs) near the IL28B gene, encoding for interferon-lambda-3.	Polyethylene Glycols	159-162	interferon lambda 3	Homo sapiens	275-280
20659305-1	2011	Recently, genome-wide association studies in patients affected by HCV infection have identified a strong association between sustained virological response to peg-interferon/ribavirin and spontaneous viral clearance and common single nucleotide polymorphisms (SNPs) near the IL28B gene, encoding for interferon-lambda-3.	Polyethylene Glycols	159-162	interferon lambda 3	Homo sapiens	300-319
20659305-1	2011	Recently, genome-wide association studies in patients affected by HCV infection have identified a strong association between sustained virological response to peg-interferon/ribavirin and spontaneous viral clearance and common single nucleotide polymorphisms (SNPs) near the IL28B gene, encoding for interferon-lambda-3.	Ribavirin	174-183	interferon lambda 3	Homo sapiens	275-280
20659305-1	2011	Recently, genome-wide association studies in patients affected by HCV infection have identified a strong association between sustained virological response to peg-interferon/ribavirin and spontaneous viral clearance and common single nucleotide polymorphisms (SNPs) near the IL28B gene, encoding for interferon-lambda-3.	Ribavirin	174-183	interferon lambda 3	Homo sapiens	300-319
21931540-13	2011	These findings support a role for natural killer (NK) cell activation in PegIFN/R treatment-induced clearance, partially mediated by IL28B.	pegifn	73-79	interferon lambda 3	Homo sapiens	133-138
21820962-4	2011	We also discuss the recent discovery of single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL28B, that correlate strongly with the ability to achieve a sustained virological response to therapy with pegylated IFN-alpha plus ribavirin in patients with chronic hepatitis C.	Ribavirin	245-254	interferon lambda 3	Homo sapiens	94-105
21820962-4	2011	We also discuss the recent discovery of single nucleotide polymorphisms (SNPs) near the human IFN-lambda3 gene, IL28B, that correlate strongly with the ability to achieve a sustained virological response to therapy with pegylated IFN-alpha plus ribavirin in patients with chronic hepatitis C.	Ribavirin	245-254	interferon lambda 3	Homo sapiens	112-117
21884576-3	2011	Two IL28B single nucleotide polymorphisms (SNPs), rs8099917 and rs12979860, predict response to (PegIFN/R) therapy in treatment of HCV infection.	pegifn	97-103	interferon lambda 3	Homo sapiens	4-9
21884576-3	2011	Two IL28B single nucleotide polymorphisms (SNPs), rs8099917 and rs12979860, predict response to (PegIFN/R) therapy in treatment of HCV infection.	r	104-105	interferon lambda 3	Homo sapiens	4-9
22044696-0	2011	Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin.	Ribavirin	107-116	interferon lambda 3	Homo sapiens	36-40
21745312-0	2011	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.	Ribavirin	130-139	interferon lambda 3	Homo sapiens	15-30
21739446-1	2011	An association has been reported between genetic polymorphism near IL28B gene and the prevalence of mutation of hepatitis C virus (HCV) core region residue 70, both of which have been associated with a lack of virologic response to antiviral combination therapy with peginterferon (PEG-IFN) and ribavirin.	peginterferon	267-280	interferon lambda 3	Homo sapiens	67-72
21739446-1	2011	An association has been reported between genetic polymorphism near IL28B gene and the prevalence of mutation of hepatitis C virus (HCV) core region residue 70, both of which have been associated with a lack of virologic response to antiviral combination therapy with peginterferon (PEG-IFN) and ribavirin.	peg-ifn	282-289	interferon lambda 3	Homo sapiens	67-72
21739446-1	2011	An association has been reported between genetic polymorphism near IL28B gene and the prevalence of mutation of hepatitis C virus (HCV) core region residue 70, both of which have been associated with a lack of virologic response to antiviral combination therapy with peginterferon (PEG-IFN) and ribavirin.	Ribavirin	295-304	interferon lambda 3	Homo sapiens	67-72
21147186-2	2011	METHODS: Donor and recipient genotypes of IL28B rs12979860C>T single nucleotide polymorphism were determined in 91 patients with HCV liver graft reinfection, 47 of whom were treated with pegylated interferon-alpha (PEG-IFN-alpha) and ribavirin.	Ribavirin	237-246	interferon lambda 3	Homo sapiens	42-47
21147186-6	2011	More important, donor IL28B rs12979860 CC vs. CT/TT genotypes were associated with rapid, complete early, and sustained virologic response (RVR, cEVR, SVR) to treatment with PEG-IFN-alpha and ribavirin (p=0.003, 0.0012, 0.008, respectively), but weaker associations of recipient genotypes with RVR, cEVR, and SVR were observed as well (p=0.0046, 0.115, 0.118, respectively).	peg-ifn-alpha	174-187	interferon lambda 3	Homo sapiens	22-27
21147186-6	2011	More important, donor IL28B rs12979860 CC vs. CT/TT genotypes were associated with rapid, complete early, and sustained virologic response (RVR, cEVR, SVR) to treatment with PEG-IFN-alpha and ribavirin (p=0.003, 0.0012, 0.008, respectively), but weaker associations of recipient genotypes with RVR, cEVR, and SVR were observed as well (p=0.0046, 0.115, 0.118, respectively).	Ribavirin	192-201	interferon lambda 3	Homo sapiens	22-27
21742841-0	2011	IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.	Ribavirin	69-78	interferon lambda 3	Homo sapiens	0-5
21147189-3	2011	Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNlambda3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV.	peg-ifn	174-181	interferon lambda 3	Homo sapiens	66-71
21147189-3	2011	Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNlambda3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV.	peg-ifn	174-181	interferon lambda 3	Homo sapiens	93-103
21147189-3	2011	Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNlambda3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV.	Ribavirin	186-189	interferon lambda 3	Homo sapiens	66-71
21147189-3	2011	Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNlambda3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV.	Ribavirin	186-189	interferon lambda 3	Homo sapiens	93-103
21670772-0	2011	Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.	Ribavirin	103-112	interferon lambda 3	Homo sapiens	43-48
22977564-6	2011	Multivariate analysis showed that IL-28B TT homozygosity (P=0.014) and the platelets number (P=0.030) was associated with the early suppression of HCV-RNA at 12 weeks after the start of PEG-IFN/RBV therapy.	peg-ifn	186-193	interferon lambda 3	Homo sapiens	34-40
22977564-6	2011	Multivariate analysis showed that IL-28B TT homozygosity (P=0.014) and the platelets number (P=0.030) was associated with the early suppression of HCV-RNA at 12 weeks after the start of PEG-IFN/RBV therapy.	Ribavirin	194-197	interferon lambda 3	Homo sapiens	34-40
22977564-7	2011	The IL-28B polymorphism was a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy in patients with HCV infection.	peg-ifn	85-92	interferon lambda 3	Homo sapiens	4-10
22977564-7	2011	The IL-28B polymorphism was a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy in patients with HCV infection.	Ribavirin	93-96	interferon lambda 3	Homo sapiens	4-10
21628662-0	2011	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. BACKGROUND: Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent.	Ribavirin	83-92	interferon lambda 3	Homo sapiens	0-5
21600205-1	2011	BACKGROUND & AIMS: Polymorphisms in the interleukin-28B (IL28B) gene are associated with outcomes from infection with hepatitis C virus (HCV).	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	61-66
21628662-0	2011	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. BACKGROUND: Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent.	Ribavirin	199-208	interferon lambda 3	Homo sapiens	0-5
21628662-0	2011	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. BACKGROUND: Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent.	telaprevir	98-108	interferon lambda 3	Homo sapiens	0-5
21628662-0	2011	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. BACKGROUND: Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent.	telaprevir	214-224	interferon lambda 3	Homo sapiens	0-5
21529139-1	2011	OBJECTIVE: Several studies recently revealed that single nucleotide polymorphisms (SNPs) in the interleukin28B (IL28B) region are associated with the response to pegylated interferon-alfa (PEG-IFN-alfa) and ribavirin (RBV) treatment among hepatitis C virus (HCV)-infected individuals of European, African and Asian ancestry.	Ribavirin	207-216	interferon lambda 3	Homo sapiens	112-117
21692944-0	2011	IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.	Ribavirin	109-118	interferon lambda 3	Homo sapiens	0-5
21692944-8	2011	We conclude that the IL28B variability influences the antiviral efficiency of interferon/ribavirin therapy and has a strong impact on SVR, independently of traditional response predictors.	Ribavirin	89-98	interferon lambda 3	Homo sapiens	21-26
21529139-1	2011	OBJECTIVE: Several studies recently revealed that single nucleotide polymorphisms (SNPs) in the interleukin28B (IL28B) region are associated with the response to pegylated interferon-alfa (PEG-IFN-alfa) and ribavirin (RBV) treatment among hepatitis C virus (HCV)-infected individuals of European, African and Asian ancestry.	Ribavirin	218-221	interferon lambda 3	Homo sapiens	112-117
21869868-1	2011	Genome-wide association studies have recently identified single nucleotide polymorphisms in proximity to the interleukin-28B (IL-28B) gene that can predict sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection who are undergoing therapy with pegylated interferon (IFN) a and ribavirin.	Ribavirin	315-324	interferon lambda 3	Homo sapiens	126-132
21861317-3	2011	It is a matter of ongoing debate how to incorporate the IL28B data into the current treatment algorithms with pegylated interferon-alpha and ribavirin.	Ribavirin	141-150	interferon lambda 3	Homo sapiens	56-61
21145800-0	2011	IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.	Ribavirin	88-97	interferon lambda 3	Homo sapiens	0-4
21346780-0	2011	IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection.	Ribavirin	112-121	interferon lambda 3	Homo sapiens	0-5
21145800-1	2011	BACKGROUND & AIMS: Common genetic variation within the IL28 locus has been found to influence the effect of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	59-63
21145800-1	2011	BACKGROUND & AIMS: Common genetic variation within the IL28 locus has been found to influence the effect of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection.	Ribavirin	131-140	interferon lambda 3	Homo sapiens	59-63
21145800-7	2011	Among patients treated with peg-interferon plus ribavirin therapy, liver mRNA levels of IL28, MxA, PKR, OAS1, and ISG15 were significantly or marginally lower in responders who became negative for HCV RNA (p=0.001, 0.004, 0.014, 0.051, and 0.015, respectively).	Ribavirin	48-57	interferon lambda 3	Homo sapiens	88-92
21592993-6	2011	IL28B genotype distribution was as follows: CC, 46%; CT, 43%; and TT, 11%.	Carbon Tetrachloride	53-55	interferon lambda 3	Homo sapiens	0-5
21503910-1	2011	Variation at the IL-28B locus was recently reported to be a significant predictive factor of viral response to pegylated-interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL-28B polymorphism rs8099917 and viral and clinical factors were investigated.	Ribavirin	137-146	interferon lambda 3	Homo sapiens	17-23
21972552-2	2011	Single nucleotide polymorphisms (SNPs) associated with response to pegylated-interferon (PEG-IFN) and ribavirin (RBV) therapy were determined around IL-28B in chromosome 19, and the strong association was also observed in spontaneous viral clearance regardless of population.	peg-ifn	89-96	interferon lambda 3	Homo sapiens	149-155
21869868-1	2011	Genome-wide association studies have recently identified single nucleotide polymorphisms in proximity to the interleukin-28B (IL-28B) gene that can predict sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection who are undergoing therapy with pegylated interferon (IFN) a and ribavirin.	Ribavirin	315-324	interferon lambda 3	Homo sapiens	109-124
21537116-0	2011	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse.	Ribavirin	63-72	interferon lambda 3	Homo sapiens	10-15
21505315-0	2011	IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.	Ribavirin	127-136	interferon lambda 3	Homo sapiens	0-5
21505315-1	2011	BACKGROUND: A single nucleotide polymorphism (SNP) upstream of the IL28B gene (rs12979860) predicts sustained virological response (SVR) to peginterferon-ribavirin therapy in chronic hepatitis C patients.	Ribavirin	154-163	interferon lambda 3	Homo sapiens	67-72
21228123-3	2011	Through a genome-wide scan, we found two variants (rs8099917 and rs12979860) in the IL-28B locus that affect the outcome of PEG-IFN and ribavirin combination therapy, consistent with recent studies (P = 6.52x10(-8); odds ratio 2.46 and P = 8.63x10(-8), odds ratio 2.40, respectively).	peg-ifn	124-131	interferon lambda 3	Homo sapiens	84-90
21389156-0	2011	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.	Ribavirin	142-151	interferon lambda 3	Homo sapiens	240-255
21389156-3	2011	Next, the four SNPs associated with IL-28B were genotyped by Invader for 416 additional Japanese patients, and the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment was evaluated when the four SNPs were not in linkage disequilibrium (LD).	peg-ifn	159-166	interferon lambda 3	Homo sapiens	36-42
21145807-0	2011	Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.	Ribavirin	136-145	interferon lambda 3	Homo sapiens	29-34
21145807-1	2011	BACKGROUND & AIMS: Polymorphisms of the IL28B gene (rs12979860 and rs8099917) are associated with high sustained virological response (SVR) rates in HCV genotype 1 patients.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	44-49
21145807-11	2011	CONCLUSIONS: IL28B polymorphisms modulate early virologic response to peginterferon/ribavirin treatment.	Ribavirin	84-93	interferon lambda 3	Homo sapiens	13-18
21228123-3	2011	Through a genome-wide scan, we found two variants (rs8099917 and rs12979860) in the IL-28B locus that affect the outcome of PEG-IFN and ribavirin combination therapy, consistent with recent studies (P = 6.52x10(-8); odds ratio 2.46 and P = 8.63x10(-8), odds ratio 2.40, respectively).	Ribavirin	136-145	interferon lambda 3	Homo sapiens	84-90
21382156-7	2011	The set of odds ratios of studies demonstrated an association between SNP (rs12987960/rs8099917) in the IL28B and SVR in CHC treated with peginterferon plus ribavirin (OR: 4.6; 95% CI: 2.9-7.3).	Ribavirin	157-166	interferon lambda 3	Homo sapiens	104-109
21360545-0	2011	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.	Ribavirin	79-88	interferon lambda 3	Homo sapiens	15-20
21360545-1	2011	Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	peg-ifn	121-128	interferon lambda 3	Homo sapiens	29-44
21360545-1	2011	Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	peg-ifn	121-128	interferon lambda 3	Homo sapiens	46-51
21360545-1	2011	Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	Ribavirin	135-144	interferon lambda 3	Homo sapiens	29-44
21360545-1	2011	Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	Ribavirin	135-144	interferon lambda 3	Homo sapiens	46-51
21360545-1	2011	Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	Ribavirin	146-149	interferon lambda 3	Homo sapiens	29-44
21360545-1	2011	Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.	Ribavirin	146-149	interferon lambda 3	Homo sapiens	46-51
21360545-11	2011	IL28B polymorphism was predictive of PEG-IFN plus RBV combination treatment outcomes in patients infected with genotype 2 and, especially, with genotype 2b.	peg-ifn	37-44	interferon lambda 3	Homo sapiens	0-5
21360545-11	2011	IL28B polymorphism was predictive of PEG-IFN plus RBV combination treatment outcomes in patients infected with genotype 2 and, especially, with genotype 2b.	Ribavirin	50-53	interferon lambda 3	Homo sapiens	0-5
21360545-12	2011	In conclusion, IL-28B polymorphism affects responses to PEG-IFN-based treatment in difficult-to-treat HCV patients.	Polyethylene Glycols	56-59	interferon lambda 3	Homo sapiens	15-21
21538279-9	2011	The use of IL-28B genotyping to predict the response to pegylated interferon and ribavirin may also find its way into clinical practice.	Ribavirin	81-90	interferon lambda 3	Homo sapiens	11-17
21146242-1	2011	BACKGROUND & AIMS: A single nucleotide polymorphism (rs12979860 C/T) 3kb upstream of the interleukin 28B (IL-28B) gene was shown to be associated with hepatitis C clearance.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	110-116
21111740-9	2011	CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2.	pegifn-alpha	116-128	interferon lambda 3	Homo sapiens	13-18
21479134-1	2011	BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV).	Ribavirin	291-300	interferon lambda 3	Homo sapiens	54-69
21479134-1	2011	BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV).	Ribavirin	291-300	interferon lambda 3	Homo sapiens	71-76
21479134-1	2011	BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV).	pegifn	302-308	interferon lambda 3	Homo sapiens	54-69
21479134-1	2011	BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV).	pegifn	302-308	interferon lambda 3	Homo sapiens	71-76
21479134-1	2011	BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV).	Ribavirin	309-312	interferon lambda 3	Homo sapiens	54-69
21479134-1	2011	BACKGROUND: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV) chronic infection with pegylated interferon and ribavirin (PegIFN/RBV).	Ribavirin	309-312	interferon lambda 3	Homo sapiens	71-76
21479134-3	2011	METHODOLOGY/PRINCIPAL FINDINGS: We analyzed ten SNPs of IL28B in 191 treatment-naive patients with GT1-HCV chronic infection who received PegIFN/RBV.	pegifn	138-144	interferon lambda 3	Homo sapiens	56-61
21111740-9	2011	CONCLUSIONS: IL28B genotype and hepatic expression of ISGs are independent predictors of response to treatment with pegIFN-alpha and ribavirin in patients with chronic hepatitis C. The most accurate prediction of response was obtained with a 4-gene classifier comprising IFI27, ISG15, RSAD2, and HTATIP2.	Ribavirin	133-142	interferon lambda 3	Homo sapiens	13-18
22087138-0	2011	Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B.	Ribavirin	133-142	interferon lambda 3	Homo sapiens	39-44
21374656-1	2011	UNLABELLED: Polymorphisms near the IL28B gene, which code for interferon (IFN)-lambda3, predict response to pegylated interferon-alpha (PEG-IFN) and ribavirin treatment in hepatitis C virus (HCV) genotype 1 infected patients.	Ribavirin	149-158	interferon lambda 3	Homo sapiens	35-40
22087138-5	2011	OBJECTIVES: To assess the associations of single nucleotide polymorphisms (SNP) of the IL28B and sustained virologic response (SVR) of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.	Ribavirin	187-196	interferon lambda 3	Homo sapiens	87-92
22087138-7	2011	Then we performed a meta-analysis comparing the SVR rate at SNP of the IL28B in individuals with PEG-interferon/ribavirin therapy.	Ribavirin	112-121	interferon lambda 3	Homo sapiens	71-76
22087138-12	2011	CONCLUSIONS: IL28B is significantly associated with response to PEG-interferon/ribavirin therapy of patients with chronic HCV infection.	Polyethylene Glycols	64-67	interferon lambda 3	Homo sapiens	13-18
21374656-7	2011	Furthermore, we show that IL28B polymorphisms are associated with relapse in patients who achieve rapid viral response to PEG-IFN/ribavirin therapy.	peg-ifn	122-129	interferon lambda 3	Homo sapiens	26-31
21374656-7	2011	Furthermore, we show that IL28B polymorphisms are associated with relapse in patients who achieve rapid viral response to PEG-IFN/ribavirin therapy.	Ribavirin	130-139	interferon lambda 3	Homo sapiens	26-31
22087138-12	2011	CONCLUSIONS: IL28B is significantly associated with response to PEG-interferon/ribavirin therapy of patients with chronic HCV infection.	Ribavirin	79-88	interferon lambda 3	Homo sapiens	13-18
21112657-1	2011	BACKGROUND & AIMS: Genetic variation in the interleukin 28B (IL28B) gene has been associated with the response to interferon-alfa/ribavirin therapy in hepatitis C virus (HCV) genotype 1-infected patients.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	65-70
21112657-1	2011	BACKGROUND & AIMS: Genetic variation in the interleukin 28B (IL28B) gene has been associated with the response to interferon-alfa/ribavirin therapy in hepatitis C virus (HCV) genotype 1-infected patients.	Ribavirin	134-143	interferon lambda 3	Homo sapiens	65-70
21129805-0	2011	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	Ribavirin	66-75	interferon lambda 3	Homo sapiens	130-135
21112657-3	2011	METHODS: In patients with chronic hepatitis C genotype 2/3 (n=267), IL28B host genotypes (rs8099917, rs12980275 and rs12979860) were analyzed for associations with sustained virologic response (SVR) to antiviral therapy with (pegylated) interferon-alfa and ribavirin and with respect to epidemiological, biochemical, and virological parameters.	Ribavirin	257-266	interferon lambda 3	Homo sapiens	68-73
21129805-11	2011	CONCLUSIONS: The IL28B polymorphism and mutations in the ISDR of HCV were significant pre-treatment predictors of response to PEG-IFN/RBV.	peg-ifn	126-133	interferon lambda 3	Homo sapiens	17-22
21129805-11	2011	CONCLUSIONS: The IL28B polymorphism and mutations in the ISDR of HCV were significant pre-treatment predictors of response to PEG-IFN/RBV.	Ribavirin	134-137	interferon lambda 3	Homo sapiens	17-22
21390311-1	2011	BACKGROUND: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C. Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B predict spontaneous resolution of HCV infection and outcome of treatment among HCV genotype 1 infected patients.	Ribavirin	130-139	interferon lambda 3	Homo sapiens	272-277
21068134-0	2011	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Ribavirin	76-85	interferon lambda 3	Homo sapiens	22-27
21068134-1	2011	BACKGROUND AND AIMS: A number of recent studies have shown that human polymorphisms near the IL28B type III interferon (IFNlambda) gene influence the response to peg-interferon plus ribavirin combination therapy for infection with chronic hepatitis C virus (HCV).	Ribavirin	182-191	interferon lambda 3	Homo sapiens	93-98
21068134-8	2011	CONCLUSIONS: IL28B polymorphisms and HCV core amino acid 70 substitutions contribute independently to an SVR to peg-interferon plus ribavirin combination therapy.	Ribavirin	132-141	interferon lambda 3	Homo sapiens	13-18
21817190-6	2011	Among a subset of patients with the IL28B genotype of TT at rs8099917, patients with variants of the ITPA gene were associated with a higher rate of receiving >80% of the expected RBV dose, a higher rate of sustained virological response (SVR), and a lower rate of relapse.	Ribavirin	183-186	interferon lambda 3	Homo sapiens	36-41
20924369-3	2011	Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV.	Ribavirin	207-216	interferon lambda 3	Homo sapiens	53-58
20924369-3	2011	Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV.	Ribavirin	207-216	interferon lambda 3	Homo sapiens	97-122
20924369-3	2011	Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV.	Ribavirin	207-216	interferon lambda 3	Homo sapiens	126-131
21817190-7	2011	CONCLUSIONS: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B.	Ribavirin	95-98	interferon lambda 3	Homo sapiens	272-277
21817190-7	2011	CONCLUSIONS: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B.	peg-ifn	167-174	interferon lambda 3	Homo sapiens	272-277
21817190-7	2011	CONCLUSIONS: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B.	Ribavirin	179-182	interferon lambda 3	Homo sapiens	272-277
21734383-3	2011	RESULTS: Single nucleotide polymorphisms near the IL28B gene location which encode for interferon (IFN)-lambda3 have a large effect in determining the likelihood of patients obtaining a cure from pegylated IFN-alpha and ribavirin combination therapy or spontaneous clearance of the HCV.	Ribavirin	220-229	interferon lambda 3	Homo sapiens	50-55
21734383-3	2011	RESULTS: Single nucleotide polymorphisms near the IL28B gene location which encode for interferon (IFN)-lambda3 have a large effect in determining the likelihood of patients obtaining a cure from pegylated IFN-alpha and ribavirin combination therapy or spontaneous clearance of the HCV.	Ribavirin	220-229	interferon lambda 3	Homo sapiens	87-111
21750736-0	2011	Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. INTRODUCTION: Polymorphisms near the IL28B gene (e.g. rs12979860) encoding interferon lambda3 have recently been associated with both spontaneous clearance and treatment response to pegIFN/RBV in chronic hepatitis C (CHC) patients.	pegifn	289-295	interferon lambda 3	Homo sapiens	144-149
22156487-2	2011	A common genetic variation near the IL28B gene has been found to affect the response to PEG-IFN plus ribavirin therapy for CHC.	peg-ifn	88-95	interferon lambda 3	Homo sapiens	36-41
22156487-2	2011	A common genetic variation near the IL28B gene has been found to affect the response to PEG-IFN plus ribavirin therapy for CHC.	Ribavirin	101-110	interferon lambda 3	Homo sapiens	36-41
21254158-1	2011	UNLABELLED: Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin.	Ribavirin	176-185	interferon lambda 3	Homo sapiens	33-38
22174846-6	2011	It was also revealed that IL28B and STAT1-nuclear translocation in hepatocytes are independent predictors of response to treatment with peginterferon and ribavirin in chronic hepatitis C patients.	peginterferon	136-149	interferon lambda 3	Homo sapiens	26-31
22174846-6	2011	It was also revealed that IL28B and STAT1-nuclear translocation in hepatocytes are independent predictors of response to treatment with peginterferon and ribavirin in chronic hepatitis C patients.	Ribavirin	154-163	interferon lambda 3	Homo sapiens	26-31
22046316-9	2011	A (TA) dinucleotide repeat, rs72258881, located in the promoter region was discovered by our functional studies of the proximal SNPs upstream of IL-28B; the transcriptional activity of the promoter increased gradually in a (TA)(n) length-dependent manner following IFN-alpha and lipopolysaccharide stimulation.	(ta) dinucleotide	2-19	interferon lambda 3	Homo sapiens	145-151
22046316-12	2011	These findings suggest that the dinucleotide repeat could be associated with the transcriptional activity of IL-28B as well as being a marker to improve the prediction of the response to interferon-based hepatitis C virus treatment.	Dinucleoside Phosphates	32-44	interferon lambda 3	Homo sapiens	109-115
22003405-0	2011	IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.	Ribavirin	116-125	interferon lambda 3	Homo sapiens	0-5
22003405-1	2011	BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons.	peginterferon	154-167	interferon lambda 3	Homo sapiens	117-122
22003405-1	2011	BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons.	Polyethylene Glycols	169-172	interferon lambda 3	Homo sapiens	117-122
21760886-0	2011	An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. BACKGROUND: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after pegylated-interferon/ribavirin treatment for chronic hepatitis C (CHC).	Ribavirin	229-238	interferon lambda 3	Homo sapiens	3-8
21760886-0	2011	An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. BACKGROUND: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after pegylated-interferon/ribavirin treatment for chronic hepatitis C (CHC).	Ribavirin	229-238	interferon lambda 3	Homo sapiens	121-126
21760886-7	2011	IL28B rs12979860-CC genotype was the strongest predictor of SVR (aOR, 7.56; p<.0001); the model also included HCV RNA (log10 IU/ml), AST:ALT ratio, Ishak fibrosis score and prior ribavirin treatment.	Ribavirin	182-191	interferon lambda 3	Homo sapiens	0-5
21750736-0	2011	Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. INTRODUCTION: Polymorphisms near the IL28B gene (e.g. rs12979860) encoding interferon lambda3 have recently been associated with both spontaneous clearance and treatment response to pegIFN/RBV in chronic hepatitis C (CHC) patients.	Ribavirin	296-299	interferon lambda 3	Homo sapiens	144-149
20950615-5	2010	The IL28B genotype can be considered, along with other factors, in predicting patient responses to therapy with pegylated IFN-alpha and ribavirin.	Ribavirin	136-145	interferon lambda 3	Homo sapiens	4-9
22303600-5	2011	Recently all interest has been turned towards the demonstration of the host polymorphism located upstream of the IL-28B gene and which is associated with sustained virological response to treatment with pegylated interferon Alfa in combination with ribavirin.	Ribavirin	249-258	interferon lambda 3	Homo sapiens	113-119
22003405-1	2011	BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons.	Ribavirin	178-187	interferon lambda 3	Homo sapiens	117-122
22003405-1	2011	BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons.	Ribavirin	189-192	interferon lambda 3	Homo sapiens	117-122
22003405-9	2011	CONCLUSIONS: IL28B SNPs have an additive allele dose effect in predicting HCV treatment outcomes in HCV/HIV coinfected persons and can be incorporated into a simple pretreatment prediction score that could minimize the risk of exposure to PEG/RBV therapy for persons with unfavorable scores.	Polyethylene Glycols	239-242	interferon lambda 3	Homo sapiens	13-18
22003405-9	2011	CONCLUSIONS: IL28B SNPs have an additive allele dose effect in predicting HCV treatment outcomes in HCV/HIV coinfected persons and can be incorporated into a simple pretreatment prediction score that could minimize the risk of exposure to PEG/RBV therapy for persons with unfavorable scores.	Ribavirin	243-246	interferon lambda 3	Homo sapiens	13-18
20889274-1	2010	A SNP has been identified (rs12979860) located in chromosome 19,3 kb upstream of the IL28B gene that encodes IFN-lambda3, which was strongly associated with the sustained virological response (SVR) to pegIFN and ribavirin in more than 1000 patients with genotype 1 chronic hepatitis C. In patients of European ancestry, as well as in African-American and Hispanic patients, the CC genotype was associated with a two-fold greater SVR rate than the TT genotype, CT being closer to TT than to CC.	pegifn	201-207	interferon lambda 3	Homo sapiens	85-90
20708617-0	2010	Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. BACKGROUND & AIMS: Patients with hepatitis C virus (HCV)-related liver disease frequently undergo orthotopic liver transplantation, but recurrent hepatitis C is still a major cause of morbidity.	Polyethylene Glycols	76-79	interferon lambda 3	Homo sapiens	12-17
20708617-0	2010	Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. BACKGROUND & AIMS: Patients with hepatitis C virus (HCV)-related liver disease frequently undergo orthotopic liver transplantation, but recurrent hepatitis C is still a major cause of morbidity.	Ribavirin	95-104	interferon lambda 3	Homo sapiens	12-17
20708617-0	2010	Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. BACKGROUND & AIMS: Patients with hepatitis C virus (HCV)-related liver disease frequently undergo orthotopic liver transplantation, but recurrent hepatitis C is still a major cause of morbidity.	Adenosine Monophosphate	152-155	interferon lambda 3	Homo sapiens	12-17
20708617-4	2010	Liver recipient and donor DNA samples were screened for single nucleotide polymorphisms near the IL28B genes (rs12980275 and rs8099917) that affect sensitivity to PEG-IFN/RBV.	peg-ifn	163-170	interferon lambda 3	Homo sapiens	97-102
20708617-4	2010	Liver recipient and donor DNA samples were screened for single nucleotide polymorphisms near the IL28B genes (rs12980275 and rs8099917) that affect sensitivity to PEG-IFN/RBV.	Ribavirin	171-174	interferon lambda 3	Homo sapiens	97-102
20708617-9	2010	CONCLUSIONS: In patients with recurrent HCV infection after orthotopic liver transplantation, combination analyses of single nucleotide polymorphisms of IL28B in recipient and donor tissues and mutations in HCV RNA allow prediction of SVR to PEG-IFN/RBV therapy.	peg-ifn	242-249	interferon lambda 3	Homo sapiens	153-158
20708617-9	2010	CONCLUSIONS: In patients with recurrent HCV infection after orthotopic liver transplantation, combination analyses of single nucleotide polymorphisms of IL28B in recipient and donor tissues and mutations in HCV RNA allow prediction of SVR to PEG-IFN/RBV therapy.	Ribavirin	250-253	interferon lambda 3	Homo sapiens	153-158
20931559-0	2010	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. UNLABELLED: Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin.	Ribavirin	386-395	interferon lambda 3	Homo sapiens	0-5
20931559-0	2010	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. UNLABELLED: Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin.	Ribavirin	386-395	interferon lambda 3	Homo sapiens	177-182
20931559-0	2010	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. UNLABELLED: Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin.	Ribavirin	386-395	interferon lambda 3	Homo sapiens	184-220
20637200-1	2010	BACKGROUND & AIMS: A single nucleotide polymorphism (SNP) upstream of the IL28B gene has been associated with response of patients with chronic hepatitis C to therapy with pegylated interferon and ribavirin and also with spontaneous clearance of acute hepatitis C in a heterogeneous population.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	78-83
20637200-1	2010	BACKGROUND & AIMS: A single nucleotide polymorphism (SNP) upstream of the IL28B gene has been associated with response of patients with chronic hepatitis C to therapy with pegylated interferon and ribavirin and also with spontaneous clearance of acute hepatitis C in a heterogeneous population.	Ribavirin	201-210	interferon lambda 3	Homo sapiens	78-83
20889274-1	2010	A SNP has been identified (rs12979860) located in chromosome 19,3 kb upstream of the IL28B gene that encodes IFN-lambda3, which was strongly associated with the sustained virological response (SVR) to pegIFN and ribavirin in more than 1000 patients with genotype 1 chronic hepatitis C. In patients of European ancestry, as well as in African-American and Hispanic patients, the CC genotype was associated with a two-fold greater SVR rate than the TT genotype, CT being closer to TT than to CC.	pegifn	201-207	interferon lambda 3	Homo sapiens	109-120
20889274-1	2010	A SNP has been identified (rs12979860) located in chromosome 19,3 kb upstream of the IL28B gene that encodes IFN-lambda3, which was strongly associated with the sustained virological response (SVR) to pegIFN and ribavirin in more than 1000 patients with genotype 1 chronic hepatitis C. In patients of European ancestry, as well as in African-American and Hispanic patients, the CC genotype was associated with a two-fold greater SVR rate than the TT genotype, CT being closer to TT than to CC.	Ribavirin	212-221	interferon lambda 3	Homo sapiens	85-90
20889274-1	2010	A SNP has been identified (rs12979860) located in chromosome 19,3 kb upstream of the IL28B gene that encodes IFN-lambda3, which was strongly associated with the sustained virological response (SVR) to pegIFN and ribavirin in more than 1000 patients with genotype 1 chronic hepatitis C. In patients of European ancestry, as well as in African-American and Hispanic patients, the CC genotype was associated with a two-fold greater SVR rate than the TT genotype, CT being closer to TT than to CC.	Ribavirin	212-221	interferon lambda 3	Homo sapiens	109-120
20804372-0	2010	Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.	Ribavirin	52-61	interferon lambda 3	Homo sapiens	65-70
21048934-0	2010	IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.	Ribavirin	79-88	interferon lambda 3	Homo sapiens	0-5
21048934-1	2010	Recent genome-wide association studies report that the SNP rs8099917, located 8.9 kb upstream of the start codon of IL28B, is associated with both disease chronicity and therapeutic response to pegIFN-alpha and RBV in patients infected with genotype 1 HCV.	pegifn-alpha	194-206	interferon lambda 3	Homo sapiens	116-121
21048934-1	2010	Recent genome-wide association studies report that the SNP rs8099917, located 8.9 kb upstream of the start codon of IL28B, is associated with both disease chronicity and therapeutic response to pegIFN-alpha and RBV in patients infected with genotype 1 HCV.	Ribavirin	211-214	interferon lambda 3	Homo sapiens	116-121
20804372-1	2010	BACKGROUND: Variation in the IL28B gene is associated with sustained virologic response (SVR) to pegylated interferon plus ribavirin in hepatitis C virus (HCV)-monoinfected patients with genotype 1.	Ribavirin	123-132	interferon lambda 3	Homo sapiens	29-34
20576307-1	2010	BACKGROUND & AIMS: A common genetic variation at the IL28 locus has been found to affect the response of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	57-61
20887330-1	2010	AIM:   Recent human genome-wide association studies (GWAS) revealed a strong association between IL28B gene variation and the pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment response in chronic hepatitis C patients.	Ribavirin	158-167	interferon lambda 3	Homo sapiens	97-102
20576307-1	2010	BACKGROUND & AIMS: A common genetic variation at the IL28 locus has been found to affect the response of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection.	Ribavirin	128-137	interferon lambda 3	Homo sapiens	57-61
20648473-1	2010	UNLABELLED: Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear.	peg-ifn	204-211	interferon lambda 3	Homo sapiens	39-44
20648473-1	2010	UNLABELLED: Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear.	Ribavirin	213-222	interferon lambda 3	Homo sapiens	39-44
20648473-1	2010	UNLABELLED: Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear.	telaprevir	280-290	interferon lambda 3	Homo sapiens	39-44
20648473-1	2010	UNLABELLED: Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear.	peg-ifn	291-298	interferon lambda 3	Homo sapiens	39-44
20648473-1	2010	UNLABELLED: Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is not clear.	Ribavirin	299-308	interferon lambda 3	Homo sapiens	39-44
20648473-9	2010	CONCLUSION: This study identified genetic variation near the IL28B gene and aa substitution of the core region as predictors of sustained virological response to a triple therapy of telaprevir/PEG-IFN/ribavirin in Japanese patients infected with HCV genotype 1b.	telaprevir	182-192	interferon lambda 3	Homo sapiens	61-66
20648473-9	2010	CONCLUSION: This study identified genetic variation near the IL28B gene and aa substitution of the core region as predictors of sustained virological response to a triple therapy of telaprevir/PEG-IFN/ribavirin in Japanese patients infected with HCV genotype 1b.	peg-ifn	193-200	interferon lambda 3	Homo sapiens	61-66
20648473-9	2010	CONCLUSION: This study identified genetic variation near the IL28B gene and aa substitution of the core region as predictors of sustained virological response to a triple therapy of telaprevir/PEG-IFN/ribavirin in Japanese patients infected with HCV genotype 1b.	Ribavirin	201-210	interferon lambda 3	Homo sapiens	61-66
23560893-0	2013	Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.	Ribavirin	137-146	interferon lambda 3	Homo sapiens	33-39
20176026-0	2010	Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.	Ribavirin	106-115	interferon lambda 3	Homo sapiens	34-39
19749757-0	2009	Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients.	Ribavirin	81-90	interferon lambda 3	Homo sapiens	27-32
19749758-0	2009	IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.	Ribavirin	78-87	interferon lambda 3	Homo sapiens	0-5
33768560-0	2021	Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.	Sofosbuvir	87-97	interferon lambda 3	Homo sapiens	20-35
33768560-0	2021	Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.	daclatasvir	103-114	interferon lambda 3	Homo sapiens	20-35
33768560-3	2021	We aimed to evaluate the usefulness of the reference single nucleotide polymorphism (rs12979860) interleukin 28B (CC genotype) for predicting sustained virological response to sofosbuvir plus daclatasvir in Egyptian patients infected with HCV-4.	Sofosbuvir	176-186	interferon lambda 3	Homo sapiens	97-112
33768560-3	2021	We aimed to evaluate the usefulness of the reference single nucleotide polymorphism (rs12979860) interleukin 28B (CC genotype) for predicting sustained virological response to sofosbuvir plus daclatasvir in Egyptian patients infected with HCV-4.	daclatasvir	192-203	interferon lambda 3	Homo sapiens	97-112
33768560-9	2021	WHAT IS NEW AND CONCLUSION: Our results suggest that IL28B genotype contributes to the prediction of response to sofosbuvir plus daclatasvir.	Sofosbuvir	113-123	interferon lambda 3	Homo sapiens	53-58
33768560-9	2021	WHAT IS NEW AND CONCLUSION: Our results suggest that IL28B genotype contributes to the prediction of response to sofosbuvir plus daclatasvir.	daclatasvir	129-140	interferon lambda 3	Homo sapiens	53-58
20399780-1	2010	BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection.	Adenosine Monophosphate	12-15	interferon lambda 3	Homo sapiens	73-93
20399780-1	2010	BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection.	Ribavirin	213-222	interferon lambda 3	Homo sapiens	73-93
20399780-10	2010	CONCLUSIONS: In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.	Ribavirin	85-94	interferon lambda 3	Homo sapiens	123-129
16539846-10	2006	CONCLUSION: IL-28 and IL-29 cDNAs were successfully cloned and expressed in eukaryotic cells via transfection with pcDNA3.1/V5-His-TOPO-IL-28/IL-29.	Histidine	127-130	interferon lambda 3	Homo sapiens	12-17
16539846-10	2006	CONCLUSION: IL-28 and IL-29 cDNAs were successfully cloned and expressed in eukaryotic cells via transfection with pcDNA3.1/V5-His-TOPO-IL-28/IL-29.	Histidine	127-130	interferon lambda 3	Homo sapiens	136-141
15778392-9	2005	Similarly, IFN-alpha pretreatment strongly enhanced poly(I:C)-induced activation of IFN-beta, IL-28, and IL-29 genes also in HUVECs.	Poly I-C	52-61	interferon lambda 3	Homo sapiens	94-99
23560893-3	2013	METHODS: IL-28B rs8099917 genotype was determined in 70 HCV-1 treatment-experienced patients retreated with 48-week peginterferon/ribavirin.	Ribavirin	130-139	interferon lambda 3	Homo sapiens	9-15
23560893-11	2013	CONCLUSIONS: Host IL-28B genetic variants played a role in Asian relapsers but not nonresponders retreated with peginterferon/ribavirin.	Ribavirin	126-135	interferon lambda 3	Homo sapiens	18-24
31756766-6	2020	IFN-lambda3 treatment also reduced the number of HBV-positive cells and the synthesis of covalently closed circular DNA after infection of HepG2.2.15-derived HBV to sodium taurocholate cotransporting polypeptide-transduced HepG2 cells.	Taurocholic Acid	165-184	interferon lambda 3	Homo sapiens	0-11
34216268-10	2021	Our meta-analysis results suggest that IL28B rs12979860 CC is a strong predictor for SC of hepatitis C infection in PEG IFN-a/RBV-treated patients.	Ribavirin	126-129	interferon lambda 3	Homo sapiens	39-44
34307188-0	2021	Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.	pegylated interferon-alpha	136-162	interferon lambda 3	Homo sapiens	0-19
34307188-2	2021	In this context, single nucleotide polymorphisms (SNPs) in the locus of interferon lambda 3 and 4 genes (IFNL3/4) have been important genetic markers of responsiveness to CHC as prognostic markers for the pegylated-Interferon-alpha/ribavirin (Peg-IFN-alpha/RBV).	pegylated-interferon-alpha	205-231	interferon lambda 3	Homo sapiens	105-110
34307188-2	2021	In this context, single nucleotide polymorphisms (SNPs) in the locus of interferon lambda 3 and 4 genes (IFNL3/4) have been important genetic markers of responsiveness to CHC as prognostic markers for the pegylated-Interferon-alpha/ribavirin (Peg-IFN-alpha/RBV).	Ribavirin	232-241	interferon lambda 3	Homo sapiens	105-110
33438851-12	2022	CONCLUSIONS: Detection of favourable HCV and IL28B genotype prior to commencement of PEG-IFN+RBV, and continuing it in patients with EVR is of major importance for those in whom DAA are still unavailable.	peg-ifn	85-92	interferon lambda 3	Homo sapiens	45-50
33438851-12	2022	CONCLUSIONS: Detection of favourable HCV and IL28B genotype prior to commencement of PEG-IFN+RBV, and continuing it in patients with EVR is of major importance for those in whom DAA are still unavailable.	daa	178-181	interferon lambda 3	Homo sapiens	45-50
33612760-3	2020	Several studies had demonstrated that baseline serum interferon-gamma-inducible-protein 10 (IP-10) levels and interleukin 28B polymorphisms were associated with the resistance to the standard of care pegylated interferon alpha and ribavirin (PEG-IFNalpha/RBV) therapy and development of post-treatment relapse.	pegylated interferon alpha	200-226	interferon lambda 3	Homo sapiens	110-125
33612760-3	2020	Several studies had demonstrated that baseline serum interferon-gamma-inducible-protein 10 (IP-10) levels and interleukin 28B polymorphisms were associated with the resistance to the standard of care pegylated interferon alpha and ribavirin (PEG-IFNalpha/RBV) therapy and development of post-treatment relapse.	Ribavirin	231-240	interferon lambda 3	Homo sapiens	110-125
33612760-3	2020	Several studies had demonstrated that baseline serum interferon-gamma-inducible-protein 10 (IP-10) levels and interleukin 28B polymorphisms were associated with the resistance to the standard of care pegylated interferon alpha and ribavirin (PEG-IFNalpha/RBV) therapy and development of post-treatment relapse.	peg-ifnalpha/rbv	242-258	interferon lambda 3	Homo sapiens	110-125
33612760-4	2020	Our purpose was to assess the predictive value of combining IP-10 levels and IL28B genotypes to PEG-IFNalpha/RBV therapy response in Egyptian chronic HCV infection patients with genotype 4.	peg-ifnalpha/rbv	96-112	interferon lambda 3	Homo sapiens	77-82
33205487-1	2021	Human IFN-lambda4 is expressed by only a subset of individuals who possess the DeltaG variant allele at the dinucleotide polymorphism rs368234815.	Dinucleoside Phosphates	108-120	interferon lambda 3	Homo sapiens	6-17
32353085-6	2020	The reduced response of B cells could be explained by higher expression of the soluble variant of IFN-lambdaR1 (sIFN-lambdaR1), which significantly reduced ISG induction when added with IFN-lambda3 to peripheral blood mononuclear cells or liver epithelial cells.	isg	156-159	interferon lambda 3	Homo sapiens	186-197
34307418-0	2021	Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis.	peginterferon alpha	54-73	interferon lambda 3	Homo sapiens	0-15
34307418-2	2021	Numerous studies have reported that interleukin-28B (IL-28B) genetic polymorphisms are related to the therapeutic efficacy of PEG-IFN-alpha, but the results are inconsistent.	peg-ifn-alpha	126-139	interferon lambda 3	Homo sapiens	36-51
34307418-2	2021	Numerous studies have reported that interleukin-28B (IL-28B) genetic polymorphisms are related to the therapeutic efficacy of PEG-IFN-alpha, but the results are inconsistent.	peg-ifn-alpha	126-139	interferon lambda 3	Homo sapiens	53-59
34307418-10	2021	Conclusion: This meta-analysis revealed that the IL-28B rs12979860 CC genotype and rs8099917 TT genotype indicated a better treatment response than non-CC and non-TT genotypes for PEG-IFN-alpha in patients with CHB.	peg-ifn-alpha	180-193	interferon lambda 3	Homo sapiens	49-55
31793339-4	2022	Similarly, GG-GG (PNPLA3-IL28B) is considered a high-risk signature for higher degree of fibrosis.Conclusion: IL28B rs8099917 and PNPLA3 rs738409 introduce genetic signature to identify patients at higher risk for CHC susceptibility and fibrosis progression in CHC G4.	gg-gg	11-16	interferon lambda 3	Homo sapiens	25-30
31793339-4	2022	Similarly, GG-GG (PNPLA3-IL28B) is considered a high-risk signature for higher degree of fibrosis.Conclusion: IL28B rs8099917 and PNPLA3 rs738409 introduce genetic signature to identify patients at higher risk for CHC susceptibility and fibrosis progression in CHC G4.	gg-gg	11-16	interferon lambda 3	Homo sapiens	110-115
33933854-6	2021	In IPEC-J2 cells, CDCA and LCA inhibited PDCoV replication at post-entry stages by inducing the production of interferon (IFN)-lambda3 and IFN-stimulated gene 15 (ISG15) via G protein-coupled receptor (GPCR).	Chenodeoxycholic Acid	18-22	interferon lambda 3	Homo sapiens	110-134
33933854-6	2021	In IPEC-J2 cells, CDCA and LCA inhibited PDCoV replication at post-entry stages by inducing the production of interferon (IFN)-lambda3 and IFN-stimulated gene 15 (ISG15) via G protein-coupled receptor (GPCR).	Lithocholic Acid	27-30	interferon lambda 3	Homo sapiens	110-134
28520373-0	2012	Simeprevir Therapy and IFNL3 Genotype Simeprevir is a hepatitis C virus (HCV) protease inhibitor used in combination with other drugs to treat chronic hepatitis genotype 1 or 4 infection (1).	Simeprevir	38-48	interferon lambda 3	Homo sapiens	23-28
28520373-5	2012	The FDA-approved drug label for simeprevir contains information regarding a genetic variant near the IFNL3 gene (a C to T change; rs12979860), which is a strong predictor of response to peginterferon alfa and ribavirin treatment.	Simeprevir	32-42	interferon lambda 3	Homo sapiens	101-106
28520373-5	2012	The FDA-approved drug label for simeprevir contains information regarding a genetic variant near the IFNL3 gene (a C to T change; rs12979860), which is a strong predictor of response to peginterferon alfa and ribavirin treatment.	Ribavirin	209-218	interferon lambda 3	Homo sapiens	101-106
28520373-7	2012	However, patients of all IFNL3 genotypes had highest SVR rates when being treated with regimens that included simeprevir.	Simeprevir	110-120	interferon lambda 3	Homo sapiens	25-30
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	acyclic	39-46	interferon lambda 3	Homo sapiens	169-193
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	nucleoside phosphonates	47-70	interferon lambda 3	Homo sapiens	169-193
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	adefovir dipivoxil	78-96	interferon lambda 3	Homo sapiens	169-193
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	Tenofovir	101-130	interferon lambda 3	Homo sapiens	169-193
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	Nucleosides	47-57	interferon lambda 3	Homo sapiens	169-193
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	Lamivudine	338-348	interferon lambda 3	Homo sapiens	169-193
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	entecavir	353-362	interferon lambda 3	Homo sapiens	169-193
31914336-3	2020	Currently, several DAA options are available on the market.Areas covered: This review focuses on the pharmacokinetics, efficacy, tolerability and safety profile of DCV-TRIO, a twice-daily fixed-dose combination of daclatasvir, asunaprevir and beclabuvir approved in Japan for the treatment of genotype 1 HCV infection.Expert opinion: The DCV-TRIO combination achieved good response rates in genotype 1 patients (SVR12 >= 95% in naive subtype 1b), independently from IL28B genotype, cirrhotic status and prior interferon exposure.	daclatasvir	164-167	interferon lambda 3	Homo sapiens	466-471